RECOMBINANT PROTEINS WITH CD40 ACTIVATING PROPERTIES

[0001] The disclosure relates to the field of CD40 activating proteins. More specifically, disclosed herein are recombinant proteins based on CD40 agonist antibodies with their antigen-binding fragments fused or linked to CD40 ligand (CD40L). Also disclosed is the advantageous use of such CD40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens.

[0002] CD40 is a potent activating tumor necrosis factor receptor superfamily member expressed on antigen-presenting cells (APCs) and B cells. Dendritic cells (DCs) respond to infections by internalizing antigens and activating pathogen-associated molecular patterns (PAMPs), and thus present foreign antigens on their major histocompatibility complex (MHC) molecules to antigen-specific T cells, initiating a cycle of DC maturation via CD40 ligand (CD40L) expressed on the activated T cell, which then directs cellular and humoral antigen-specific T and B cell responses to the pathogen [Elgueta et al., 2009]. Agonistic anti-CD40 antibodies are in clinical development based on the notion of directly activating APCs to stimulate immune responses either against intrinsic antigens, e.g., tumor associated antigens (TAAs), or as an adjuvant to vaccines [Dahan et al., 2016, Thompson et al., 2015, reviewed by Vonderheide and Glennie, 2017]. Directly linking antigens to anti-CD40 antibodies by chemical conjugation [Bar et al., 2003], non-covalent assembly [Flamar et al., 2013], or direct fusion [Flamar et al., 2014] elicits potent antigen-specific cellular and humoral immunity at very low antigen doses in a wide array of in vitro and in vivo settings [Flamar et al., 2013, Flamar et al., 2014, Yin et al., 2016, Yin et al., 2017]. In particular, antigen-targeting to CD40 elicits superior cellular T cell responses compared to targeting other receptors, likely due to accumulation within the early endosome compartment, as distinct to the rapid antigen entry into late endosomes characterized by targeting other DC receptors. [Yin et al., 2016, Chattergee et al., 2012].

[0003] Beyond primary screening to identify CD40-reactive monoclonal antibodies that have the most potent agonist activity, e.g., inducing cytokine secretion or CD86 surface expression on human DCs, maximizing the agonist efficacy and utility of clinical candidate anti-CD40 antibodies typically involves affinity maturation of the H and L chain combining regions [Mangsbo et al., 2014], and enhancing cross-linking of the constant region with FcR [Dahan et al., 2016]. Screening can also identify potent agonists without any need for Fc interaction [He at al., 2016], which may be problematic for human platelet activation if FcγRIIA interaction is maintained [Dahan et al., 2016]. Agonistic anti-CD40 antibodies can either bind to sites that overlap the CD40L interacting region, or may interact with a site distinct from its ligand-binding region [Gladue et al., 2011, Dahan et al., 2016, He et al., 2016], but it is not clear if this distinction has clinical relevance.

[0004] Potent activation of CD40 is not required for efficient Class I and Class II presentation of antigens via CD40-targeting in vitro [Chattergee et al., 2012, Flamar et al., 2014], however in vivo efficacy requires co-administration of Toll-like receptor (TLR) activating agents such as poly IC [Zurawski et al., 2017, Cheng et al., 2017]. However, these in vitro and in vivo studies did not utilize anti-CD40 antibody-antigen complexes or fusions with full CD40 agonist activity, and the clear benefit of agonistic anti-CD40 antibody combined with poly IC for peptide-based vaccination in non-human primates [Thompson et al., 2015] suggests CD40-targeting of antigens may be further improved by fully agonistic anti-CD40 targeting vehicles. There is further a need to provide single molecules with high potency as agonist CD40-targeting vehicles. Disclosed herein is the nature of soluble CD40L co-operation with certain agonistic anti-CD40 vehicles for enhancing CD40 activation efficacy of both anti-CD40 antibodies and anti-CD40 antibody-antigen fusion proteins. It is further herein disclosed that a method that combines both, anti-CD40 antibody and CD40L agonist fragment, into a single entity, confers at least similar or even superior potency to that observed with the two separate agents co-administered. Such CD40 activating proteins may be of great value in therapy and to adjuvant immune responses directed to administered antigens.

[0005] The disclosure relates to a CD40 activating protein comprising at least the following protein domains:

• • [0006] (i) a CD40 agonist antibody or an antigen-binding fragment thereof (αCD40); and,
  • [0007] (ii) the CD40 binding-domain of CD40L (CD40L).

[0008] In specific embodiments, said CD40 agonist antibody binds specifically to human CD40 and has at least one or more of the following properties:

• • [0009] (i) it induces the proliferation of B cells, as measured in vitro by flow cytometric analysis or by analysis of replicative dilution of CFSE-labelled cells; or,
  • [0010] (ii) it induces the secretion of cytokines, such as IL-6, IL-12 and/or IL-15 cytokine as measured in vitro with a dendritic cell activation assay.

[0011] In specific embodiments, said CD40 binding-domain of CD40L is a fragment of CD40L comprising SEQ ID NO:14.

[0012] In specific embodiments, said CD40 binding-domain of CD40L is fused to the C-terminus of a light or heavy chain of said CD40 agonist antibody or its antigen-binding fragment.

[0013] In specific embodiments, said CD40 activating protein comprises a heavy and light chain of CD40 agonist IgG antibody, preferably Fc-null and di-sulphide stabilized IgG4 or mutated silent IgG antibody.

[0014] In specific embodiments, said CD40 activating protein further comprises a peptide linker between CD40L and the light or heavy chain of said CD40 agonist antibody or its antigen-binding fragment, preferably a flexible linker FlexV1 of SEQ ID NO:15.

[0015] In specific embodiments, said CD40 agonist antibody is selected from the following antibodies:

• • [0016] (i) a humanized antibody comprising the HCDR1 of SEQ ID NO:27, HCDR2 of SEQ ID NO:28, HCDR3 of SEQ ID NO:29, LCDR1 of SEQ ID NO:30, LCDR2 of SEQ ID NO:31 and LCDR3 of SEQ ID NO:32;
  • [0017] (ii) a humanized antibody comprising VH and VL domains of SEQ ID NO:21 and SEQ ID NO:22 respectively;
  • [0018] (iii) an antibody that competes for binding to CD40 expressing cells with at least one of the antibodies identified in (i) or (ii); or,
  • [0019] (iv) an antibody that binds to the same epitope as one of the antibodies identified in (i) or (ii).

[0020] In specific embodiments, one or more antigens are fused to the heavy or light chain of said CD40 agonist antibody or its antigen-binding fragment.

[0021] Typically, said one or more antigens are viral, bacterial, or cancer antigens fused (either directly via peptide linkage, or non-covalently via e.g., dockerin-cohesin technology) to the heavy or light chain of a CD40 agonist antibody.

[0022] In specific embodiments, the CD40 activating protein comprises a light chain of the formula αCD40Light-PL-CD40L and a heavy chain of the formula αCD40Heavy-(PL-Ag)x, wherein

• • [0023] αCD40Light is a light chain of said CD40 agonist antibody;
  • [0024] αCD40Heavy is a heavy chain of said CD40 agonist antibody;
  • [0025] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0026] Ag is a viral or cancer antigen, either identical or different;
  • [0027] x is an integer from 1 to 20, for example from 3, 4, or 5;
  • [0028] CD40L is the binding domain of the ligand of CD40, for example the CD40-binding domain of CD40L comprising SEQ ID NO:14; and,
  • [0029] - is a bond.

[0030] In specific embodiments, said viral antigens are selected from HIV peptide antigens, preferably the HIV-1 antigens, such as GNG of SEQ ID NO:48 or HIV5pep of SEQ ID NO:57.

[0031] The disclosure also relates to a pharmaceutical composition, comprising the CD40 activating protein as defined above and one or more pharmaceutically acceptable excipients.

[0032] The disclosure further relates to the CD40 activating protein for use as a vaccine. In particular, said CD40 activating protein may be used in enhancing T cell specific response in a subject, in particular CD8+ T cell specific response against a viral antigen.

[0033] Said CD40 activating protein may also be used in eliciting B cell proliferation and/or inducing cytokine proliferation of dendritic cells in a subject.

[0034] In order that the present disclosure may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

[0035] As used herein, the term “CD40” has its general meaning in the art and refers to human CD40 polypeptide receptor including CD40 of SEQ ID NO:13. In specific embodiments, CD40 is the isoform of the human canonical sequence as reported by UniProtKB-P25942 (also referred as human TNR5). The ectodomain of CD40 which is recognized by certain anti-CD40 antibodies may typically be comprised between residues at position 21 and position 193 of SEQ ID NO:13.

[0036] As used herein, the term “CD40L” has its general meaning in the art and refers to human CD40L polypeptide, for example, as reported by UniProtKB-P25942, including its CD40-binding domain of SEQ ID NO:14. CD40L may be expressed as a soluble polypeptide and is the natural ligand of CD40 receptor.

[0037] As used herein, the term “protein” refers to any organic compounds made of amino acids arranged in one or more linear chains (also referred as “polypeptide chains”) and folded into a globular form. The amino acids in such polypeptide chain are joined together by the peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. The term “protein” further includes, without limitation, peptides, single chain polypeptide or any complex proteins consisting primarily of two or more chains of amino acids. It further includes, without limitation, glycoproteins or other known post-translational modifications. It further includes known natural or artificial chemical modifications of natural proteins, such as without limitation, glycoengineering, pegylation, hesylation and the like, incorporation of non-natural amino acids, amino acid modification for chemical conjugation or other molecule, etc. . . . .

[0038] As used herein, a “complex protein” refers more specifically to a protein which is made of at least two polypeptide chains, wherein said at least two polypeptide chains are associated together under appropriate conditions via either non-covalent binding or covalent binding, for example, by disulphide bridge or peptide bond.

[0039] A “heterodimeric protein” refers to a protein that is made of at least two polypeptide chains, forming a complex protein, wherein said two polypeptide chains have different amino acid sequences.

[0040] The terms “polypeptide,” “peptide” and “protein” expressly include glycoproteins, as well as non-glycoproteins. In specific embodiments, the term “polypeptide” and “protein” refers to any polypeptide or protein that can be encoded by a gene and translated using cell expression system and DNA recombinant means, such as mammalian host cell expression system.

[0041] The term “recombinant protein”, as used herein, includes proteins that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further below), (b) fusion proteins isolated from a host cell transformed to express the corresponding protein, e.g., from a transfectoma, etc. . . . .

[0042] As used herein, the term “fusion protein” refers to a recombinant protein comprising at least one polypeptide chain which is obtained or obtainable by genetic fusion, for example by genetic fusion of at least two gene fragments encoding separate functional domains of distinct proteins.

[0043] The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds to an antigen.

[0044] In natural antibodies of rodents and primates, two heavy chains are linked to each other by disulfide bonds, and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chains, lambda (1) and kappa (k). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each chain contains distinct sequence domains. In typical IgG antibodies, the light chain includes two domains, a variable domain (VL) and a constant domain (CL). The heavy chain includes four domains, a variable domain (VH) and three constant domains (CH1, CH2 and CH3, collectively referred to as CH). The variable regions of both light (VL) and heavy (VH) chains determine binding recognition and specificity to the antigen. The constant region domains of the light (CL) and heavy (CH) chains confer important biological properties such as antibody chain association, secretion, trans-placental mobility, complement binding, and binding to Fc receptors (FcR).

[0045] The Fv fragment is the N-terminal part of the Fab fragment of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain. The specificity of the antibody resides in the structural complementarity between the antibody combining site and the antigenic determinant. Antibody combining sites are made up of residues that are primarily from the hypervariable or complementarity determining regions (CDRs). Occasionally, residues from nonhypervariable or framework regions (FR) can participate in the antibody binding site, or influence the overall domain structure and hence the combining site. Complementarity Determining Regions or CDRs refer to amino acid sequences that together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site. The light and heavy chains of an immunoglobulin each have three CDRs, designated L-CDR1, L-CDR2, L-CDR3 and H-CDR1, H-CDR2, H-CDR3, respectively. An antigen-binding site, therefore, typically includes six CDRs, comprising the CDRs set from each of a heavy and a light chain V region. Framework Regions (FRs) refer to amino acid sequences interposed between CDRs. Accordingly, the variable regions of the light and heavy chains typically comprise 4 framework regions and 3 CDRs of the following sequence: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0046] The residues in antibody variable domains are conventionally numbered according to a system devised by Kabat et al. This system is set forth in Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (Kabat et al., 1992, hereafter “Kabat et al.”). The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues in SEQ ID sequences. The actual linear amino acid sequence may contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues may be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence. The CDRs of the heavy chain variable domain are located at residues 31-35 (H-CDR1), residues 50-65 (H-CDR2) and residues 95-102 (H-CDR3) according to the Kabat numbering system. The CDRs of the light chain variable domain are located at residues 24-34 (L-CDR1), residues 50-56 (L-CDR2) and residues 89-97 (L-CDR3) according to the Kabat numbering system. For the agonist antibodies described hereafter, the CDRs have been determined using CDR finding algorithms from www.bioinf.org.uk—see the section entitled «How to identify the CDRs by looking at a sequence» within the Antibodies pages. The predicted CDRs of some agonist antibodies, such as 11B6, 12E2, 12B4, CP (CP-870,893 from Pfizer) or 24A3 are described in the Examples below.

[0047] The term “antigen-binding fragment” of an antibody (or simply “antibody fragment”), as used herein, refers to full length or one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., the ectodomain of CD40). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding fragment” of an antibody include a Fab fragment, a monovalent fragment consisting of the V_L, V_H, C_L and CH1 domains; a F(ab)₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the V_H and CH1 domains; a Fv fragment consisting of the V_L and V_H domains of a single arm of an antibody; a dAb fragment (Ward et al., 1989 Nature 341:544-546), which consists of a V_H domain, or any fusion proteins comprising such antigen-binding fragments.

[0048] Furthermore, although the two domains of the Fv fragment, V_L and V_H, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single chain protein in which the V_L and V_H regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al., 1988 Science 242:423-426; and Huston et al., 1988 Proc. Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding fragment” of an antibody. These antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0049] As used herein, the term “IgG Fc region” is used to define the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc region and variant Fc regions. The human IgG heavy chain Fc region is generally defined as comprising the amino acid residue from position C226 or from P230 to the carboxyl-terminus of the IgG antibody. The numbering of residues in the Fc region is that of the EU index of Kabat. The C-terminal lysine (residue K447) of the Fc region may be removed, for example, during production or purification of the antibody. Accordingly, a composition of antibodies of the invention may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue.

[0050] The term “K_assoc” or “K_a”, as used herein, is intended to refer to the association rate of a particular antibody-antigen interaction, whereas the term “K_dis” or “K_d,” as used herein, is intended to refer to the dissociation rate of a particular antibody-antigen interaction.

[0051] The term “K_D”, as used herein, is intended to refer to the dissociation constant, which is obtained from the ratio of K_d to K_a (i.e., K_d/K_a) and is expressed as a molar concentration (M). K_D values for antibodies can be determined using methods well established in the art. A method for determining the K_D of a protein or an antibody is by using surface plasmon resonance, for example by using a biosensor system such as a Biacore® system.

[0052] As used herein, the term “binding specificity” refers to the ability of an antibody to detectably bind to an antigen recombinant polypeptide, such as recombinant CD40 polypeptide, with a K_D of 100 nM or less, 10 nM or less, 5 nM or less, as measured by Surface Plasmon Resonance (SPR) measurements, for example as determined in the Examples.

[0053] An antibody that “does not cross-react with a particular antigen” is intended to refer to an antibody that binds to that antigen, with a K_D of 100 nM or greater, or a K_D of 1 mM or greater, or a K_D of 10 mM or greater, said affinity being measured for example using similar Surface Plasmon Resonance (SPR) measurements, as disclosed in the Examples. In certain embodiments, such antibodies that do not cross-react with the antigen exhibit essentially undetectable binding against these proteins in standard binding assays.

[0054] The isolated CD40 activating protein according to the present disclosure is a protein that has binding specificity to CD40 and activating or agonist properties with respect to CD40 receptor. A CD40 activating protein may have cross-reactivity to other antigens, such as related CD40 molecules from other species. Moreover, in specific embodiments, an isolated CD40 activating protein may be substantially free of other cellular material and/or chemicals.

[0055] The phrases “an antibody recognizing an antigen” and “an antibody having specificity for an antigen” are used interchangeably herein with the term “an antibody which binds specifically to an antigen”.

[0056] Specificity can further be exhibited by, e.g., an about 10:1, about 20:1, about 50:1, about 100:1, 10.000:1 or greater ratio of affinity/avidity in binding to the specific antigen versus nonspecific binding to other irrelevant molecules (in this case the specific antigen is a CD40 polypeptide). The term “affinity”, as used herein, means the strength of the binding of an antibody to an epitope.

[0057] The present disclosure relates to the unexpected finding that fusion proteins of CD40L with certain CD40 agonist antibodies (e.g., derived from agonist mAb 11B6 or 12B4 as described in WO2010/104748), exhibit superior CD40 activating properties compared to the corresponding agonist antibody alone or the combined administration of such agonist antibody with soluble CD40L (sCD40L).

[0058] “Humanized antibody” as used herein, refers broadly to include antibodies made by a non-human cell having variable and constant regions which have been altered to more closely resemble antibodies that would be made by a human cell. For example, by altering the non-human antibody amino acid sequence to incorporate amino acids found in human germline immunoglobulin sequences. The humanized antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs. The antibodies as used herein may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). In particular, the term “humanized antibody” include antibodies that comprise a silent variant of Fc IgG region.

[0059] In specific embodiments, the term «humanized antibody» include antibodies which have the 6 CDRs of a murine antibody, but humanized framework and constant regions.

[0060] More specifically, the term “humanized antibody”, as used herein, may include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0061] As used herein, a «CD40 agonist» antibody is intended to refer to an antibody that increase CD40 mediated signaling activity in the absence of CD40L in a cell-based assay, such as the B cell proliferation assay. Such assay is described in more details in the examples below.

[0062] As used herein, the term “silent” antibody refers to an antibody that exhibits no or low ADCC activity. As used herein, the term “ADCC” or “antibody dependent cell cytotoxicity” activity refers to cell depleting activity. ADCC activity can be measured by ADCC assays as described in the literature.

[0063] Silenced effector functions can be obtained by mutation in the Fc region of the antibodies and have been described in the Art: Strohl 2009 (LALA & N297A); Baudino 2008, D265A (Baudino et al., J. Immunol. 181 (2008): 6664-69, Strohl, Colo. Biotechnology 20 (2009): 685-91). Examples of silent Fc IgG1 antibodies comprise L234A and L235A mutations in the IgG1 Fc amino acid sequence.

[0064] As used herein, a protein or antibody with «CD40 activating» properties refers to a protein or antibody that is able to increase CD40 mediated signaling activity. In particular, as used herein, a protein with CD40 activating properties has at least one or more of the following properties:

• • [0065] (i) it induces the proliferation of B cell, as measured in vitro by flow cytometric analysis, for example as measured with the B cell proliferation assay described in the Examples below e.g., by analysis of replicative dilution of CFSE-labelled cells;
  • [0066] (ii) it induces the secretion of cytokines, such as IL-6, IL-12, or IL-15, as measured in vitro with a dendritic cell activation assay described in the Examples below.

[0067] In specific embodiment, said CD40 activating protein of the present disclosure has at least the same activating properties as a soluble version of CD40L, the natural ligand of CD40 receptor.

[0068] In specific embodiments, said CD40 activating protein includes a CD40 binding domain of CD40L which is not a trimeric form.

[0069] In specific embodiments, said CD40 activating protein of the present disclosure is tetravalent with respect to CD40 binding.

[0070] In specific embodiments, said CD40 activating protein includes a bivalent CD40 agonist antibody with one monomeric CD40 binding domain of CD40L covalently or non-covalently bound to each arm of said bivalent antibody, preferably via the C-terminal part of each arm of the bivalent antibody, either the light chain or heavy chain of each arm.

[0071] In other specific embodiments, said CD40 activating protein of the present disclosure has at least similar activating properties as a reference CD40 agonist antibody being typically selected among the following CD40 agonist (including partial agonist) antibodies: 11B6, 12B4, CP-870,893 or 24A3, typically 11B6 antibody or a humanized version.

[0072] In other specific embodiments, said CD40 activating protein of the present disclosure has at least similar activating properties, and may be even at least 10 fold, at least 50 fold, or at least 100 fold more active than Mega sCD40L, a known trimer version of soluble CD40L, for eliciting secretion of cytokines as measured in the dendritic cell activation assay as described in the Examples below.

[0073] As used herein, the term «Mega sCD40L» refers to the trimeric CD40 ligand molecules linked via the collagen domain of Adiponectin/ACRP30/AdipoQ, also marketed as MEGACD40L® and described in Kornbluth et al., 2012.

[0074] In other specific embodiment, said CD40 activating protein of the present disclosure has at least the same activating properties as a combined composition of soluble CD40L with the same CD40 agonist antibody (or its antigen-binding fragment) as present in said CD40 activating protein.

[0075] As used herein, the term, “optimized” means that a nucleotide sequence has been altered to encode an amino acid sequence using codons that are preferred in the production cell or organism, generally a eukaryotic cell, for example, a Chinese Hamster Ovary cell (CHO) or a human cell. The optimized nucleotide sequence is engineered to retain completely or as much as possible the amino acid sequence originally encoded by the starting nucleotide sequence. The amino acid sequences encoded by optimized nucleotide sequences are also referred to as optimized.

[0076] As used herein, the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i. e., % identity=number of identical positions/total number of positions×100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.

[0077] The percent identity between two amino acid sequences can be determined using the Needleman and Wunsch algorithm (NEEDLEMAN, and Wunsch).

[0078] The percent identity between two nucleotide or amino acid sequences may also be determined using for example algorithms such as EMBOSS Needle (pair wise alignment; available at www.ebi.ac.uk). For example, EMBOSS Needle may be used with a BLOSUM62 matrix, a “gap open penalty” of 10, a “gap extend penalty” of 0.5, a false “end gap penalty”, an “end gap open penalty” of 10 and an “end gap extend penalty” of 0.5. In general, the “percent identity” is a function of the number of matching positions divided by the number of positions compared and multiplied by 100. For instance, if 6 out of 10 sequence positions are identical between the two compared sequences after alignment, then the identity is 60%. The % identity is typically determined over the whole length of the query sequence on which the analysis is performed. Two molecules having the same primary amino acid sequence or nucleic acid sequence are identical irrespective of any chemical and/or biological modification.

[0079] As used herein, the term “subject” includes any human or nonhuman animal. The term “nonhuman animal” includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.

[0080] As used herein, “Dendritic Cells” (DCs) refers to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology and high levels of surface MHC-class II expression. These cells can be isolated from a number of tissue sources, and conveniently, from peripheral blood, as described in the Examples below.

[0081] The CD40 Activating Protein of the Present Disclosure

[0082] The present disclosure relates to a CD40 activating protein comprising at least the following protein domains:

• [0083] (i) a CD40 agonist antibody (αCD40) or an antigen-binding fragment thereof; and,
• [0084] (ii) the CD40 binding domain of CD40L (CD40L), typically of SEQ ID NO:14 or its functional fragment with at least 90%, 95% or 100% identity to SEQ ID NO:14.

[0085] In certain embodiments, the CD40 binding domain of CD40L (preferably as a monomeric form) is covalently or non-covalently attached to the C-terminus of a light or heavy chain of said CD40 agonist antibody or its antigen-binding fragment, optionally via a linker, such as a peptidic or chemical linker. In one embodiment, the CD40 binding-domain of CD40L is non-covalently attached to the C-terminus of the light chain of a CD40 agonist antibody or its antigen-binding fragment.

[0086] In certain embodiments, the CD40 binding domain of CD40L is fused to the C-terminus of a light or heavy chain of said CD40 agonist antibody or its antigen-binding fragment, optionally via a linker, such as a peptidic linker. Typically, the CD40 binding-domain of CD40L is fused to the C-terminus of the light chain of a CD40 agonist antibody or its antigen-binding fragment, optionally via a linker, such as a peptidic linker.

[0087] In other specific embodiments, said CD40 binding domain of CD40L is conjugated to the CD40 agonist antibody or its antigen-binding fragment using chemical coupling. Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety. Examples of linker types that have been used to conjugate a moiety to an antibody include, but are not limited to, hydrazones, thioethers, esters, disulfides and peptide-containing linkers, such as valine-citruline linker. A linker can be chosen that is, for example, susceptible to cleavage by low pH within the lysosomal compartment or susceptible to cleavage by proteases, such as proteases preferentially expressed in tumor tissue such as cathepsins (e.g., cathepsins B, C, D). For further discussion of types of linkers and methods for conjugating therapeutic agents to antibodies, see also Panowski et al., 2013 for a review on antibody drug conjugates.

[0088] In certain embodiments, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a light chain of the formula αCD40Light-PL-CD40L and a heavy chain of the formula αCD40Heavy, wherein

• • [0089] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0090] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0091] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0092] CD40L is the CD40-binding domain of CD40 ligand, for example comprising SEQ ID NO:14, or its functional fragment with at least 90%, 95% or 100% identity to SEQ ID NO:14.

[0093] In a more specific embodiment, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a light chain of the formula αCD40Light-PL-CD40L and a heavy chain of the formula αCD40Heavy-PL-BP1, wherein

• • [0094] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0095] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0096] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0097] BP1 is a first member of a binding pair BP1/BP2 to permit non-covalent coupling to a second member BP2 of said binding pair BP1/BP2.

[0098] In another specific embodiment, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a heavy chain of the formula αCD40Heavy-PL-CD40L and a light chain of the formula αCD40Light-PL-BP1, wherein

• • [0099] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0100] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0101] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0102] BP1 is a first member of a binding pair BP1/BP2 to permit non-covalent coupling to a second member BP2 of said binding pair BP1/BP2.

[0103] Any binding pairs, typically binding pair of polypeptide domains known in the art may be used for the above embodiments of DC40 activating proteins. Examples of said binding pair BP1/BP2 include without limitation dockering domain/cohesin domain, or mSA2/biotin, as described below.

[0104] In a more specific embodiment, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a light chain of the formula αCD40Light-PL-CD40L and a heavy chain of the formula αCD40Heavy-PL-Doc, wherein

• • [0105] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0106] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0107] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0108] Doc is a dockerin domain or multiple domains to permit non-covalent coupling to cohesin fusion proteins as described in US20160031988A1 and US20120039916A1, for example comprising SEQ ID NO:111, or any functional variant thereof.

[0109] In other specific embodiments, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a light chain of the formula αCD40Light-PL-CD40L and a heavy chain of the formula αCD40Heavy-PL-mSA2, wherein

• • [0110] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0111] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0112] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0113] mSA2 is a monomeric streptavidin 2 domain to permit non-covalent coupling to biotin labelled or fusion proteins as described in Lim et al (Biotechnology Bioeng 2013, 110, 57-67), for example comprising SEQ ID NO:168, or any functional variant thereof.

[0114] In other specific embodiments, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a heavy chain of the formula αCD40Heavy-PL-CD40L and a light chain of the formula αCD40Light, wherein

• • [0115] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0116] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0117] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0118] CD40L is the CD40-binding domain of CD40 ligand, for example comprising SEQ ID NO:14, or its functional fragment with at least 90%, 95% or 100% identity to SEQ ID NO:14.

[0119] In a other more specific embodiment, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a heavy chain of the formula αCD40Heavy-PL-CD40L and a light chain of the formula αCD40Light-PL-Doc, wherein

• • [0120] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0121] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0122] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0123] Doc is a dockerin domain or multiple domains to permit non-covalent coupling to cohesin fusion proteins as described in US20160031988A1 and US20120039916A1, for example comprising SEQ ID NO:111, or any functional variant thereof.

[0124] In other specific embodiments, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a heavy chain of the formula αCD40Heavy-PL-CD40L and a light chain of the formula αCD40Light-PL-mSA2, wherein

• • [0125] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0126] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0127] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0128] mSA2 is a monomeric streptavidin 2 domain to permit non-covalent coupling to biotin labelled or fusion proteins as described in Lim et al (Biotechnology Bioeng 2013, 110, 57-67), for example comprising SEQ ID NO:168, or any functional variant thereof.

[0129] Preferred embodiments of αCD40Light, αCD40Heavy, and CD40L are further described in the next sections.

[0130] In certain embodiments, said CD40 activating protein further comprises one or more antigens «Ag» fused or conjugated or coupled by non-covalent coupling to either the corresponding heavy or light chain of said CD40 agonist antibody or its antigen-binding fragment. Said antigens may be conjugated directly to a polypeptide chain of the CD40 activating protein, for example at the C-terminal end of a polypeptide chain of the CD40 activating protein, and, optionally via peptide linker, such as FlexV1, f1, f2, f3, or f4 as described below. They can be also coupled by non-covalent coupling, for example as included in cohesin fusion proteins for coupling with dockerin domain, and/or biotin fusion proteins for coupling with monomeric streptavidin 2 domain.

[0131] As used herein, the term «antigen» or «Ag» refers to any antigen that can be used in a vaccine, whether it involves a whole microorganism or a portion thereof, and various types: (e.g., peptide, protein, glycoprotein, polysaccharide, glycolipid, lipopeptide, etc). Thus, the term “antigen” refers to a molecule that can initiate a humoral and/or cellular immune response in a recipient of the antigen. The antigen is usually a key molecule encoded by a pathogen that causes a disease for which vaccination would be advantageous treatment.

[0132] In specific embodiments, the Ag is a peptide concatamer. The Ag may also comprise a polynucleotide, the sequence of which is chosen so as to encode the antigen whose expression by the individuals to which the polynucleotide is administered is desired, in the case of the immunization technique referred to as DNA immunization.

[0133] Typically, as used herein, the Ag is selected from a viral or other infectious disease antigen, or a cancer antigen.

[0134] In certain embodiments, the Ag is selected from infectious disease antigens selected from bacterial, viral, parasitic, and fungal antigens. Typically, the Ag is at least one viral antigen. For example, at least one viral antigen comprise peptides from an adenovirus, retrovirus, picornavirus, herpesvirus, rotaviruses, hantaviruses, coronavirus, togavirus, flavirvirus, rhabdovirus, paramyxovirus, orthomyxovirus, bunyavirus, arenavirus, reovirus, papilomavirus, parvovirus, poxvirus, hepadnavirus, rotovirus or spongiform virus. In another aspect, the at least one viral antigen comprise peptides from at least one of HIV, CMV, hepatitis A, B, and C, influenza; measles, polio, smallpox, rubella, respiratory syncytial, herpes simplex, varicella zoster, Epstein-Barr, Japanese encephalitis, rabies, flu, or cold viruses.

[0135] In specific embodiments, said viral antigens are selected from one or more of the following antigenic domains: HIV-1 Gag p24 (SEQ ID NO:45), Nef (SEQ ID NO:46), and Gag p17 (SEQ ID NO:47) (including the combination of the three antigens called GNG, see the detailed of the amino acid sequence below) or the combination of HVP16 E6 and HPV16 E7 antigens (HPV 16 E6/E7) (also as referred to HPV, see the detailed amino acid sequence below).

[0136] GNG sequence is of the following formula: (from C-terminal to N-terminl): FlexV1-LE-gag17-VDf3-VD-nef-EF-f4-QF p24-6×His] (flexible linker sequences) wherein

• • [0137] FlexV1 is a peptide linker of SEQ ID NO:15
  • [0138] LE is a dipeptide of Leu-Glu;
  • [0139] Gag17 is a HIV-1 viral antigen of the following amino acid sequence: MGARASILSGGELDRWEKIRLRPGGNKQYKLKHIVWASRELERFAVNPGL LETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALD KIEEEQNKS (SEQ ID NO:47);
  • [0140] VD is a dipeptidic linker of Valine and Aspactic acid;
  • [0141] f3 is a peptidic linker of the following amino acid sequence: TVTPTATATPSAIVTTITPTATTKP (SEQ ID NO:53);
  • [0142] nef is a HIV-1 viral antigen of the following amino acid sequence MGGKWSKRSVVGWPTVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTA ANNADCAWLEAQEEEEVGFPVRPQVPLRPMTYKGALDLSHFLKEKGGLEG LIYSQKRQDILDLWVYHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVPVEP EKVEEANEGENNSLLHPMSLHGMDDPEREVLVWKFDSRLAFHHMARELH PEYYKDC (SEQ ID NO:46);
  • [0143] EF is a dipeptidic linker of glutamic acid and phenyalalnine;
  • [0144] f4 is a flexible linkr TNGSITVAATAPTVTPTVNATPSAA (SEQ ID NO:54); QF is a dipetidic linker of glutamine and phenylalanine;
  • [0145] P24 is a HIV-1 viral antigen of the following amino acid sequence AQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKA FSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWD RVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKR WIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNW MTETLLVQNANPDCKTILKALGPGATLEEMMTACQGVG (SEQ ID NO:45); and,
  • [0146] 6-His is the C-terminal hexahistidine tag of HHHHHH.

[0147] A full amino acid sequence of GNG consists of SEQ ID NO:48.

[0148] Alternative GNG sequences may be used, for example, using GNG sequences with the same HIV-1 peptide sequences but with other peptidic linkers.

[0149] HPV is of the following formula: Flex-v1-HPV16E6-HPV16E7-f1 wherein FlexV1 are as described above and

• • [0150] HPV16E6-HVP16E7 has the following amino acid sequence:

(SEQ ID NO: 55)

MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRR

EVGDFAFRDLCIVYRDGNPYAVCDKCLKEYSKISEYRHYCYSVYGTT

LEQQYNKPLCDLLIRCINCQKPLCPEASMHGDTPTLHEYMLDLQPET

TDLYGYGQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCK

• • [0151] f1 is the flexible linker of the following amino acid sequence

	(SEQ ID NO: 56)
	ASSSVSPTTSVHPTPTSVPPTPTKSSPAS

[0152] A full amino acid sequence of HPV consists of SEQ ID NO:57.

[0153] In other specific embodiments, said viral antigens are selected from one or more of the following HIV antigenic domains: Gag p17 (17-35) of SEQ ID NO:16, Gag p17-p24 (253-284) of SEQ ID NO:17 and Nef (116-145) of SEQ ID NO:18, Pol 325-344 (RT 158-188) of SEQ ID NO:19 and Nef (66-97) of SEQ ID NO:20.

[0154] In preferred embodiments, said viral antigens are selected from the following combination of the 5 HIV antigenic domains: Gag p17 (17-35) of SEQ ID NO:16, Gag p17-p24 (253-284) of SEQ ID NO:17 and Nef (116-145) of SEQ ID NO:18, Pol 325-344 (RT 158-188) of SEQ ID NO:19 and Nef (66-97) of SEQ ID NO:20, also as comprised in the HIV5pep sequence of the following formula:

[0155] FlexV1-gag p17 (17-35)-f1-gag p17-p24 (253-284)-f2-nef (116-145)-f3-nef (66-97)-f4-Pol 325-344 (RT158-188), wherein

[0156] FlexV1, f1, f2, f3, f4 are described above.

[0157] A specific embodiment of HIV5pep amino acid sequence is described in SEQ ID NO:112.

[0158] In other specific embodiments, the Ag is selected from tumor associated antigens selected from CEA, prostate specific antigen (PSA), HER-2/neu, BAGE, GAGE, MAGE 1-4, 6 and 12, MUC-related protein (Mucin) (MUC-1, MUC-2, etc.), GM2 and GD2 gangliosides, ras, myc, tyrosinase, MART (melanoma antigen), MARCO-MART, cyclin Bl, cyclin D1, Pmel 17 (gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, prostate serum antigen (PSA), PRAME (melanoma antigen), β-catenin, MUM-I-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10, C-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance protein (LRP), Bcl-2, and Ki-67. In another aspect, the Ag is selected from tumor associated antigens comprising antigens from leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors, gastric cancer, colon cancer, liver cancer, pancreatic cancer, genitourinary tumors such cervix, uterus, ovarian cancer, vaginal cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, vascular tumors, or cancers of the lip, nasopharynx, pharynx and oral cavity, esophagus, rectum, gall bladder, biliary tree, larynx, lung and bronchus, bladder, kidney, brain and other parts of the nervous system, thyroid, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and leukemia. Such tumor associated antigens include patient-specific tumor mutated proteins containing known or potential T cell epitopes.

[0159] In specific embodiments, the CD40 activating protein of the present disclosure refers to a complex protein comprising two heterodimers, each heterodimer consisting of one heavy and one light chains of amino acids, stably associated together, for example via one or more disulfide bonds. Typically, the heavy chain comprises at least the VH region, preferably at least the CH1-VH regions of a CD40 agonist antibody and the light chain comprises at least the VL region, preferably at least the CL-VL regions of said CD40 agonist antibody. At least, said heavy or light chain is fused or conjugated to at least the CD40 binding domain of CD40L, optionally via a linker, for example a peptidic linker.

[0160] In specific embodiments, said CD40 activating protein of the present disclosure comprises heavy and light chains of a CD40 agonist IgG antibody, including isotype constant region or IgG Fc region, preferably IgG4 or mutated silent IgG Fc.

[0161] In a more specific embodiment, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a light chain of the formula αCD40Light-PL-CD40L and a heavy chain of the formula αCD40Heavy-(PL-Ag)x, wherein

• • [0162] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0163] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0164] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0165] Ag is a viral or cancer antigen, either identical or different;
  • [0166] x is an integer from 1 to 20, for example from 3, 4, or 5;
  • [0167] CD40L is the binding domain of the ligand of CD40 comprising SEQ ID NO:14 or a functional fragment thereof with at least 90%, 95% or 100% identity to SEQ ID NO:14; and
  • [0168] is a covalent bond.

[0169] In another more specific embodiment, said CD40 activating protein as disclosed herein is an antibody-like protein comprising a heavy chain of the formula αCD40Heavy-PL-CD40L and a light chain of the formula αCD40Light-(PL-Ag)x, wherein

• • [0170] αCD40Light is a light chain of a CD40 agonist antibody;
  • [0171] αCD40Heavy is a heavy chain of a CD40 agonist antibody;
  • [0172] PL is a bond or a peptide linker, either identical or different, preferably FlexV1 of SEQ ID NO:15;
  • [0173] Ag is a viral or cancer antigen, either identical or different;
  • [0174] x is an integer from 1 to 20, for example from 3, 4, or 5;
  • [0175] CD40L is the binding domain of the ligand of CD40 comprising SEQ ID NO:14 or a functional fragment thereof with at least 90%, 95% or 100% identity to SEQ ID NO:14; and
  • [0176] is a covalent bond.

[0177] In specific embodiments, the PL is a peptide linker preferably ensuring optimal activating properties and yield in cell production.

[0178] In specific embodiments, the -(PL-Ag)x is located at the carboxy terminus of the heavy chain of said CD40 activating antibody-like protein.

[0179] Typically, a schematic representation of an embodiment of said CD40 activating protein is shown in FIG. 1. Preferred embodiments of αCD40Light, αCD40Heavy, and CD40L are further described in the next sections.

[0180] In certain embodiments, peptide linkers may incorporate glycosylation sites or introduce secondary structure. Additionally these linkers may increase the efficiency of expression or stability of the fusion protein and as a result the efficiency of antigen presentation to a dendritic cell. Such linkers may include the flexV1, f1, f2, f3 and/or f4 linkers. These examples and others are discussed in WO 2010/104747, the contents of which are incorporated herein by reference. In particular, flexV1 is a polypeptide of SEQ ID NO:15.

[0181] In a more specific embodiment, said CD40 activating protein comprises PAB3405 CD40 agonist antibody consisting of SEQ ID NO 1 and SEQ ID NO 2.

[0182] In another specific embodiment, said CD40 activating protein comprises PAB3408 CD40 agonist antibody consisting of SEQ ID NO 3 and SEQ ID NO 4.

[0183] In another specific embodiment, said CD40 activating protein consists of a heavy chain polypeptide comprising SEQ ID NO: 5 and a light chain comprising SEQ ID NO 6.

[0184] In another specific embodiment, said CD40 activating protein consists of a heavy chain polypeptide comprising SEQ ID NO: 5 and a light chain comprising SEQ ID NO 8.

[0185] In another specific embodiment, said CD40 activating protein consists of a heavy chain polypeptide comprising SEQ ID NO 9 and a light chain comprising SEQ ID NO 10.

[0186] In another specific embodiment, said CD40 activating protein consists of a heavy chain polypeptide comprising SEQ ID NO 11 and a light chain comprising SEQ ID NO 12.

[0187] In another specific embodiment, said CD40 activating protein consists of a light chain polypeptide of SEQ ID NO 109 and a heavy chain polypeptide of SEQ ID NO:110.

[0188] CD40 activating proteins with amino acid sequences having at least 90%, for example, at least 95%, 96%, 97%, 98%, or 99% identity to any one of the above defined amino acid sequences are also part of the present disclosure.

[0189] The CD40 Agonist Antibody for Use in Preparing the Fusion Protein of Present Disclosure

[0190] The skilled person may use CD40 agonist antibodies already known in the art or generate de novo novel CD40 activating antibodies using antibody screening technologies.

[0191] More specifically, said CD40 agonist antibody (or its antigen-binding fragment) for use in the CD40 activating protein of the present disclosure have one or more of the following advantageous properties:

• • [0192] (i) it binds to CD40 ectodomain with a K_D of 500 nM or less, for example between 50 or less and 500 nM, as measured by SPR binding assay, for example as described in the Examples below;
  • [0193] (ii) it induces the proliferation of B cell, as measured in vitro by flow cytometric analysis, for example as measured with the B cell proliferation assay described in the Examples below; and/or
  • [0194] (iii) it induces the secretion of cytokines, such as IL-6, IL-12, or IL-15, as measured in vitro with a dendritic cell activation assay described in the Examples below.

[0195] In specific embodiments, said CD40 agonist antibody has one or more of the following properties:

• • [0196] (i) it binds to CD40 ectodomain with a K_D of 500 nM or less, for example between 50 and 500 nM, as measured by SPR, for example as described in the Examples below;
  • [0197] (ii) the proliferation of B cell as measured in a B cell proliferation assay with said agonist antibodies can be further increased, typically at least 10 fold, or at least 100 fold, in the presence of a suboptimal dose of soluble CD40L, for example using the assay as described in the Examples below; and/or,
  • [0198] (iii) the secretion of cytokines, such as IL-6, IL-12, or IL-15, can be potentiated, typically at least 10 fold, or at least 100 fold, or at least 1000 fold, in the presence of a suboptimal dose of soluble CD40L, as measured in vitro with a dendritic cell activation assay, for example using the assay described in the Examples below.

[0199] In specific embodiment, a CD40 agonist antibody is an antibody which has CD40 mediated signaling activity in the absence of CD40L in a cell-based assay which is at least similar to the CD40 mediated signaling activity of a reference CD40 agonist antibody as measured in the same cell-based assay, said reference CD40 agonist antibody being typically selected among the following CD40 agonist antibodies: mAb1, mAb2, mAb3, mAb4, mAb5 and mAb6 as described below.

[0200] In specific embodiments, said CD40 agonist antibody does not compete with sCD40L for binding to CD40.

[0201] In specific embodiments, in the presence of a constant suboptimal amount (6 nM) of soluble human CD40L, a CD40 agonist antibody has an EC50 (as measured in the B cell proliferation assay described in the examples) that is between 1 and 200 fold the EC50 measured for CD40 agonist antibody mAb5 (CP-870,893), preferably between and 1 and 150 fold, or between, 1 and 100 fold.

[0202] In other specific embodiments, in the presence of a constant suboptimal amount (6 nM) of soluble human CD40L, a CD40 agonist antibody has an EC50 (as measured in the B cell proliferation assay described in the examples) that is equal or less than the EC50 of mAb 1 (11B6) antibody.

[0203] The relative EC50 values as measured in the B cell proliferation assay are further described in the Examples (see Tables for FIGS. 2 and 3).

[0204] To select novel CD40 agonist antibodies, a variety of methods of screening antibodies have been described in the Art. Such methods may be divided into in vivo systems, such as transgenic mice capable of producing fully human antibodies upon antigen immunization and in vitro systems, consisting of generating antibody DNA coding libraries, expressing the DNA library in an appropriate system for antibody production, selecting the clone that express antibody candidate that binds to the target with the affinity selection criteria and recovering the corresponding coding sequence of the selected clone.

[0205] These in vitro technologies are known as display technologies, and include without limitation, phage display, RNA or DNA display, ribosome display, yeast or mammalian cell display. They have been well described in the Art (for a review see for example: Nelson et al., 2010 Nature Reviews Drug discovery, “Development trends for human monoclonal antibody therapeutics” (Advance Online Publication) and Hoogenboom et al. in Method in Molecular Biology 178:1-37, O'Brien et al., ed., Human Press, Totowa, N.J., 2001). In one specific embodiment, human recombinant CD40 agonist antibodies are isolated using phage display methods for screening libraries of human recombinant antibody libraries with CD40 binding and agonist properties.

[0206] Repertoires of V_H and V_L genes or related CDR regions can be separately cloned by polymerase chain reaction (PCR) or synthesized by DNA synthesizer and recombined randomly in phage libraries, which can then be screened for antigen-binding clones. Such phage display methods for isolating human antibodies are established in the art or described in the examples below. See for example: U.S. Pat. Nos. 5,223,409; 5,403,484; and U.S. Pat. No. 5,571,698 to Ladner et al.; U.S. Pat. Nos. 5,427,908 and 5,580,717 to Dower et al.; U.S. Pat. Nos. 5,969,108 and 6,172,197 to McCafferty et al.; and U.S. Pat. Nos. 5,885,793; 6,521,404; 6,544,731; 6,555,313; 6,582,915 and 6,593,081 to Griffiths et al.

[0207] In a certain embodiment, human antibodies directed against CD40 can be identified using transgenic or transchromosomic mice carrying parts of the human immune system rather than the mouse system. These transgenic and transchromosomic mice include mice referred to herein as HuMAb mice and KM mice, respectively, and are collectively referred to herein as “human Ig mice.”

[0208] The HuMAb mouse (Medarex, Inc.) contains human immunoglobulin gene miniloci that encode un-rearranged human heavy (μ and γ) and K light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous μ and K chain loci (see e.g., Lonberg, et al., 1994 Nature 368(6474): 856-859).

[0209] In another embodiment, human CD40 agonist antibodies can be raised using a mouse that carries human immunoglobulin sequences on transgenes and transchomosomes such as a mouse that carries a human heavy chain transgene and a human light chain transchromosome. Such mice, referred to herein as “KM mice”, are described in detail in PCT Publication WO 02/43478 to Ishida et al.

[0210] Monoclonal antibodies (mAbs) can also be produced by conventional monoclonal antibody methodology e.g., the standard somatic cell hybridization technique of Kohler and Milstein, 1975 Nature 256: 495. Many techniques for producing monoclonal antibody can be employed e.g., viral or oncogenic transformation of B lymphocytes.

[0211] An animal system for preparing hybridomas is the murine system. Hybridoma production in the mouse is a well established procedure. Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art. Fusion partners (e.g., murine myeloma cells) and fusion procedures are also known.

[0212] Chimeric or humanized antibodies can be prepared based on the sequence of a murine monoclonal antibody prepared as described above. DNA encoding the heavy and light chain immunoglobulins can be obtained from the murine hybridoma of interest and engineered to contain non-murine (e.g., human) immunoglobulin sequences using standard molecular biology techniques. For example, to create a chimeric antibody, the murine variable regions can be linked to human constant regions using methods known in the art (see e.g., U.S. Pat. No. 4,816,567 to Cabilly et al.). To create a humanized antibody, the murine CDR regions can be inserted into a human framework using methods known in the art. See e.g., U.S. Pat. No. 5,225,539 to Winter, and U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 to Queen et al.

[0213] It is further contemplated that monoclonal antibodies may be further screened or optimized for their CD40 agonist properties as above defined. In particular, it is contemplated that monoclonal antibodies may have 1, 2, 3, 4, 5, 6, or more alterations in the amino acid sequence of 1, 2, 3, 4, 5, or 6 CDRs of monoclonal antibodies or humanized antibodies provided herein. It is contemplated that the amino acid in position 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of CDR1, CDR2, CDR3, CDR4, CDR5, or CDR6 of the VJ or VDJ region of the light or heavy variable region of antibodies may have an insertion, deletion, or substitution with a conserved or non-conserved amino acid. Such amino acids that can either be substituted or constitute the substitution are disclosed above.

[0214] CD40 agonist antibodies known in the art for use in preparing the CD40 activating proteins of the disclosure include the recombinant CD40 agonist antibodies mAb 1, mAb2, mAb3, mAb4, mAb5 and mAb6, which are structurally characterized by their variable heavy and light chain amino acid and nucleotide sequences as described in the Tables 1 and 2 below:

TABLE 1
Variable heavy and light chain amino acid sequences of mAbl-mAb6
	VH	VL
Antibody	Amino acid sequence	Amino acid sequence
mAb1 [11B6	SEQ ID NO: 21	SEQ ID NO: 22
VH/VkV2]
mAb2	SEQ ID NO: 23	SEQ ID NO: 22
[11B6 VHV3/VkV2]
mAb3	SEQ ID NO: 58	SEQ ID NO: 59
[12B4]
mAb4	SEQ ID NO: 60	SEQ ID NO: 61
[24A3]
mAb5	SEQ ID NO: 62	SEQ ID NO: 63
[CP870893]
mAb 6	SEQ ID NO: 64	SEQ ID NO: 65
[12E12]

TABLE 2
Variable heavy and light chain nucleotide (nt) coding
sequences of mAb1-mAb6
		VH	VL
	Antibody	Nt coding sequence	Nt coding sequence
	mAb1 [11B6	SEQ ID NO: 24	SEQ ID NO: 25
	VH/VkV2]
	mAb2	SEQ ID NO: 26	SEQ ID NO: 25
	[11B6
	VHV3/VkV2]
	mAb3	SEQ ID NO: 66	SEQ ID NO: 67
	[12B4]
	mAb4	SEQ ID NO: 68	SEQ ID NO: 69
	[24A3]
	mAb5	SEQ ID NO: 70	SEQ ID NO: 71
	[CP870, 893]
	mAb 6	SEQ ID NO: 72	SEQ ID NO: 73
	[12E12]

[0215] Other CD40 agonist antibodies which may be used include any chimeric or humanized antibodies comprising the 6 CDRs of the above defined mAb1, mAb2, mAb3, mAb4, mAb5 or mAb6.

[0216] Examples of the amino acid sequences of the VH CDR1s (also called HCDR1), VH CDR2s (also called HCDR2), VH CDR3s (also called HCDR1), VL CDR1s (also called LCDR1), VL CDR2s (also called LCDR2), VL CDR3s (also called HCDR3) of some CD40 agonist antibodies according to the disclosure are shown in Table 3.

[0217] In Table 3, the CDR regions of the antibodies of the present disclosure are delineated using the Kabat numbering (Kabat et al., 1992, hereafter “Kabat et al.”).

TABLE 3
CDR regions of mAb1, mAb2, mAb3, mAb4,
mAb5 and mAb6 according to Kabat numbering
Original
antibody	HCDR1	HCDR2	HCDR3	LCDR1	LCDR2	LCDR3
mAb1 [11B6	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
VH/VkV2]	NO: 27	NO: 28	NO: 29	NO: 30	NO: 31	NO: 32
mAb2	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
[11B6	NO: 27	NO: 28	NO: 29	NO: 30	NO: 31	NO: 32
VHV3/VkV2]
mAb3	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
[12B4]	NO: 74	NO: 75	NO: 76	NO: 77	NO: 78	NO: 79
mAb4	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
[24A3]	NO: 80	NO: 81	NO: 82	NO: 83	NO: 84	NO: 85
mAb5	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
CP870893	NO: 86	NO: 87	NO: 88	NO: 89	NO: 90	NO: 91
mAb6	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID	SEQ ID
[12E12]	NO: 92	NO: 93	NO: 94	NO: 95	NO: 96	NO: 97

[0218] In specific embodiments, a CD40 agonist antibody is selected from the following antibodies:

• • [0219] (i) a humanized antibody comprising the 6 CDRs of mAb1, mAb2, mAb3, mAb4, mAb5 or mAb6;
  • [0220] (ii) a humanized antibody comprising VH and VL domains of SEQ ID NO:21 and SEQ ID NO:22 respectively;
  • [0221] (iii) an antibody that competes for binding to CD40 expressing cells with at least one of the antibodies identified in (i) or (ii),
  • [0222] (iv) an antibody that binds to the same epitope as one of the antibodies identified in (i) or (ii).

[0223] In particular, in specific embodiments, a CD40 agonist antibody binds to an epitope region comprising or consisting of amino acid residues 36-59 of SEQ ID NO:13 (CDR1 region of CD40). More specifically, it binds to an epitope region comprising or consisting of amino acid residues 50-58 of CD40. In certain embodiments, a CD40 agonist antibody has direct contact to at least the following amino acid residues: E56 and E58. In other embodiments, a CD40 agonist antibody has direct contact to at least the following amino acid residues: D50 and E58.

[0224] Other examples of CD40 agonist antibodies are described in WO2010/009346, WO2010/104747 and WO2010/104749. Other anti-CD40 agonist antibodies in development include:

[0225] CP-870,893—a fully human IgG2 CD40 agonist antibody developed by Pfizer. It binds CD40 with a K_D of 3.48×10⁻10 M, but does not block binding of CD40L (see e.g., U.S. Pat. No. 7,338,660).

[0226] SGN-40 is a humanized IgG1 antibody developed by Seattle Genetics from mouse antibody clone S2C6, which was generated using a human bladder carcinoma cell line as the immunogen. It binds to CD40 with a KD of 1.0×10⁻9 M and works through enhancing the interaction between CD40 and CD40L, thus exhibiting a partial agonist effect (Francisco J A, et al., Cancer Res, 60: 3225-31, 2000).

[0227] Also, US20120301488A1 by APEXIGEN describes another anti-CD40 agonstic mAb. AbbVie Biotherapeutics Inc United States Patent Application 20170342159 describes another agonist antibody.

[0228] CDX-1140, an agonist CD40 antibody by Celldex is another agonist antibody.

[0229] Any other known antibodies can be potentially combined with linked CD40L using the method revealed in this application to increase their biological activity.

[0230] Nucleic Acid Molecules Encoding the CD40 Activating Proteins of the Disclosure

[0231] Also disclosed herein are the nucleic acid molecules that encode the CD40 activating proteins of the present disclosure.

[0232] Examples of nucleic acid molecules are those encoding the variable light and heavy chain amino acid sequences of the CD40 activating antibody-like proteins as disclosed in the previous section, and using the genetic code and, optionally taking into account the codon bias depending on the host cell species.

[0233] Typically, nucleic acid molecules encoding the CD40 activating protein of the disclosure comprises coding sequences of CD40 agonist antibody consisting of SEQ ID NO 1 and SEQ ID NO 2, for example the nucleic acids of SEQ ID NO:33 and SEQ ID NO:34 respectively.

[0234] In specific embodiments, nucleic acid molecules encoding the CD40 activating protein comprises coding sequences of CD40 agonist antibody consisting of SEQ ID NO 3 and SEQ ID NO 4, for example the nucleic acids of SEQ ID NO:35 and SEQ ID NO:36 respectively.

[0235] In another specific embodiment, nucleic acid molecules encoding the CD40 activating protein comprising coding sequences encoding a heavy chain polypeptide comprising SEQ ID NO 5 and a light chain comprising SEQ ID NO 6, for example the nucleic acids of SEQ ID NO:37 and SEQ ID NO:38 respectively.

[0236] In another specific embodiment, nucleic acid molecules encoding the CD40 activating protein comprise coding sequences of a heavy chain polypeptide comprising SEQ ID NO: 5 and coding sequences of a light chain comprising SEQ ID NO: 8 for example the nucleic acids of SEQ ID NO:39 and SEQ ID NO:37 respectively.

[0237] In another specific embodiment, nucleic acid molecules encoding the CD40 activating protein comprise coding sequences of a heavy chain polypeptide comprising SEQ ID NO: 9 and coding sequences of a light chain comprising SEQ ID NO: 10 for example the nucleic acids of SEQ ID NO:41 and SEQ ID NO:42 respectively.

[0238] In another specific embodiment, nucleic acid molecules encoding the CD40 activating protein comprise coding sequences of a heavy chain polypeptide comprising SEQ ID NO: 11 and coding sequences of a light chain comprising SEQ ID NO: 12 for example the nucleic acids of SEQ ID NO:43 and SEQ ID NO:44 respectively.

[0239] In another specific embodiment, nucleic acid molecules encoding the CD40 activating protein comprise coding sequences of a heavy chain polypeptide comprising SEQ ID NO: 110 and coding sequences of a light chain comprising SEQ ID NO: 109 for example the nucleic acids of SEQ ID NO:114 and SEQ ID NO:113 respectively.

[0240] Nucleic acids encoding CD40 activating proteins of the disclosure with nucleotide sequences having at least 90%, for example, at least 95%, 96%, 97%, 98%, or 99% identity to any one of the above defined nucleotides sequences are also part of the present disclosure.

[0241] The present disclosure also pertains to nucleic acid molecules that derive from the latter sequences having been optimized for protein expression in mammalian cells, for example, CHO or HEK cell lines.

[0242] The nucleic acids may be present in whole cells, in a cell lysate, or may be nucleic acids in a partially purified or substantially pure form. A nucleic acid is “isolated” or “rendered substantially pure” when purified away from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis and others well known in the art (Ausubel et al., 1988). A nucleic acid of the disclosure can be, for example, DNA or RNA and may or may not contain intronic sequences. In an embodiment, the nucleic acid may be present in a vector such as a phage display vector, or in a recombinant plasmid vector.

[0243] Nucleic acids of the disclosure can be obtained using standard molecular biology techniques. Once DNA fragments encoding, for example, VH and VL segments are obtained, these DNA fragments can be further manipulated by standard recombinant DNA techniques, for example to convert the variable region genes to full-length antibody chain genes, to Fab fragment genes or to an scFv gene.

[0244] Generation of Transfectomas Producing CD40 Activating Proteins

[0245] The CD40 activating proteins of the present disclosure can be produced in a host cell transfectoma using, for example, a combination of recombinant DNA techniques and gene transfection methods as is well known in the art (Morrison, 1985).

[0246] For example, to express the CD40 activating proteins, DNAs encoding said CD40 activating proteins can be obtained by standard molecular biology or biochemistry techniques (e.g., DNA chemical synthesis, PCR amplification or cDNA cloning using a hybridoma that expresses the antibody of interest) and the DNAs can be inserted into expression vectors such that the genes are operatively linked to transcriptional and translational control sequences. In this context, the term “operatively linked” is intended to mean that a gene is ligated into a vector such that transcriptional and translational control sequences within the vector serve their intended function of regulating the transcription and translation of the CD40 activating protein. The expression vector and expression control sequences are chosen to be compatible with the expression host cell used. If the CD40 activating proteins include distinct polypeptide, for example one sequence encoding a heavy chain of a CD40 activating antibody-like protein as disclosed in the above sections and another encoding a light chain of said CD40 activating antibody-like protein, the heavy and light chain encoding genes can be inserted into separate vector or, more typically, both genes are inserted into the same expression vector. The genes are inserted into the expression vector by standard methods (e.g., ligation of complementary restriction sites on the protein gene and vector, or blunt end ligation if no restriction sites are present).

[0247] Signal peptides may be further used for secretion of the polypeptides out of the expression cells, such as an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin protein).

[0248] In addition, the recombinant expression vectors disclosed herein carry regulatory sequences that control the expression of the CD40 activating proteins in a host cell. The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of the respective genes. It will be appreciated by those skilled in the art that the design of the expression vector, including the selection of regulatory sequences, may depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. Regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus (e.g., the adenovirus major late promoter (AdMLP)), and polyoma. Alternatively, nonviral regulatory sequences may be used, such as the ubiquitin promoter or P-globin promoter. Still further, regulatory elements composed of sequences from different sources, such as the SRa promoter system, which contains sequences from the SV40 early promoter and the long terminal repeat of human T cell leukemia virus type 1.

[0249] Additionally, the recombinant expression vectors of the present disclosure may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see, e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017, all by Axel et al.). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr-host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).

[0250] For expression of the CD40 activating proteins, the expression vector is transfected into a host cell by standard techniques. The various forms of the term “transfection” are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate precipitation, DEAE-dextran transfection and the like. It is theoretically possible to express the binding proteins of the present disclosure in either prokaryotic or eukaryotic host cells. Expression of recombinant proteins in eukaryotic cells, for example mammalian host cells, yeast or filamentous fungi, is discussed because such eukaryotic cells, and in particular mammalian cells, are more likely than prokaryotic cells to assemble and secrete a properly folded and immunologically active antibody.

[0251] In one specific embodiment, a cloning or expression vector according to the disclosure comprises one or more of the nucleics acids as described in the previous section, operatively linked to suitable promoter sequences.

[0252] Mammalian host cells for expressing the recombinant antibodies of the disclosure include Chinese Hamster Ovary (CHO cells) including dhfr-CHO cells (described in Urlaub and Chasin, 1980) used with a DHFR selectable marker, CHOK1 dhfr+ cell lines, NSO myeloma cells, COS cells and SP2 cells, for example GS CHO cell lines together with GS Xceed™ gene expression system (Lonza), or HEK cells. When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient for expression of the antibody in the host cells and, optionally, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered and purified for example from the culture medium after their secretion using standard protein purification methods.

[0253] In one specific embodiment, the host cell of the disclosure is a host cell transfected with an expression vector having the coding sequences of the CD40 activating proteins as disclosed in the previous section.

[0254] The latter host cells may then be further cultured under suitable conditions for the expression and production of said CD40 activating protein.

[0255] Pharmaceutical Compositions

[0256] In another aspect, the present disclosure provides a composition, e.g., a pharmaceutical composition, containing an CD40 activating protein, formulated together with a pharmaceutically acceptable carrier.

[0257] Pharmaceutical compositions disclosed herein also can be administered in combination therapy, i.e., combined with other agents. For example, the combination therapy can include CD40 activating protein of the present disclosure, combined with at least one anti-viral, anti-inflammatory, vaccine adjuvant and/or another anti-proliferative agent.

[0258] As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The carrier should be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). In one embodiment, the carrier should be suitable for subcutaneous route. Depending on the route of administration, the active compound, i.e., CD40 activating protein, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

[0259] Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. (Remington and Gennaro, 1995). Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc.

[0260] The form of the pharmaceutical compositions, the route of administration, the dosage and the regimen naturally depend upon the condition to be treated, the severity of the illness, the age, weight, and sex of the patient, etc.

[0261] The pharmaceutical compositions of the disclosure can be formulated for a topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular administration and the like.

[0262] Preferably, the pharmaceutical compositions contain vehicles, which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.

[0263] The doses used for the administration can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the relevant pathology, or alternatively of the desired duration of treatment.

[0264] To prepare pharmaceutical compositions, an effective amount of the CD40 activating protein may be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

[0265] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders or lyophilisates for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[0266] Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0267] Pharmaceutically acceptable salts which may be used in the formulation include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

[0268] The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.

[0269] Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0270] The preparation of more, or highly concentrated solutions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small tumor area.

[0271] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.

[0272] For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

[0273] The CD40 activating protein may be formulated within a therapeutic mixture to comprise about 0.0001 to 1.0 milligrams, or about 0.001 to 0.1 milligrams, or about 0.1 to 1.0 or even 1.0 to about 10 milligrams per dose. Multiple doses can also be administered.

[0274] Vaccine Compositions

[0275] The disclosure also relates to a vaccine comprising a CD40 activating protein of the disclosure and a pharmaceutically acceptable vehicle.

[0276] As used herein, the term “vaccine” is intended to mean a composition which can be administered to humans or to animals in order to induce an immune response; this immune response can result in a production of antibodies or simply in the activation of certain cells, in particular antigen-presenting cells, T lymphocytes and B lymphocytes. In certain embodiments the vaccine is capable of producing an immune response that leads to the production of neutralizing antibodies in the patient with respect to the antigen provided in the vaccine. The vaccine can be a composition for prophylactic purposes or for therapeutic purposes, or both.

[0277] Vaccines may include an effective amount of the CD40 activating proteins of the disclosure, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such compositions can also be referred to as inocula. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions. The vaccine compositions of the present disclosure may include classic pharmaceutical preparations. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0278] In addition, if desired, the vaccine can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants that may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, MTP-PE and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. Other examples of adjuvants include DDA (dimethyldioctadecylammonium bromide), Freund's complete and incomplete adjuvants and QuilA. In addition, immune modulating substances such as lymphokines (e.g., IFN-[gamma], IL-2 and IL-12) or synthetic IFN-[gamma] inducers such as poly I:C or poly ICLC (Hiltonol) can be used in combination with adjuvants described herein.

[0279] In certain embodiments, the adjuvant may be selected among poly ICLC, CpG, LPS, Immunoquid, PLA, GLA or cytokine adjuvants such as IFNα. In other embodiments the adjuvant may be a toll-like receptor agonist (TLR). Examples of TLR agonists that may be used comprise TLR1 agonist, TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, TLR6 agonist, TLR7 agonist, TLR8 agonist or TLR9 agonist.

[0280] The vaccine preparation of CD40 activating protein as the active immunogenic ingredient, may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to infection can also be prepared. The preparation may be emulsified, encapsulated in liposomes. The active immunogenic ingredients are often mixed with carriers which are pharmaceutically acceptable and compatible with the active ingredient.

[0281] Methods of Use of the CD40 Activating Proteins of the Disclosure

[0282] By eliciting an immune response to the antigen(s) present in the CD40 activating proteins, the CD40 activating proteins of the disclosure may be useful as a drug, in particular for treating or preventing cancer or infectious disorders.

[0283] In some embodiments, the CD40 activating proteins may be used in a method for treating or preventing from a viral infection or cancer disorder in a subject comprising administering a CD40 activating protein of the disclosure to the subject.

[0284] Yet further aspects relate to a method for eliciting and/or enhancing B cell and/or T cell response against a viral or tumor associated antigen, in a subject in need thereof, comprising administering to said subject in need thereof, a CD40 activating protein or vaccine of the disclosure.

[0285] Further aspects relate to a method for inducing IgG binding antibody responses to the antigens in a subject in need thereof, the method comprising administering the CD40 activating protein of the disclosure or the vaccine composition of the disclosure.

[0286] In some embodiments, the method further comprises administration of an immunostimulant. In some embodiments, the immunostimulant is administered sequentially or concomitantly to a vaccine or therapeutic composition.

[0287] In some embodiments, the immunostimulant is mixed with a vaccine composition extemporaneously prior to injection of the vaccine composition to the subject.

[0288] Additionally, the methods of the disclosure may also comprise the administration of one or more adjuvants. The adjuvants may be attached or conjugated directly or indirectly to one or more of the vaccine components, such as an antigen or CD40 activating protein. In other embodiments, the adjuvants may be provided or administered separately from the vaccine composition. In certain embodiments the adjuvant is poly ICLC, CpG, LPS, Immunoquid, PLA, GLA or cytokine adjuvants such as IFNα. In other embodiments the adjuvant may be a toll-like receptor agonist (TLR). Examples of TLR agonists that may be used comprise TLR1 agonist, TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, TLR6 agonist, TLR7 agonist, TLR8 agonist or TLR9 agonist.

[0289] In some embodiments, the administration comprises intradermal, intramuscular, or subcutaneous administration.

[0290] In some embodiments, the viral vaccine, e.g., a CD40 activating protein comprising a viral antigen, is used in a method for potentiating an immune response to at least one viral epitope comprising administering to a patient such viral vaccine as described herein.

[0291] In some embodiments, such viral vaccine is used to prevent healthy subject to be infected by said virus, comprising administering such viral vaccine of the present disclosure, e.g. to a healthy subject, not infected by said virus (preventive treatment). In other embodiments, the viral vaccine of the present disclosure is used in a method of treating a patient in the early stages of the viral infection comprising administering to a patient said viral vaccine.

[0292] It is contemplated that at least one viral antigen elicits at least one of a humoral and/or a cellular immune response in a host, preferably a human patient or a primate.

[0293] Administration of vaccines or pharmaceutical compositions according to the present disclosure will be via any common route so long as the target tissue is available via that route in order to maximize the delivery of antigen to a site for maximum (or in some cases minimum) immune response. Administration of vaccines will generally be by orthotopic, intradermal, mucosally, subcutaneous, intramuscular, intraperitoneal or intravenous injection. Other areas for delivery include: oral, nasal, buccal, rectal, vaginal or topical. Vaccines of the disclosure are preferably administered parenterally, by injection, for example, either subcutaneously or intramuscularly.

[0294] Vaccines or pharmaceutical compositions of the present disclosure may be administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be administered depends on the subject to be treated, including, e.g., capacity of the subject's immune system to synthesize antibodies, and the degree of protection or treatment desired. Suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination with a range from about 0.1 mg to 1000 mg, such as in the range from about 1 mg to 300 mg, or in the range from about 10 mg to 50 mg.

[0295] Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and may be peculiar to each subject. It will be apparent to those of skill in the art that the therapeutically effective amount of CD40 activating proteins of this disclosure will depend, inter alia, upon the administration schedule, the unit dose of antigen administered, whether the CD40 activating protein is administered in combination with other therapeutic agents, the immune status and health of the recipient, and the therapeutic activity of the particular CD40 activating protein.

[0296] A vaccine may typically be given in a single dose schedule or in a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may include, e.g., 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent dose(s) after several months. Periodic boosters at intervals of 1-5 years, usually 3 years, are desirable to maintain the desired levels of protective immunity. The course of the immunization can be followed by in vitro proliferation assays of peripheral blood lymphocytes (PBLs) co-cultured with the antigen, and by measuring the levels of IFN-[gamma] released from the primed lymphocytes. The assays may be performed using conventional labels, such as radionucleotides, enzymes, fluorescent labels and the like. These techniques are known to one skilled in the art and can be found in U.S. Pat. Nos. 3,791,932, 4,174,384 and 3,949,064.

[0297] A vaccine may be provided in one or more “unit doses”. Unit dose is defined as containing a predetermined-quantity of the vaccine calculated to produce the desired responses in association with its administration, i.e., the appropriate route and treatment regimen. The quantity to be administered, and the particular route and formulation, are within the skill of those in the clinical arts. The subject to be treated may also be evaluated, in particular, the state of the subject's immune system and the protection desired. A unit dose need not be administered as a single injection but may include continuous infusion over a set period of time. The amount of vaccine delivered can vary from about 0.001 to about 0.05 mg/kg body weight, for example between 0.1 to 5 mg per subject.

[0298] Further aspects relate to a kit comprising a CD40 activating protein of the disclosure, a nucleic acid of the disclosure, an expression vector of the disclosure, or a host cell of the disclosure, and; optionally, instructions for use of the kit. The kit may be used to perform the methods described herein. In some embodiments, the kit is for eliciting a T cell response and/or a B cell response in a subject; wherein the kit comprises the CD40 activating protein of the disclosure or the vaccine of the disclosure.

[0299] The disclosure will be further illustrated by the following examples. However, these examples should not be interpreted in any way as limiting the scope of the present invention.

[0331] 1. Methods

[0332] Method for MDDC Preparation—Protocol

[0333] 1 M human blood monocytes/mL were cultured in a six well plate (2 mL per well) in RPMI medium+10% FBS+10 ng/mL human IL-4+100 ng/mL human GM-CSF.

[0334] Half of the medium was changed at day 2 and at day 4, maintaining the same concentration of IL-4 and GM-CSF. Cells were harvested at day 5 without scraping but with gentle washing and plated in a 96 well v bottom plate in 200 uL at 100,000 cells per well. Typically, 1M DCs were derived from 2M monocytes. Different concentrations of the anti-CD40 mAbs or anti-CD40 IgG4 fusion proteins and 10 ng/mL IL-4 and 100 ng/mL GM-CSF were added, and after 24 or 48 hours supernatants were tested for secreted cytokines and the cells were stained for cell surface activation markers.

[0335] Surface Plasmon Resonance (SPR) Binding Assay—PROTOCOL

[0336] Surface plasmon resonance (SPR) assay binding measurements were performed on a SensiQ Pioneer instrument (SensiQ Technologies, Inc., Oklahoma City, Okla., USA). Protein A or Protein G (100 μg/mL in 10 mM NaAc pH4.5) were immobilized using amine coupling chemistry on COOH2 or COOH5 sensor chips at 25° C. following the manufacturer's recommended protocols. Running buffer was 10 mM HEPES, 3.4 mM EDTA, 0.005% Tween 20, 8.8 g/L NaCl, pH 7.5. Subsequently, Channel 1 was used to inject anti-CD40 mAbs at a concentration of 125 nM (Injection Fast, 10 μL/min for 4 min); Channel 1-2 were used to inject a dilution series of cohesin-human CD40 ectodomain protein (P3398) (25, 12.5, 6.25, 3.125, 1.6, 0.8 nM at 25 uL/min for 2 min); finally, surfaces were regenerated through injection of 20 mM NaOH for 1 min (25 μL). The binding data were analyzed with Qdat software (SensiQ Technologies, Inc.).

[0337] T Cell Expansion—PROTOCOL

[0338] After been thawed and washed, 2M PBMC were cultured at 37′C in presence of O₂ in 1 mL cRPMI+10% AB serum in a 24 well flat bottom plate. Cells were treated with different concentrations (1 nM, 0.1 nM and 0.01 nM) of αCD40 abs or controls. In order to have enough T cells at the end of the culture, the conditions were done in triplicate. At day 2, 1 mL of cRPMI+10% AB serum and IL-2 at a final concentration of 100 U/mL were added to each well. Half media was changed at day 4 and at day 6 adding fresh IL-2 without doubling the concentration. Cells were let rest until day 10, when they were harvested and washed twice in PBS with 2 mM EDTA. Cells were subsequently resuspended in cRPMI+10% AB serum in a volume which allowed an equal distribution of the cells between the conditions needed, with a final volume of 200 μL per condition, counted and let them rest 0/N at 37′C in presence of O₂ in 50 mL tubes.

[0339] At day 11, cells were plated in a 96 well plate V bottom and re-stimulated with 2 μM peptides or controls for one hour at 37′C in presence of O₂. After one hour, 0.175 μL of Golgi Stop and 0.45 μL of Brefeldin in a volume of 50 μL of cRPMI+10% AB serum were added in each well and the cells were incubated for additional 4 hours. Subsequently, cells were spin down and ICS staining was performed using the following antibodies: αCD3 BV711, αCD4 Pe-Cy7, αCD8 Pacific Blue, αCD56 Pe-Cy5, αCD16 APC-H7, αCD45 Pacific Orange, αNKG2C Alexa Fluor 700, αNKG2D PECF594, αCD69 FITC, αTNF-α APC, αINF-γ PE. Aqua was used as viability dye. After staining, cells were resuspended in BD fixative and analyzed at BD LSR II Flow Cytometer.

[0340] B Cell Proliferation Assay—Protocol

[0341] Human PBMCs were thawed using benzonaide 1:10 in RPMI medium (1 μL in 5 mL), the cells were wash 2× in PBS and resuspended to have a Cf 10M/mL in PBS, then stained with CSFE Cf 1.25 μM (Ci=5 mM) for 7 min RT in the dark. Labeling was stopped by adding 10 mL FBS and leave the cells in the cold for 5 min, then washed 2× in PBS, and resuspended in RPMI medium with 10% FBS to distribute 1M cells/mL per well. Human IL-4 (10 ng/mL) and human IL-21 (5 ng/mL) were added to the cells along with various amounts of anti-CD40 mAbs or anti-CD40 IgG4 fusion proteins. 6 Days. CD19 APC: 1 μl; CD27 APC-H7: 1 μl; CD38 PE-Cy7: 0.5 μl; Live/Dead Aqua: 1 μl.

[0342] Dendritic Cell Activation Assay—Protocol

[0343] 1 M human blood monocytes/mL were cultured in a six well plate (2 mL per well) in RPMI medium+10% FBS+10 ng/mL human IL-4+100 ng/mL human GM-CSF. Half of the medium was changed at day 2 and at day 4, maintaining the same concentration of IL-4 and GM-CSF. Cells were harvested at day 5 without scraping but with gentle washing and plated in a 96 well v bottom plate in 200 μL at 100,000 cells per well. Typically, 1M DCs were derived from 2M monocytes. Different concentrations of the anti-CD40 mAbs or anti-CD40 IgG4 fusion proteins and 10 ng/mL IL-4 and 100 ng/mL GM-CSF were added, and after 24 or 48 hours supernatants were tested for secreted cytokines and the cells were stained for cell surface activation markers.

[0344] T Cell Expansion Assay with HIV5 Long Peptides: ICS—Protocol

[0345] All culture is done in 10% AB (unfiltered) in cRPMI:

• • [0346] cRPMI
  • [0347] Hepes (1M) [12.5 ml per 500 ml]
  • [0348] NEAA (10×) [5 ml per 500 ml]
  • [0349] 2ME (1000×) [450 μl per 500 ml; 50 uM final]
  • [0350] NaPyruvate (10×) [5 ml per 500 ml]
  • [0351] Pen Strep (10,000 U/10,000 U) [5 ml per 500 ml]
  • [0352] pH to 7.4 with NaOH

[0353] Thaw cells with 10% AB cRPMI (with 50 U benzonase in initial dilution of cells) Wash 2× with 1×PBS, 2 mM EDTA. Resuspend cells in 10% AB cRPMI at a concentration of 2×10e6/ml in a 50 ml loose capped tube and allow cells to rest overnight, at 37C CO2 5%.

[0354] Next day (Day 0): Recount and adjust, based on viability/density, to 2×10e6/ml (per well)*

[0355] Day 0: Plate cells in 24 well plate:

[0356] Target for about 6 wells per test molecule condition (so you have enough cells at end of T cell expansion—You also need a set of ‘cells only’ without test molecule, as control for re-stimulation)

• • [0357] (Typically this will require 6×10e7 donor PBMC's, if testing 4 different test molecules and a negative cell only control)

[0358] Plate cells in a 24 well plate at 2×10e6/well (1 ml at set up)* in 10% AB cRPMI Add test molecules at 1 nM “final”**

• • [0359] this can be done in 50 ul vol to add to the 1 ml of cells
  • [0360] OR adjust cell vol for ‘equal vol’ addition of cells and test molecules (500 μl+500 ul)*
  • [0361] **Range for test molecules has been tested between 30 nM and 0.1 nM: For our comparative vaccine assessment, we are using 1 nM, final.
  • [0362] Make fresh from concentrated stock and do not store at low protein concentrations.

[0363] Day 2: Following culture set up and protein stimulation, add 1 ml of 10% AB cRPMI containing IL2 (so that final IL-2 concentration in well is 100 U/ml)

[0364] Day 4: Remove 1 ml and add 1 ml of 100 U/ml IL2 in 10% AB cRPMI

[0365] Day 6: Remove 1 ml and add 1 ml of 100 U/ml IL2 in 10% AB cRPMI

[0366] Day 8: Harvest all pools per test molecule condition (depending on test molecule, cell number and type/morphology will vary). Wash away IL2 (2× wash with 1×PBS, 2 mM EDTA). Resuspend cells in 10% AB cRPMI at a concentration of 2×10e6/ml in a 50 ml loose capped tube and allow cells to rest overnight, at 37C CO2 5%.

[0367] Day 9: Filter (cells aggregate with CD40L constructs), count and dispense equal amount of cells (per total cells accumulated per donor) to allow for re-stimulation with peptides. (Cell count/viability will vary per PBMC donor; peptide conditions remain the same) Typically, cells are about 1-5 million per test point, depending on the donor. Cells will be plated at 100 ul vol.

[0368] Set up peptide stimulation in a 96 well-V-bottom plate: 100 μl of cells (˜1-5×10e6 per 100 μl)+100 μl of peptide (or solvent/control SEB) in V-bottom 96 well plate: (7 conditions divided across each donor)

[0369] Solvent (highest vol of highest amount of peptide used), Peptides at 10 uM (can use at 2 uM to 10 uM), SEB at 2 μg/ml. 1 hour at 37C, CO2 5%.

[0370] After 1 hour of stimulation at 37C, CO2 5%, add 50 μl of 10% AB cRPMI media containing 0.175 μl Golgi stop/0.45 ul of BrefeldinA: (BD Golgi Stop, Cat 51-2092KZ; BrefeldinA, Cat 420601)

[0371] After 4 hours at 37C, CO2 5%, proceed with Intracellular staining:

[0372] Intracellular Staining Protocol:

• • [0373] Continuing in 96 well V bottom plate, post peptide re-stimulation, Golgi/BFA block:
  • [0374] Wash cells (1× w/200 μl 1×PBS): (Cfg 1600 RPM 10 min; flick plate to remove wash)
  • [0375] Resuspend cells in 50 μL Aqua* (1 ul Aqua/50 μl of 1×PBS per sample needed) for 20 min at 4′C.
  • [0376] Wash cells (1× in 200 μl with FACS Buffer): (Cfg 1600 RPM 10 min; flick plate to remove wash)
  • [0377] Stain cells in a cocktail of cell surface markers: (αCD3 Per-CP 3 μL, αCD4 PE-Cy7 0.5 μL and αCD8 Pacific Blue 1 μL) in a total volume of 50 μL/sample in FACS Buffer for 30 min in ice.
  • [0378] Wash cells (2× with FACS Buffer): (Cfg 1600 RPM 10 min; flick plate to remove wash)
  • [0379] Resuspend cells in 200 μL of Cytofix/Cytoperm** solution for 20 min at 4′C.
  • [0380] Subsequently, spin cells, then wash cells 2× in 1× Filtered (0.45 μm) Perm/Wash** solution
  • [0381] Stain cells in a cocktail of anti-cytokines: (αTNFα APC 1 μL and αINFY PE 2 μL) in a total volume of 50 μL Perm/Wash**/sample.
  • [0382] Incubate for 30 min at RT
  • [0383] Wash cells (2× with Perm/Wash** buffer): (Cfg 1600 RPM 10 min; flick plate to remove wash)
  • [0384] Resuspend in BD Fixative (˜200 μl per sample).

[0385] **BD Fixation/Permeablization Kit Cat #554714

[0386] FACS Buffer: PBS+2% FCS or BSA+2 mM EDTA

[0387] BD Fixative Stabilizing Fixative 3× concentrate: 1:3 in water Cat #338036

[0388] *Aqua Live/Dead Invitrogen L34966 (reconstitute 50 ul DMSO per tube, use 1 μl/sample)

[0389] CD40 Receptor Cluster Formation Assay—Protocol.

[0390] ExpiCHO-S cells (Thermo Fisher) stably expressing a human CD40-eGFP or a human CD40-mCherry fusion protein were used as a model to study CD40 cluster formation. The cells were incubated in CD CHO/M5 media (Gibco) at a concentration of 1E6 cells/mL in a 6 well plate with rounded cover slides of 25 mm diameter (Electron Microscopy Science) at 37° C. in the presence of 10 nM anti-CD40 antibody. After 1 hour the cover slides were gently washed with PBS twice and then resuspended in 1% PFA (Thermo Fisher) for 10 min at room temperature. Two more washes in PBS followed, and finally the cover slides were mounted on super frosted microscope slides (Fisherbrand) using ProLong Gold antifade reagent with DAPI (Invitrogen). The slides were left o/n at room temperature in the dark. The day after, the slides were imaged by Leica TCS SP5 Confocal Microscopy and subsequently analyzed with ImageJ software.

[0391] Anti-CD40 mAb Internalization Assay Protocol.

[0392] CHO cells stably transfected with a CET 1019 HS-puro-Scel vector (Millipore Sigma) carrying a human CD40 cDNA insert (NM_001250.6 residues 31 to 864, C928) were grown in CD CHO/M5 media (Gibco) with puromycin selection to establish a bulk stably transfected cell population. Cells were dispensed in culture media with 1% BSA (250K in 50 μl) in V bottom 96 well plates and 100 nM of each test mAb fused at the H-chain C-terminus to a flex V1 Doc Var1 module (Flamar et al., 2012) in non-covalent association with a Cohesin-mCherry fusion protein (C3808, LDITH6 residues fused to a Cohesin domain from cellulosomal-scaffolding protein A [Hungateiclostridium thermocellum] WP_065674352.1 residues 1044-1213 with a f1 flexible linker AVY25163.1 residues 580-608 to mCherry ANF29837.1 residues 330-562 preceded by codons encoding ML and followed by a KEPEA sequence used for C-tag affinity matrix CaptureSelect™ (Thermo Fisher, 191307005) purification of the encoded secreted protein. The tested antibodies saturate CD40 binding sites on these cells at 100 nM (data not shown). At 30 min intervals, the labeled antibody complex was added to cells kept at 37° C. in a cell culture incubator, and at the last (zero) time point an equal volume of ice cold PBS was added to all time points with centrifugation at 1600 rpm for 6 min with liquid removal by flicking. Then 110 μl of cold PBS was added to one time course row (for total binding analysis) and 100 μl of ice cold 0.1M Glycine, 0.1 M NaCl pH 2.5 was added to a parallel time course row (i.e, acid stripping treatment to selectively remove cell surface bound mAb). After 1 min, 10 μl of 1M Tris HCl pH 9 was added to the acid treatment row to neutralize the acid and a further 100 μl cold PBS was added to all rows followed by centrifugation at 1600 rpm for 6 min with liquid removal by flicking. Note that mCherry fluorescence is not compromised by the acid treatment in this time frame (data not shown). After a final wash in PBS, cells were resuspended in 100 μl of PBS and 75 μl was dispensed into Black Fluor Micro 2 plates (Thermo Fisher) for reading fluorescence at Ex 570_Em 625 nM in a SpectraMax Paradigm instrument (Molecular Devices).

SEQUENCE NAMING CONVENTION EXEMPLIFIED:
11B6-5
PAB3405
rAB-pIRES2[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-]
rAB-IRES2-CI2[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]
C3677 rAB-pIRES2[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C
SEQ ID NO: 1
EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPY
NGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGT
TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
AS-
+C3862 rAB-IRES2-CI2
C3682 rAB-IRES2-CI2[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]
SEQ ID NO: 2
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKV
SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAS-
PAB3408
11B6-8
rAB-pIRES2[mAnti-CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
rAB-IRES2-CI2[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]
C3678 rAB-pIRES2[mAnti-CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
SEQ ID NO: 3
EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWIGRINPY
NGATSYNQNFKDRVTLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGT
TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
AS
C3682 rAB-IRES2-CI2[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]
SEQ ID NO: 4
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKV
SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAS
From these two were derived the two variants with CD40L attached:
PAB3470
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
hCD40Ligand]
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C]
C3724rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
hCD40Ligand]
SEQ ID NO: 5
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKV
SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECASQ
TPTNTISVTPTNNSTPTNNSNPKPNPASMQKGDQNPQIAAHVISEASSKTTSVLQW
AEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCL
KSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGT
GFTSFGLLKL
+C3725 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C]
SEQ ID NO: 6
EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPY
NGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGT
TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
AS-
PAB3471
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-vl-hCD40Ligand]
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
C3724 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-vl-
hCD40Ligand]
SEQ ID NO: 5
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKV
SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECASQ
TPTNTISVTPTNNSTPTNNSNPKPNPASMQKGDQNPQIAAHVISEASSKTTSVLQW
AEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCL
KSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGT
GFTSFGLLKL
+C3726 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
SEQ ID NO: 8
EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMEIWVRQAPGQGLEWIGRINPY
NGATSYNQNFKDRVTLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGT
TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
AS
We selected PAB3470 to attach HIV-5pep
PAB3499 (no CD40L)
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-Flex-vl-Pep-gag17-
f1-gag253-f2-nef116-f3-nef66-f4-pol158]
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]
C3735 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-Flex-v1-Pep-
gag17-f1-gag253-f2-nefl16-f3-nef66-f4-pol158]
SEQ ID NO: 9
EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPY
NGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGT
TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
ASQTPTNTISVTPTNNSTPTNNSNPKPNPASEKIRLRPGGKKKYKLKHIVASSSVSPT
TSVHPTPTSVPPTPTKSSPASNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDASPTSTP
ADSSTITPTATPTATPTIKGASHTQGYFPDWQNYTPGPGVRYPLTFGWLYKLASTV
TPTATATPSAIVTTITPTATTKPASVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL
ASTNGSITVAATAPTVTPTVNATPSAAASAIFQSSMTKILEPFRKQNPDIVIYQYMD
DLYAS
+C3739 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C9+
SEQ ID NO: 10
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKV
SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECAS
PAB3498
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-Flex-vl-Pep-
gag17-f1-gag253-f2-nef116-f3-nef66-f4-pol158]
rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-hCD40Ligand]
C3735 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-Flex-v1-Pep-gag17-f1-
gag253-f2-nef116-f3-nef66-f4-pol158]
SEQ ID NO: 11
EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPY
NGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGT
TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV
HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC
PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
ASQTPTNTISVTPTNNSTPTNNSNPKPNPASEKIRLRPGGKKKYKLKHIVASSSVSPT
TSVHPTPTSVPPTPTKSSPASNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDASPTSTP
ADSSTITPTATPTATPTIKGASHTQGYFPDWQNYTPGPGVRYPLTFGWLYKLASTV
TPTATATPSAIVTTITPTATTKPASVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL
ASTNGSITVAATAPTVTPTVNATPSAAASAIFQSSMTKILEPFRKQNPDIVIYQYMD
DLYAS
+C3524 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
hCD40Ligand]
SEQ ID NO: 12
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKV
SNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECASQ
TPTNTISVTPTNNSTPTNNSNPKPNPASMQKGDQNPQIAAHVISEASSKTTSVLQW
AEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCL
KSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGT
GFTSFGLLKL
Seq ID NO: 13: CD40L
MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFT
ETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWH
CTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSC
ETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTN
KAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
Leader or Signal sequence 1-20;
Ectodomain residues 21-193;
Transmembrane sequence 194-215;
Cytoplasmic sequence 216-277.
This is the isoform that has been chosen as the “canonical” sequence as reported by
UniProtKB—P25942 (TNR5_HUMAN) which also describes sequence variants.
Other CD40 antibodies: Variable domain sequences for HC and KC
The amino acid at the end of the H chain V regions is usually a Lysine, but may be more
typically replaced by Serine (as in the CP sequence—this has no effect on activity)
12B4 HC [manti-CD40_12B4.2C10_H-LV-hIgG4H-C]
(SEQ ID NO: 98)
EVQLQQSGPELVKPGASVKMSCKASGYTFTDYVLHWVKQKPGQGLEWIGYINP
YNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGYPAYSGY
AMDYWGQGTSVTVSSAK
12B4 KC [manti-CD40_12B4.2C10_K-LV-hIgGK-C]
(SEQ ID NO: 99)
DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHS
GVPSRFSGSGSGTDYSLTISNLEQEDIATYFCHHGNTLPWTFGGGTK
12E12 HC [manti-CD40_12E12.3F3_H-V-hIgG4H-C]
(SEQ ID NO: 100)
EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLEWVAYINSG
GGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCARRGLPFHAMD
YWGQGTSVTVSSAK
12E12 KC [manti-CD40_12E12.3F3_K-V-hIgGK-C]
(SEQ ID NO: 101)
DIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLLIYYTSILHS
GVPSRFSGSGSGTDYSLTIGNLEPEDIATYYCQQFNKLPPTFGGGTK
12E12 H2 Humanized HC [hAnti-CD40VH2-LV-hIgG4H-C]
(SEQ ID NO: 102)
EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWVAYINS
GGGSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGLPFHAM
DYWGQGTLVTVSSAK
12E12 H3 Humanized HC [hAnti-CD40VH3-LV-hIgG4H-C]
(SEQ ID NO: 103)
EVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWVAYINS
GGGSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGLPFHAM
DYWGQGTLVTVSSAK
12E12 K2 Humanized KC [hAnti-CD40VK2-LV-hIgGK-C]
(SEQ ID NO: 104)
DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYTSILHS
GVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTK
Pfizer HC [manti-hCD40_CP870893H-LV-hIgG4H-C]
(SEQ ID NO: 105)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWI
NPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGY
CTNGVCSYFDYWGQGTLVTVSSAS
Pfizer KC [manti-hCD40_CP870893K-LV-hIgGK-C]
(SEQ ID NO: 106)
DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQ
SGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTK
24A3 HC [manti-hCD40_24A3.3F1_H-LV-hIgG4H-C]
(SEQ ID NO: 107)
DVQLQESGPDLVKPSQSLSLTCTVTGYSITSDYSWHWIRQFPGNKLEWMGYIYYS
GSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDSATYFCARFYYGYSFFDYWGQ
GTTLTVSSAK
24A3 KC [manti-hCD40_24A3.3F1_K-LV-hIgGK-C]
(SEQ ID NO: 108)
QIVLTQSPAFMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLAS
GVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTK
11B6 hCD40L Humanized HC fused to a dockerin domain—which when paired with
11B6 hCD40L Humanized KC [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
hCD40Ligand]makes humanized 11B6-CD40L-Dockerin for non-covalent coupling to
any cohesin-antigen fusion.
(SEQ ID NO: 109)
DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYK
VSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEI
KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECASQ
11B6 hCD40L Humanized HC [mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-
(SEQ ID NO: 110)
EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINP
YNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQ
GTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTS
GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG
PPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV
DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIE
KTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS
Flex linkers amino acid sequences:
(flexV1, SEQ ID NO: 15)
QTPTNTISVTPTNNSTPTNNSNPKPNP
(f1, SEQ ID NO: 56)
ASSSVSPTTSVHPTPTSVPPTPTKSSPAS
(f2, SEQ ID NO: 130)
PTSTPADSSTITPTATPTATPTIKG
(f3, SEQ ID NO: 53)
TVTPTATATPSAIVTTITPTATTKP
(f4, SEQ ID NO: 54)
TNGSITVAATAPTVTPTVNATPSAA

[0393] 2. Results

[0394] Some Agonist Including Partial Agonist Anti-CD40 Antibodies can Synergize with Soluble CD40L for CD40 Activation.

[0395] CD40 expressed on B cells, when engaged by CD40L expressed on antigen-activated CD4⁺ helper T cells secreting cytokines interleukin-4 and interleukin-21, drives the proliferation of B cells, events that are typically confined to germinal centers of lymphoid organs. We tested a matched panel of anti-human CD40 antibodies formatted as human IgG4 and human κ light chain for their efficacy in driving proliferation of human peripheral B cells in the presence of IL-4 and IL-21 (FIG. 2). These antibodies covered a >100-fold range of agonist efficacies with rank order CP>12E12≥12B4>11B6>24A3 (CP is CP-870,893, a Pfizer Inc. antibody tested in various clinical trials, (Vonderheide et al., 2013).

[0396] Repeating this assay in the presence of a fixed suboptimal concentration of soluble CD40L (sCD40L) had no effect on the dose-response of the 12B4 and 12E12 antibodies, slightly increased the potency of the CP antibody, but synergized with the 11B6 and 24A3 antibodies to greatly (>100-fold) increase their efficacy (FIG. 2). The synergistic co-operation of these two weak CD40 agonist signals suggests that the interaction of these specific mAbs with CD40 potentiates productive interaction with CD40L, or visa versa. Synergism between substances that activate distinct receptors on a single cell is a well-known phenomenon, e.g., co-operative effects can be observed between agonistic anti-CD40 mAbs and FcRII (Dahan, et al., 2016), but in this case our two activating agents are acting on the same receptor type.

Antibody (hIgG4)	11B6	12B4	12E12	CP	24A3
EC50 (nM) B cell	≥10	>0.1 <1	>0.1 <1	>0.01 <0.1	>10
EC50/EC50 CP	≥100	≈10	≈10	1	≥1000
EC50 w/sCD40L	≥0.1	>0.1 <1	>0.1 <1	>0.01 <0.1	≥1 <10
(nM)
Δ w/sCD40L (fold)	≥100	≈0	≈0	≈0	≈100
Table for FIG. 2. Limits for the efficacious dose for 50% of maximum B cell proliferation (EC50) are given as nanomolar values (nM).
Also calculated are EC50 ratio relative to the CP-870, 893 (CP) strong agonist antibody; EC50 value in the presence of a constant suboptimal amount (6 nM) of soluble human CD40L; and fold difference (Δ) in EC50 value in the presence of a constant suboptimal amount (6 nM) of soluble human CD40L.

[0397] Sentinel dendritic cells (DCs), when exposed to foreign antigens and pathogen-derived danger signals, process and present antigen peptides in their major histocompatibility molecules (MEW) to cognate antigen-specific T cells (Hivroz et al., 2012). CD40 expressed on the dendritic cells interacts with CD40L expressed on adjacent antigen-activated T cells, and this event is critical for initiating immunity, partly via increasing expression of cell surface DC activation molecules (e.g, CD68 and HLA) and invoking secretion of inflammatory cytokines by the DCs (Ma and Clark, 2009). Thus we, assayed the panel of anti-CD40 human IgG4 mAbs for their ability to initiate cytokine secretion on matured human monocyte-derived DC (MDDC). As with the B cell proliferation assay, these antibodies elicited cytokine production over a similar >1000-fold range of efficacies with a similar rank order CP>12B4≥12E12>11B6>24A3 (FIG. 3). When assayed with a sub-optimal dose of sCD40L, there was no effect on the dose-response of the 12B4 and 12E12 antibodies. However, low dose sCD40L increased the potency of the CP antibody by ≈100-fold, while strong synergy for DC activation (≥100-fold) was again observed between sCD40L and the 11B6 and 24A3 antibodies (FIG. 3). The difference in efficacy between antibody alone and antibody with sCD40L was greater than observed with the B cell proliferation assay, indicating a greater potential for co-operation between these two agonist types on MDDCs.

Antibody (hIgG4)	11B6	12B4	12E12	CP	24A3
EC50 (nM) cytokines	>>10	>10	>>10	≈0.1	>>10
EC50/EC50 CP	>1000	≥100	>1000	1	>1000
EC50 w/sCD40L (nM)	≅≥0.1	>10 ≥100	>>10 >0.1	≥0.01	≥10
			<1
Δ w/sCD40L (fold)	>1000	≅0	≅0	≈100	>1000
Table for FIG. 3. Limits for the efficacious dose for 50% of maximum secretion of IL-40 p40 or IL-15 by MDDCs (EC50) are given as nanomolar values (nM).
Also calculated are EC50 ratio relative to the CP-870, 893 (CP) strong agonist antibody; EC50 value in the presence of a constant suboptimal amount (6 nM) of soluble human CD40L; and fold difference (Δ) in EC50 value in the presence of a constant suboptimal amount (60 nM) of soluble human CD40L.

[0398] The panel of anti-human CD40 mAbs we studied all bind with relatively high affinity to

[0399] CD40 as determined by surface plasmon resonance (SPR), with rank order for on-rate of 11B6>12B4>12E12>24A3>CP and rank order for off-rate 12B4>11B6>24A3>12E12>CP (Table 1). Previous studies with agonistic anti-CD40 antibodies have shown no apparent correlation between these kinetic parameters and activation potential (Hagar et al., 2003) and the SPR data for the mAbs within this study are in accord with this conclusion.

TABLE 4
Kinetic parameters and affinity constants for the interaction between
immobilized anti-human CD40 IgG4 mAbs and liquid phase soluble human CD40 ectodomain.
Surface plasmon resonance analysis of the kinetics of soluble liquid phase human
CD40 ectodomain with immobilized antibody was performed as
described in Materials and Methods.
mAb	11B6	12B4	12E12	CP	24A3
Kd (nM)	217	100	33	71	97
Ka (M−1s−1)	3.0E+05	2.5E+05	1.5E+05	4.6E+04	8.3E+04
kd (s−1)	6.4E−02	2.7E−02	4.6E−03	2.2E−03	8.0E−03

[0400] One possible mechanism for the synergy between sCD40L and anti-CD40 mAb activation of CD40 could be via their access to separate sites on the CD40 ectodomain. It is known that the agonistic anti-CD40L mAb CDX-1140 interacts with CD40 at a site distinct from CD40L and similar synergy between sCD40L and this mAb was observed (He et al., 2016).

[0401] Thus we tested our panel of anti-human CD40 IgG4 antibodies for their ability to prevent the binding of CD40 to CD40L expressed on the surface of L cells. The 12B4 and 12E12 antibodies in stoichiometric amounts prevented CD40 binding to cell surface CD40L, while >20-fold higher levels of the CP antibody were required to even partially block CD40 binding to CD40L, while the 11B6 and 24A3 antibodies had a minimal effect on CD40L binding to CD40 even at the highest mAb doses (FIG. 4).

[0402] These data were consistent for these mAbs either as the original mouse antibodies or reformatted as hIgG4. Based on their affinity constants (Table 4) all of these antibodies would have fully occupied CD40 binding sites at the key discriminating concentration of 1 μg/ml where 12E12 and 12B4 mAbs fully block CD40L binding. These data show that the 12B4 and 12E12 mAbs bind to sites on CD40 that are absolutely required for CD40-CD40L interaction, while the CP, 11B6, and 24A3 mAbs bind to CD40 sites with minimal interference to CD40-CD40L interaction.

[0403] Thus synergy between sCD40L and anti-CD40 mAb for B cell and DC activation is associated with simultaneous access of both these agonists to distinct parts of CD40L.

[0404] Antigens Fused to Agonistic Anti-CD40 mAbs can Dull CD40 Activation Efficacy but Some Anti-CD40 mAb-Antigen Fusions Synergize with sCD40L to Restore CD40 Activation Potency.

[0405] Fusion of antigens to the C-terminus of chimeric or humanized agonistic antibodies can dull or eliminate the agonistic property of the parent antibody [Flamar et al., 2013]. A panel of anti-CD40 antibodies matched to the human IgG4 isotype with and without concatenated strings of HIV-1 long T cell epitope-rich peptides from the Gag, Nef, and Pol gene regions grafted to their H and/or L chain C-termini [Flamar et al., 2013] were tested for their relative efficacy in evoking human B cell proliferation and human dendritic cell activation.

[0406] The agonistic 11B6, 12B4, 12E12, and CP IgG4 mAbs became very weak agonists for eliciting B cell proliferation when the concatenated five HIV-1 long peptide regions interspersed with glycosylated flexible linkers were grafted to their H chain C-termini (FIG. 5). Addition of suboptimal levels of sCD40L restored the B cell proliferation potency of the 11B6-HIV5pep and CP-HIV5pep mAbs to the levels characteristic of the analogous ‘naked’ anti-CD40 11B6 and CP mAbs incubated with sCD40L, but had no significant effect on the 12B4-HIV5pep or 12E12-HIV5pep mAbs (FIG. 5).

[0407] These same four anti-CD40-HIV5pep fusion proteins were also of very low potency for up-regulation of activation markers on MDDCs, and a suboptimal level of sCD40L potentiated the activity of the 11B6-HIV5pep and CP-HIV5pep, but had no effect on the 12B4-HIV5pep or 12E12-HIV5pep fusion proteins (FIG. 6). However, the extent of sCD40L potentiation was ˜5-10 fold less than that observed with the 11B6 and CP ‘naked’ mAbs (FIG. 6).

[0408] sCD40L Co-Operates with Anti-CD40.HIV5pep to Expand Antigen-Specific Memory CD8⁺ T Cells in PBMCs from HIV-1-Infected Individuals.

[0409] PBMC and DC-T cell co-culture systems are useful in vitro assays for validating DC-targeting prototype vaccine constructs, in particular for selecting the best receptor to target e.g., for cellular T cell response (Yin et al., 2016), as well as confirming the efficacy of the selected fused antigen for eliciting a broad range of T cell peptide specificities for both CD4⁺ and CD8⁺ T cell responses across a range of HLA types (Flamar et al., 2013). Based on such tests CD40-targeting is particularly attractive, however the potential contribution of activation of CD40 concomitant with the characteristic antigen internalization into the early endosome DC compartment has not been addressed (Chattergee et al., 2012; Yin et al., 2016).

[0410] We tested the efficiency of anti-CD40 mAbs fused to HIV5pep for HIV-1 antigen-specific T cell expansion in HIV-1⁺ donor PBMC cultures with and without a low dose of sCD40L. A striking augmentation of antigen-specific CTL expansion was observed via co-administration of sub-optimal level of sCD40L with anti-CD40 11B6 and CP HIV5pep vaccines, but not with the anti-CD40 12E12 and 12B4 HIV5pep vaccines (FIG. 7).

[0411] CD40L Fused to Agonist Anti-CD40 Antibodies can Maximize CD40 Activation.

[0412] Synergistic cooperation between sCD40L and agonistic anti-CD40 mAbs may be a valuable property in vivo, e.g., via allowing the CD40L on activated T cells access to CD40 on DCs already occupied by the mAb. Alternatively, agonistic anti-CD40 mAb and sCD40L could be delivered simultaneously in vivo for possible therapeutic benefit via the enhanced CD40 activation observed in vitro.

[0413] Trimeric sCD40L has shown efficacy in preclinical studies (Stone et al., 2009) and may become available in the future for actual clinical validation of combining sCD40L with synergizing agonistic mAbs.

[0414] Here we explored the novel concept of physically associating sCD40L with agonistic mAb by direct fusion with an obvious potential benefit of establishing a single agent highly active agonist. For this purpose, the entire ectodomain of human CD40L was fused to the L chain C-termini of the anti-CD40 mAbs via a glycosylation-rich flexible linker sequence (called flex V1 or ASQTPTNTISVTPTNNSTPTNNSNPKPNPAS (SEQ ID NO:15); Flamar et al., 2013). These ‘bivalent’ anti-CD40-CD40L mAbs were efficiently expressed in 293 and CHO cells as homogeneous secreted products (data not shown).

[0415] Anti-CD40 IgG4 mAbs 11B6 and 12B4 fused to CD40L were tested relative to the non-fused mAbs for their efficacy in eliciting B cell proliferation. Both of these CD40L fused mAbs were highly potent in this assay, matching the efficacy of the highly potent CP mAb co-administered with sub-optimal sCD40L (see FIG. 2). In both cases the CD40L adduct greatly increased the potency of the parent mAb (>1,000-fold for 11B6 and >100-fold for 12B4) and the increase for the 11B6 mAb was >10-fold more robust that when co-administered with sCD40L (FIG. 8). CD40L fused to the control IgG4 mAb was also active in inducing B cell proliferation, but ˜10-fold less than the 11B6 and 12B4-CD40L fusion proteins (FIG. 8), highlighting the benefit of combining via direct linkage CD40L with anti-CD40 antibody binding.

[0416] A full panel of anti-CD40 IgG4 mAbs fused to CD40L was tested relative to the non-fused mAbs for their efficacy in eliciting DC activation. Remarkably, directly linking CD40L to all the mAbs except 12E12 dramatically increased their efficacy (i.e., the maximal response) compared to the synergy observed with adding unlinked sCD40L to the 11B6, CP, and 24A3 mAbs (FIG. 9). Furthermore, consistent with the B cell proliferation assay mAb 12B4, which competes directly with CD40L for CD40 occupancy, also benefited greatly from CD40L fusion (FIG. 9). Note that hCD40L directly fused to a ontrol (non-DC binding) IgG4 had only minimal activity on MDDCs, suggesting that the CD40L-antiCD40 mAb fusion approach is preferentially efficaceous for DC activation.

[0417] Directly Linking CD40L to Agonistic Anti-CD40 mAb 11B6 Increases Affinity and Activation Efficacy.

[0418] We used SPR analysis to probe the impact upon the CD40 binding kinetics of anti-CD40 11B6 and anti-CD40 12E12 mAbs of CD40L fused to their L chain C-termini by immobilizing them onto a protein A/G surface and flowing soluble human CD40 ectodomain over them in the liquid phase. The CD40L adduct on the anti-CD40 12E12 mAb did no significantly alter the antibody on- or off-rates compared to the parental anti-CD40 12E12 mAb (data not shown). This was expected since the anti-CD40 12E12 mAb competes for the CD40L binding site on CD40, and a human IgG4 control mAb with CD40L fused in a similar manner to the L chain showed no detectable binding to CD40 in this format (data not shown). In contrast, the CD40L adduct on the anti-CD40 11B6 mAb significantly altered the antibody off-rate compared to the parental anti-CD40 11b6 mAb (data not shown). Specifically, while the on-rate was marginally impacted, the off-rate decreased by ˜15-fold, indicating cooperatively between the anti-CD40 mAb and CD40L in binding to CD40.

[0419] Agonistic Properties of Anti-CD40 mAbs Dulled by Antigen Fusion can be Restored Via Direct Fusion of CD40L to their Light Chain C-Termini.

[0420] Agonistic properties of anti-CD40 mAbs can be reduced or eliminated via fusion to some antigens. For example, the HIV5pep antigens fused to the H chain C-termini greatly reduce agonistic properties when carried by 11B6, 12B4, or 12E12 mAb vehicles, but co-administered sCD40L potentiates the activity of the anti-CD40 11B6 HIV5pep fusion protein (FIGS. 5 and 6). In a similar manner, fusion of CD40L to the L chain of the anti-CD40 11B6-HIV5pep protein also potentiates activity for B cell proliferation and MDDC cytokine production (FIG. 10A). FIG. 10B shows that anti-CD40 11B6 bearing the HIV5pep antigens at the H chain C-terminus (11B6-HIV5pep in FIG. 12) has minimal efficacy for CD40 activation as determined by the B cell proliferation assay. However, addition of a low dose of sCD40L (11B6-HIV5pep+sCD40L) or fusion of human CD40L to the L chain C-terminus (11B6-CD40L-HIV5pep) results in highly potent CD40 activation, to a greater extent that can be achieved by the CP-970,893 IgG4 antibody.

Antibody	11B6-	11B6-HIV5	11B6-	11B6-CD40L	IgG4-
(hIgG4)	CD40L	pep + sCD40L	HIV5pep	HIV5pep	CD40L
EC50 (nM)	>0.1 <1	>1 <10	>10	>0.1 <1	>10
B cell
Table for FIG. 10-B. Limits for the efficacious dose for 50% of maximum B cell proliferation (EC50) are given as nanomolar values (nM).

[0421] Anti-CD40 11B6 mAb Directly Fused to CD40L is a Superior Agonist Compared to a Highly Active Dimer-Trimer Form of Soluble CD40L.

[0422] MEGACD40L® (Mega sCD40L) is a widely used (Kornbluth et al., 2012) high activity protein in which two trimeric CD40 ligand molecules are artificially linked via the collagen domain of Adiponectin/ACRP30/AdipoQ (see Miconnet and Pantaleo, Vaccine 2008). FIG. 10C shows responses of human MDDCs to a dose range of Mega sCD40L and anti-CD40 11B6-CD40L mAbs with and without HIV5pep antigen fused to the H chain C-terminus. Anti-CD40 11B6-CD40L was ≈100-fold more active than Mega sCD40L for eliciting cytokine secretion in this assay, as well as 100-fold more active than Mega sCD40L co-administered with 10 nM anti-CD40 11B6, indicating that physical linkage of anti-CD40 11B6 with CD40L was essential for this very high activity. Importantly, anti-CD40 11B6-CD40L linked to the HIV5pep antigens via the H chain C-terminus was also ≈10-fold more active than Mega sCD40L.

	11B6-CD40L-	11B6-CD40L-	Mega	11B6-
Antibody (hIgG4)	HIV5pepk	HIV5pep	sCD40L	CD40L
EC50 (nM) IL-12	>0.1 ≤1	>0.1 ≤1	>1 <10	>0.01 ≤0.1
p40
EC50/11B6-CD40L	≅10	≅10	≈100	1
EC50 (nM)TNFα	>0.1 ≤1	>0.1 ≤1	>1 <10	>0.01 ≤0.1
EC50/11B6-CD40L	≈10	≅10	≈100	1
EC50 (nM) IL-15	>0.1 ≤1	>0.1 ≤1	≥1 ≤10	>0.01 ≤0.1
EC50/11B6-CD40L	≈10	≅10	≈100	1
Table for FIG. 10C. Limits for the efficacious dose for 50% of maximum cytokine secretion (EC50) are given as nanomolar values (nM).

[0423] To test if CD40L fusion to agonistic anti-CD40 mAb L chain C-termini could also increase their agonist potency while fused to other antigens, we compared their agonistic activities when fused at their H chain C-termini to concatenated HIV-1 Gag p24 Nef Gag p17 (called GNG) or HPV 16 E6/E7 (called HPV) antigens with or without CD40L directly fused to the L chain. These two antigens did not significantly dull the low potency of B cell CD40 activation of the parent 11B6 mAb, but CD40L L chain fusion potentiated the activation to levels equal to co-administered sCD40 (FIG. 11). The 11B6 mAb fused to GNG at the H chain C-termini and CD40L at the L chain C-termini was equipotent for MDDC activation compared to the 11B6-CD40L mAb without fused antigen, and both 11B6 and 11B8-GNG synergized strongly with sCD40L), while 11B6-CD40L-GNG was equal in potency to 11B6-GNG+sCD40 (FIG. 11). These data were similar for 11B6 fused to the HPV antigens in that CD40L fused to the L chain restored the full agonist activity seen with 11B6-HPV+sCD40 (FIG. 11). These 11B6-CD40L-antigen fusions were equipotent to strong agonist activities observed with the 12B4-CD40L mAb, as well as the CD mAb+sCD40L. Interestingly the 12E12-HPV mAb interferes with sCD40L action, but the anti-CD40 12E12-CD40L-HPV mAb format restored strong agonist activity (FIG. 11).

[0424] The full ‘high’ agonist activity observed on B cell proliferation with the anti-CD40 11B6-CD40L-GNG protein was recapitulated by the high cytokine secretion responses of MDDCs to 11B6-CD40L-GNG in contrast to very weak agonist activity of 11B6-GNG (FIG. 12). Note that the efficacy of the 11B6-CD40L molecules is strikingly higher than the standard full agonist anti-CD40 CP IgG4 antibody.

[0425] Anti-CD40. Gag p17-Nef-Gag p24 Vaccine Directly Linked to CD40L Increases Specific Memory CD8⁺ T Cell Responses In Vitro.

[0426] To test directly if the improved agonist properties of anti-CD40 11B6-GNG mAb with linked CD40L impacted the efficacy of HIV-1-specific T cell expansion, HIV-1-infected donor PBMCs were incubated with a low doses of anti-CD40 11B6-GNG-CD40L and various control GNG fusion mAbs for 9 days with IL-2 feeding followed by stimulation with pools of peptides from Gag p17, Gag p24, and Nef. In both donors the 11B6-GNG mAbs with directly linked CD40L or co-administered sCD40L elicited strikingly superior Nef-specific CD8⁺ T cell responses (FIG. 13).

[0427] To test directly if the improved agonist properties of anti-CD40 11B6-HIV5pep mAbs with linked CD40L impacted the efficacy of HIV-1-specific T cell expansion, HIV-1-infected donor PBMCs were incubated with a low doses of anti-CD40 11B6-GNG-CD40L and various control GNG fusion mAbs for 9 days with IL-2 feeding followed by stimulation with individual long peptides corresponding to the five Gag p17, Gag p24, Nef, and Pol epitope components of HIV5pep. The general trend for elicited HIV-1 peptide-specific T cell responses was that the 11B6-HIV5pep mAbs with directly linked CD40L elicited superior HIV-1-specific CD8⁺ T cell responses and lesser HIV-1-specific CD4⁺ T cell responses (FIG. 14).

[0428] The in vitro culture system combining anti-CD40 DC targeting vaccine with sCD40L has potential value for enhancing yields of e.g., ex vivo expanded CTL for cellular therapy applications. However, as an in vivo vaccine strategy this is constrained by the need to co-administer two different protein agents associated with potentially complex dosing/pharmacokinetic, GMP production, and licensing issues. The novel bivalent antibody format of directly linking CD40L to anti-CD40 DC-targeting mAbs solves this issue.

[0429] Expansion by CD40-Targeted GNG Antigen of HIV-1-Specific T Cells in HIV-1-Infected Donor PBMC Cultures.

[0430] HIV-1⁺ donor PBMCs were cultured with a dose range of anti-CD40-GNG fusion proteins (from left to right 1 0.1, 0.01 nM) with and without a low dose of sCD40L (100 ng/ml; 6 nM) and IL-2 for 9 days, followed by stimulation with a pools HIV-1 Gag p17, Nef, and Gag p24 peptides for 6 h, then analyzed by ICS The data show the percentage at the end of the culture of antigen-specific (A) CD4⁺ (B) CD8⁺ T cells producing IFNγ+TNFα in response to peptide stimulation (see FIG. 26). Similar data was observed using PBMCs from t other donors (FIG. 27).

[0431] Anti-CD40-CD40L Targeted HIV5pep Antigens Preferentially Expand Many HIV-1-Specific CD8⁺ T Cell Responses in HIV-1-Infected Donor PBMC Cultures

[0432] HIV-1⁺ donor PBMCs were cultured for 9 days with IL-2 and anti-CD40 HIV5pep fusion proteins (1 nM; 2 nM for KIH proteins), followed by stimulation with long peptides specific for each of the five HIV-1 gag, nef, and pol regions for 6 h with BFA, then analyzed by ICS. FIG. 28 shows collated data from experiments with each of the indicated protein pairs tested on four donors. Each point represents the % value for IFNγ⁺+TNFα⁺ HIV5pep-specific CD8⁺ (panel A, black filled squares) or CD4⁺ (panel B, open grey circles) T cells for each response specific to each long peptide elicited in each donor comparing anti-CD40 11B6-CD40L-HIV5pep KIH Gen 2 and anti-CD40 11B6-CD40L-HIV5pep Gen 1 (Y axis) to anti-CD40 12E12-HIV5pep KIH Gen 2 and anti-CD40 12E12-HIV5pep Gen 2 (X axis). Panel A highlights the responses that were ≤20% of the expanded culture and excludes the potent patient 2 response to the nef66 peptide (38±7% elicited by anti-CD40 11B6-CD40L-HIV5pep vaccines versus 48±10% elicited by anti-CD40-HIV5pep vaccines. Panel B shows the whole dataset.

[0433] Fusion of CD40L to Anti-CD40 11B6 Augments Adjuvant-Free Antibody Response in an In Vivo Mouse Model.

[0434] To test the potential of combining CD40L fusion to anti-CD40 11B6 antibody for increasing vaccine efficacy, human CD40 transgenic mice were vaccinated with anti-CD40 11B6 delivery vehicles coupled to HIV-1 Env gp140, with and without the CD40L light chain fusion. Vaccination with anti-CD40 11B6-CD40L directly fused to gp140 was compared to vaccination with anti-CD40 11B6-CD40L non-covalently coupled to a cohesion-gp140 fusion protein, to anti-CD40 11B6 non-covalently coupled to a cohesion-gp140 fusion protein, and to non-CD40 targeted cohesin-gp140. Both anti-CD40 11B6-CD40L non-covalently coupled to cohesion-gp140 fusion protein and anti-CD40 11B6-CD40L directly fused to gp140 elicited serum anti-gp140 IgG titers that were detected as early as 1 week after a single vaccination, and both vaccines increase responses to similar extents after subsequent two vaccinations (FIG. 16). Vaccination with anti-CD40 11B6 non-covalently linked to cohesin-gp140 elicited serum anti-gp140 IgG titers that were detected only after a second vaccination, and responses increased further after the third vaccination, but the titers were significantly reduced compared to the two anti-CD40 11B6-CD40L-based vaccines. Non-targeted cohesin-gp140 failed to elicit any detectable anti-gp140 IgG responses even after three vaccinations using a three-fold molar excess of gp140 compared to the CD40-targeting vaccines. These results should be considered in the context of results in the non-human primate model, where anti-CD40 12E12-gp140 vaccinations elicited only modest anti-gp140 IgG responses compared to the same vaccine co-administered with the adjuvant poly IC (Zurawski et al., 2016). The mouse data suggest the likelihood that CD40L linked to the anti-CD40 11B6-gp140 construct confers ‘adjuvant-like’ property to this protein vaccine.

[0435] Anti-CD40 11B6-CD40L Elicits Potent Activation of CD40 in an In Vivo Mouse Model.

[0436] CP-870,893 infusion in cancer patients undergoing chemotherapy triggers immune activation detected by increased plasma inflammatory cytokines (i.e., cytokine release syndrome), increased B cell expression of co-stimulatory molecules, and transient depletion of B cells (Beatty et al., 2013). In these patients, dose-limiting toxicity was determined to be 0.2 mg/kg, although 0.3 mg/kg was the limit determined in patients receiving this anti-CD40 agonist alone (Vonderheide et al., 2016). To appraise the biological activity of anti-CD40 11B6-CD40L in vivo, we tested the short-term (24 h) effects of CP-870,893 hIgG4 and anti-CD40 11B6-CD40L at a dose of 10 μg (≈0.5 mg/Kg). Wild type or human CD40 BAC transgenic mice on either a wild type (Taconic strain) or CD40 KO (ImmuRx strain) C57BL/6 background were injected (intraperitoneal) with CP-870,893 hIgG4 or the molar equivalent of anti-CD40 11B6-CD40L and were sacrificed 24 h later. Blood was collected for assay of cytokines (serum via Luminex®) and cells from PBMC, skin draining lymph node, and spleen, were analyzed by flow cytometry. B cells were characterized by analysis of the activation markers CD69, MHC-II, OX40L and CD86. The results are shown in FIG. 17 and show that while CP-870,893 hIgG4 has minimal or no activity in these tests, of anti-CD40 11B6-CD40L elicits robust B cell depletion associated with activation, as well as cytokine secretion as detected in the circulation. These data predict that very low doses of anti-CD40 11B6-CD40L compared to CP-870,893 would be required when used clinically as an adjuvant in e.g., cancer therapy.

[0437] Fusion of CD40L to Anti-CD40 11B6 Increases Both Efficacy and Potency of Cell Killing Directed by CD40 Ectodomain Fused to FAS Transmembrane and Intracellular Domains.

[0438] FAS (CD95) belongs to the tumor necrosis factor receptor (TNF-R) family that contain an intra-cellular ‘death domain’ and can trigger apoptosis in response to its physiological ligand, FASL (Strasser et al., 2009). We constructed a fusion protein expressing human CD40 ectodomain residues 21-193 fused to human FAS residues 187-350 and established stably transfected Chinese Hamster Ovary (CHO) cells expressing the CD40 ectodomain linked to the FAS transmembrane and intracellular domains. CD40 agonists elicit killing of these cells as determined by loss of mitochondrial reduction of the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Mossman, 1983). In this assay anti-CD40 11B6 IgG4 and anti-CD40 12E12 IgG4 show similar efficacy (as determined by maximal decrease in MTT reduction) and similar potency (EC₅₀≈2.5 nM and 1 nM, respectively), but anti-CD40 11B6-CD40L IgG4 has increased efficacy (i.e., greater maximal decrease in MTT reduction) and significantly increased potency (EC50 2.5 pM) (FIG. 18). This data re-enforces conclusions drawn from tests of the superiority of anti-CD4011B6-CD40L efficacy seen in B cell and DC assays.

[0439] Anti-CD40 11B6-CD40L Enhances CD40-Mediated Clustering and Internalization

[0440] We compared the rate and extent of CD40-mediated internalization of anti-CD40 11B6-CD40L versus anti-CD40 12E12. These two antibodies are well matched for their binding to CD40 based on SPR analysis (KD of 12 and 28 nM, respectively, FIG. 24), but they differ dramatically in potency of CD40 activation (FIGS. 9,18). Since ligand engagement leads to the formation of cross-linked CD40 lipid rafts (clusters) on the cell membrane, an event followed by CD40 internalization and downstream signaling (Wang et al. 2015), we compared the ability of anti-CD40 11B6-CD40L versus anti-CD40 12E12 to cluster and internalize cell surface CD40.

[0441] We first compared the ability of these two anti-CD40 antibodies to induce the formation of cross-linked CD40 lipid rafts (clusters) on the cell membrane. We used CHO cells expressing a human CD40-eGFP fusion protein or a human CD40-mCherry fusion as a model to visualize cluster formation through confocal microscopy. Treating the cells for 1 hour at 37° C. with 10 nM anti-CD4011B6-CD40L induced stronger CD40 cluster formation compared to the same treatment with anti-CD40 12E12 (FIG. 23). This data is concordant with the increased signaling potency of the anti-CD40 11B6-CD40L antibody since CD40 clustering is likely the initial trigger for CD40 activation.

[0442] We then used CHO cells expressing human CD40 as a model and assayed anti-CD40-mediated binding and internalization of a non-covalently attached mCherry module. Binding of both antibodies was rapid and reached saturation within ˜30 min at 37° C. and at 0° C. (FIGS. 24 A and B). Treating the cells in cold isotonic acid buffer (pH 2.5) for one minute removed ˜75% of the cell-associated anti-CD40 12E12 label when binding was performed at 0° C. (FIG. 24 A). When binding was performed at 37° C., there was a trend (residual label 29±3% versus 26±3%, n.s.) to greater label retention at 37° C., perhaps reflecting slight internalization. In contrast, when anti-CD40 11B6-CD40L binding was performed at 0° C., the acid stripping removed only ˜60% of the cell-associated label versus the 26±3% observed with the anti-CD40 12E12 mAb, and this difference between the two mAbs is significant (p<0.0001, FIG. 24 B) indicating anti-CD40 11B6-CD40L internalization is readily detectable even at 0° C. Internalization of the anti-CD40 11B6-CD40L label was much greater at 37° C., with acid-resistant label increasing from 50-90% over the 4.5 hour time course (FIG. 24 B). Thus, anti-CD40 11B6-CD40L internalizes to a much greater extent than anti-CD40 12E12, with significant internalization detectable even at 0° C. This property is a sole result of the CD40L adduct since the binding and internalization properties of the anti-CD40 11B6 mAb without fusion to CD40L were very similar to the anti-CD40 12E12 mAb (FIG. 24 C).

[0443] Anti-CD40 11B6 Recognizes an Epitope on CD40 that is Distinct from Anti-CD40 12E12 and Anti-CD40 CP.

[0444] Yu et al. (2018) summarized the knowledge of relationships between agonist anti-CD40 mAbs and their sites of interaction with CD40. For example anti-CD40 CP binds within the CD40 CRD1 region (i.e., no binding if removed) and also binding is lost when residues 23-37 are deleted or residues 27-28 RE are replaced with AA. Also, Singh et al. (1998) reported that individual substitutions of the negatively charged residues Glu74, Asp84, and Glu117 in CD40 disrupted CD40L binding. This mapping shows distinct sites of interaction on CD40 for CD40L versus the CP antibody. Using the method of Wan et al., 2012, residues R27 and E28 were individually replaced with A and the mutated CD40 ectodomains were tested for binding to anti-CD40 CP, anti-CD40 12E12, and anti-CD40 11B6 (±CD40L). As expected the R27A and E28A mutations abrogated or greatly reduced binding to the anti-CD40 CP mAb (FIG. 19). However, these mutations did not affect binding of anti-CD40 11B6 or 12E12 mAbs. The data clearly differentiate the binding sites on CD40 of the anti-CD40 CP mAb from the anti-CD40 11B6 or 12E12 mAbs.

[0445] Epitope Mapping of Anti-CD40 Agonistic Antibody 12E12 and 11B6

[0446] Two approaches were used to define CD40 residues that were important for interaction/binding to the two claimed antibodies (12E12 and 11B6), as well as to differentiate them from the other agonistic antibody CP-870,893 (referred herin as CP). The first approach is based on PepScan (Netherland based company) “Precision Epitope Mapping” platform. The second approach built upon the PepScan data by undertaking Ala-scanning mutagenesis of selected hydrophilic residues of the human CD40 ectodomain coupled to antibody binding analysis.

[0447] Using these approaches, the aim was to identify differences in epitopes on CD40 specific to these three antibodies.

[0448] Six 12E12 binding peptide regions were identified from Pepscan analysis and the Ala mutagenesis covered charged residues in all but one of these peptides (which has no highly charged residues):

	(SEQ ID NO: 153)
	(SEQ ID NO: 154)
	QCCSLCQPGQ;
	(SEQ ID NO: 155)
	(SEQ ID NO: 156)
	(SEQ ID NO: 157)
	(SEQ ID NO: 158)

[0449] Nine 11B6 binding peptide regions were highlighted and the Ala mutagenesis covered charged residues in 8 of these 9 peptides (excluding one which has no highly charged residues):

	(SEQ ID NO: 159)
	INSQCCSLCQPGQ;
	(SEQ ID NO: 160)
	(SEQ ID NO: 161)
	(SEQ ID NO; 162)
	(SEQ ID NO: 163)
	(SEQ ID NO: 164)
	(SEQ ID NO: 165)
	(SEQ ID NO: 166)
	(SEQ ID NO: 167)

[0450] The data derived from the Ala-mutagenesis study are summarized in FIG. 25. Underlined are the four CDR structural homology regions of CD40. Residue numbers for some of the mutations are shown. Grey highlights show the residues that were changed. P is the Pfizer CP mAb; E is 12E12; B is 11B6; L is 11B6-CD40L; - means no effect on any mAb tested; a small letter below the sequence indicates reduced binding; letter in CAPS means no binding.

[0451] The mutagenesis did result in discriminating with high confidence the epitopes for CP, 11B6, and 12E12 binding—even though all three mAbs had clear epitope components in the CDR1 region. This CP interaction was disrupted by changes in residues R27 and E28 (verifying published information); 11B6 interaction involved interaction with residue K29, as well as E56 and E58; the combined 11B6-CD40L binding was specifically abrogated by the K46A change; and the 12E12 interaction was dependent on D50 and E58. Thus, the data show some overlap of epitopes for these three mAbs, but distinct differences in key contact sites.

[0452] Other Examples of the Fusion Proteins of the Present Disclosure

[0453] The following alternative fusion proteins A1-A5 have been prepared. The FIG. 22 shows cartoons representing the structure of each fusion proteins, with the antigens either at the C-terminus of light or heavy chains, and/or with the presence of flexible linker.

[0454] PAB3588 C3334 (SEQ ID NO:131)×C3792 (SEQ ID NO:133)

[0455] [manti-CD40_11B6.1C3_H-LV-hIgG4H-C-Nhe-Not][manti-CD40_11B6.1C3_Syn_K-LV-hIgGK-C-hCD40Ligand]

[0456] PAB3618 C3823 (SEQ ID NO:135)×C3739 (SEQ ID NO:137)

[0457] [mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-Flex-v1-hCD40Ligand] [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]

[0458] PAB3475 C3724 (SEQ ID NO:139)×C3726 (SEQ ID NO:141)

[0459] [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK—C-Flex-v1-hCD40Ligand][mAnti-CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]

[0460] PAB3615 C3821 (SEQ ID NO:143)×C3739 (SEQ ID NO:137)

[0461] [mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C-hCD40Ligand] [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]

[0462] PAB3470 C3724 (SEQ ID NO: 139)×C3725 (SEQ ID NO:145)

[0463] [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK—C-Flex-v1-hCD40Ligand][mAnti-CD40-11B6.1C3-VH-v2-LV-hIgG4H-C]

[0464] Super Agonist Properties are Observed Irrespective of the Position of the CD40L at Either the C-Terminus of the L Chain or the C-Terminus of the H Chain and of the Presence or Absence of a Flexible Linker Joining Sequence.

[0465] Human MDDCs were cultured with a dose range (shown left to right in FIG. 20: 10, 1, 0.1, 0.01 nM) of each anti-CD40 11B6-CD40L isoform and the extent of cytokine secretion was determined after 24 h. Data in FIG. 20 represent a summation of the values for each cytokine tested normalized to the highest value within the experiment and averaged for replicated responses with two different donors. Error bars are the standard error of the mean. The cartoons shown below each titration series indicate the L chain or H chain CD40L fusion isoforms and F indicates the presence of the Flex V1 linker. The results show no significant differences between the values for each dose across this series.

[0466] Superagonist Activity of CD40L Fused to Anti-CD40 Antibody is Independent of CD40L Positioning as Defined by Efficacy and Potency of Cell Killing Directed by CD40 Ectodomain Fused to FAS Transmembrane and Intracellular Domains.

[0467] FAS (CD95) belongs to the tumor necrosis factor receptor (TNF-R) family that contain an intra-cellular ‘death domain’ and can trigger apoptosis in response to its physiological ligand, FASL (Strasser et al., 2009). We constructed a fusion protein expressing human CD40 ectodomain residues 21-193 fused to human FAS residues 187-350 and established stably transfected Chinese Hamster Ovary (CHO) cells expressing the CD40 ectodomain linked to the FAS transmembrane and intracellular domains. CD40 agonists elicit killing of these cells as determined by loss of mitochondrial reduction of the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Mossman, 1983). FAS and CD40 are in the same TNF-R family and mechanisms of receptor activation (external to the cell) are similar—but the intracellular signalling pathways are different, i.e, apoptosis versus selected cytokine and cell surface marker activation). This fusion construct provides a convenient surrogate assay format for analysis of CD40 activation based on transfected CHO cells. In this assay anti-CD40 11B6 IgG4 and anti-CD40 12E12 IgG4 show similar efficacy (as determined by maximal decrease in MTT reduction) and similar potency (EC₅₀≈2.5 nM and 1 nM, respectively), but anti-CD40 11B6-CD40L IgG4 has increased efficacy (i.e., greater maximal decrease in MTT reduction) and significantly increased potency (EC50 2.5 pM) (FIG. 21). Thus CD40L fusion to the partial agonist anti-CD40 11B6 mAb can greatly increase the potency and efficacy for on three distinct CD40-bearing cell types.

Tables 5 and 6: Useful sequences for practicing the invention
SEQ ID	Type	Brief description
1	aa	Amino acid sequence of PAB3405 heavy chain C3677 [mAnti-
		CD40-11B6.1.C3-VH-v2-LV-hIgG4H-C]
2	aa	Amino acid sequence of PAB3405 light chain C3862 [mAnti-CD40-
		11B6.1C3-Vk-v2-LV-hIgGK-C]
3	aa	Amino acid sequence of PAB3408 heavy chain C3678 [mAnti-
		CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
4	aa	Amino acid sequence of PAB3408 light chain C3682 [mAnti-CD40-
		11B6.1C3-Vκ-v2-LV-hIgGK-C]
5	aa	Amino acid sequence of PAB3470 and PAB3471 light chain C3724
		[mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
		hCD40Ligand]
6	aa	Amino acid sequence of PAB3470 heavy chain C3725 [mAnti-
		CD40-11B6.1C3-VH-v2-LV-hIgG4H-C]
7	aa	Nucleotide coding sequence of human CD40 (SEQ ID NO: 13)
8	aa	Amino acid sequence of PAB3471 heavy chain C3726 [mAnti-
		CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
9	aa	Amino acid sequence of PAB3499 heavy chain C3735 [mAnti-
		CD40-11B6.1C3-VH-v2-L-V-hIgG4H-C-Flex-v1-Pep-gag17-f1-
		gag253-f2-nef116-f3-nef66-f4-pol158]
10	aa	Amino acid sequence of PAB3499 light chain C3739 [mAnti-CD40-
		11B6.1C3-Vκ-v2-LV-hIgGK-C]
11	aa	Amino acid sequence of PAB3498 heavy chain C3735 [mAnti-
		CD40-11B6.1C3-VH-v2-L-V-hIgG4H-C-Flex-v1-Pep-gag17-f1-
		gag253-f2-nef116-f3-nef66-f4-pol158]
12	aa	Amino acid sequence of PAB3498 light chain C3524 [mAnti-CD40-
		11B6.1C3-Vk-v2-LV-hIgGK-C-Flexv1-hCD40L]
13	aa	Full amino acid sequence of human CD40
14	aa	Amino acid sequence of CD40 binding domain of human CD40L
15	aa	Amino acid sequence of FlexV1 peptidic linker
16	aa	Amino acid sequence of Gag p17 (17-35)
17	aa	Amino acid sequence of Gag p17-p24 (253-284)
18	aa	Amino acid sequence of Nef (116-145)
19	aa	Amino acid sequence of Pol 325-344 (RT 158-188)
20	aa	Amino acid sequence of Nef (66-97)
21	aa	Amino acid sequence of variable heavy chain region (VH) (v2) of
		Humanized 11B6
22	aa	Amino acid sequence of variable light chain (VL) Vk (v2) of
		humanized 11B6 VL
23	aa	Amino acid sequence of variable heavy chain region VH (v3) of
		humanied 11B6
24	nt	Nucleotide sequence encoding SEQ ID NO: 21
25	nt	Nucleotide sequence encoding SEQ ID NO: 22
26	nt	Nucleotide sequence encoding SEQ ID NO: 23
27	aa	Amino acid sequence of HCDR1 of Humanized 11B6 VH V2
28	aa	Amino acid sequence of HCDR2 of Humanized 11B6 VH V2
29	aa	Amino acid sequence of HCDR3 of Humanized 11B6 VH V2
30	aa	Amino acid sequence of LCDR1 of Humanized 11B6 VkV2
31	aa	Amino acid sequence of LCDR2 of Humanized 11B6 VkV2
32	aa	Amino acid sequence of LCDR3 of Humanized 11B6 VkV2
33	nt	Nucleotide sequenc of PAB3405 heavy chain
34	nt	Nucleotide sequenc of PAB3405 light chain
35	nt	Coding Sequence of SEQ ID NO: 3
36	nt	Coding Sequence of SEQ ID NO: 4
37	nt	Coding Sequence of SEQ ID NO: 5
38	nt	Coding Sequence of SEQ ID NO: 6
39	nt	Coding sequence of SEQ ID NO: 8
40	aa	Amino acid of mAb 12E12 HC [manti-CD40_12E12.3F3_H-V-
		hIgG4H-C]
41	nt	Coding Sequence of SEQ ID NO: 9
42	nt	Coding Sequence of SEQ ID NO: 10
43	nt	Coding Sequence of SEQ ID NO: 11
44	nt	Coding Sequence of SEQ ID NO: 12
45	aa	Amino acid sequence of Gag p24 as used in GNG
46	aa	Amino acid sequence of Nef as used in GNG
47	aa	Amino acid sequence of Gag p17 as used in GNG
48	aa	Amino acid sequence of GNG as used in the example
49	nt	Nucleotide sequence of Gag p24 as used in GNG
50	nt	Nucleotide sequence of Nef as used in GNG
51	nt	Nucleotide sequence of Gag p17 as used in GNG
52	nt	Nucleotide sequence of GNG as used in the example
53	aa	Amino acid sequence of flexible linker f3
54	aa	Amino acid sequence of flexible linker f4
55	aa	Amino acid sequence of HV16E6HPV16E7 as used in HPV sequence
56	aa	Amino acid sequence of flexible linker f1
57	aa	Full amino acid sequence of HPV sequence
58	aa	VH amino acid sequence of mAb3 (12B4)
59	aa	VL amino acid sequence of mAb3 (12B4)
60	aa	VH amino acid sequence of mAb4 (24A3 HC) [manti-
		hCD40_24A3.3F1_H-LV-hIgG4H-C]
61	aa	VL amino acid sequence of mAb4 (24A3 KC) [manti-
		hCD40_24A3.3F1_K-LV-hIgGK-C]
62	aa	VH amino acid sequence of mAb5 (CP)
		[manti-hCD40_CP870893H-LV-hIgG4H-C]
63	aa	VL amino acid sequence of mAb5 (CP) [manti-hCD40_CP870893K-
		LV-hIgGK-C]
64	aa	VH amino acid sequence of mAb6 (12E12 H3 Humanized HC
		[hAnti-CD40VH3-LV-hIgG4H-C])
65	aa	VL amino acid sequence of mAb6 (Humanized K2 12E12)
66	nt	Coding sequence of SEQ ID NO: 58
67	nt	Coding sequence of SEQ ID NO: 59
68	nt	Coding sequence of SEQ ID NO: 60
69	nt	Coding sequence of SEQ ID NO: 61
70	nt	Coding sequence of SEQ ID NO: 62
71	nt	Coding sequence of SEQ ID NO: 63
72	nt	Coding sequence of SEQ ID NO: 64
73	nt	Coding sequence of SEQ ID NO: 65
74	aa	HCDR1 amino acid sequence of mAb3 (12B4)
75	aa	HCDR2 amino acid sequence of mAb3 (12B4)
76	aa	HCDR3 amino acid sequence of mAb3 (12B4)
77	aa	LCR1 amino acid sequence of mAb3 (12B4)
78	aa	LCDR2 amino acid sequence of mAb3 (12B4)
79	aa	LCDR3 amino acid sequence of mAb3 (12B4)
80	aa	HCDR1 amino acid sequence of mAb4 (24A3)
81	aa	HCDR2 amino acid sequence of mAb4 (24A3)
82	aa	HCDR3 amino acid sequence of mAb4 (24A3)
83	aa	LCDR1 amino acid sequence of mAb4 (24A3)
84	aa	LCDR2 amino acid sequence of mAb4 (24A3)
85	aa	LCDR3 amino acid sequence of mAb4 (24A3)
86	aa	HCDR1 amino acid sequence of mAb5 (CP)
87	aa	HCDR2 amino acid sequence of mAb5 (CP)
88	aa	HCDR3 amino acid sequence of mAb5 (CP)
89	aa	LCDR1 amino acid sequence of mAb5 (CP)
90	aa	LCDR2 amino acid sequence of mAb5 (CP)
91	aa	LCDR3 amino acid sequence of mAb5 (CP)
92	aa	HCDR1 amino acid sequence of mAb6 (humanized 12E12)
93	aa	HCDR2 amino acid sequence of mAb6 (humanized 12E12)
94	aa	HCDR3 amino acid sequence of mAb6 (humanized 12E12)
95	aa	LCDR1 amino acid sequence of mAb6 (humanized 12E12)
96	aa	LCDR2 amino acid sequence of mAb6 (humanized 12E12)
97	aa	LCDR3 amino acid sequence of mAb6 (humanized 12E12)
98	aa	12B4 HC [manti-CD40_12B4.2C10_H-LV-hIgG4H-C]
99	aa	12B4 KC [manti-CD40_12B4.2C10_K-LV-hIgGK-C]
100	aa	12E12 HC [manti-CD40_12E12.3F3_H-V-hIgG4H-C]
101	aa	12E12 KC [manti-CD40_12E12.3F3_K-V-hIgGK-C]
102	aa	12E12 H2 Humanized HC [hAnti-CD40VH2-LV-hIgG4H-C]
103	aa	12E12 H3 Humanized HC [hAnti-CD40VH3-LV-hIgG4H-C]
104	aa	12E12 K2 Humanized KC [hAnti-CD40VK2-LV-hIgGK-C]
105	aa	Pfizer HC [manti-hCD40_CP870893H-LV-hIgG4H-C]
106	aa	Pfizer KC [manti-hCD40_CP870893K-LV-hIgGK-C]
107	aa	24A3 HC [manti-hCD40_24A3.3F1_H-LV-hIgG4H-C]
108	aa	24A3 KC [manti-hCD40_24A3.3F1_K-LV-hIgGK-C]
109	aa	Complete sequence (C3724) FlexV1 hCD40L
110	aa	11B6 hCD40L Humanized HC [mAnti-CD40-11B6.1C3-VH-v2-LV-
		hIgG4H-C-CthermoDockerin] (C3737) (CthermoDockerin)
111	aa	Amino acid sequence of CthermoDockerin
112	aa	Amino acid sequence of HIV5pep
113	nt	Coding sequence of SEQ ID NO: 109
114	nt	Coding sequence of SEQ ID NO: 110
115	nt	Coding sequence of SEQ ID NO: 112
116	aa	C3336 rAB-cetHS-puro-CI2[manti-CD40_11B6.1C3_H-LV-
		hIgG4H-C-Flex-v1-HPV16E6-HPV16E7-f1]
117	aa	C3735 rAB-cetHS-puro[mAnti-CD40-11B6.1C3-VH-v2-LV-
		hIgG4H-C-Flex-v1-Pep-gag17-f1-gag253-f2-nef116-f3-nef66-f4-
		pol158]
118	nt	Coding sequence of SEQ ID NO: 117
119	aa	12E12 KC [manti-CD40_12E12.3F3_K-V-hIgGK-C]
120	nt	Coding sequence of SEQ ID NO: 119
121	aa	C3678 [mAnti-CD40-11B6.1C3-VH-v3-LV-hIgG4H-C]
122	aa	C3682 [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C]
123	aa	C3724 [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
		hCD40Ligand]
124	aa	C566 Ecoli-pET28 [Cohesin-var1-FluM1-6xHis] Cohesin mutant
		(Cys to Ala change; C38A) fused to Influenza matrix protein 1
125	nt	Coding sequence of SEQ ID NO: 124
126	nt	Coding sequence of SEQ ID NO: 40
127	aa	Coding sequence of SEQ ID NO: 102
128	nt	Coding sequence of SEQ ID NO: 121
129	nt	Coding sequence of SEQ ID NO: 122
130	aa	Flex linker amino acid sequence
131	aa	C3334 [manti-CD4∅_11B6.1C3_H-LV-hIgG4H-C-Nhe-Not]
132	nt	Coding sequence of SEQ ID NO: 130
133	aa	C3792 [manti-CD4∅_11B6.1C3_Syn_K-LV-hIgGK-C-hCD4∅Ligand]
134	nt	Coding sequence of SEQ ID NO: 132
135	aa	C3823 [mAnti-CD4∅-11B6.1C3-VH-v2-LV-hIgG4H-C-Flex-v1-
		hCD4∅Ligand]
136	nt	Coding sequence of SEQ ID NO: 134
137	aa	C3739 [mAnti-CD4∅-11B6.1C3-VK-v2-LV-hIgGK-C]
138	nt	Coding sequence of SEQ ID NO: 136
139	aa	C3724 [mAnti-CD40-11B6.1C3-Vκ-v2-LV-hIgGK-C-Flex-v1-
		hCD40Ligand]
140	nt	Coding sequence of SEQ ID NO: 138
141	aa	C3726 [mAnti-CD4∅-11B6.1C3-VH-v3-LV-hIgG4H-C]
142	nt	Coding sequence of SEQ ID NO: 140
143	aa	C3821 [mAnti-CD4∅-11B6.1C3-VH-v2-LV-hIgG4H-C-hCD4∅Ligand]
144	nt	Coding sequence of SEQ ID NO: 142
145	aa	C3725 [mAnti-CD4∅-11B6.1C3-VH-v2-LV-hIgG4H-C]
146	nt	Coding sequence of SEQ ID NO: 144
147	aa	C3678 [mAnti-CD4∅-11B6.1C3-VH-v3-LV-hIgG4H-C]
148	nt	Coding sequence of SEQ ID NO: 146
149	aa	C3682 [mAnti-CD4∅-11B6.1C3-VK-v2-LV-hIgGK-C]
150	nt	Coding sequence of SEQ ID NO: 148
151	aa	Mam-cetHS-puro[hCD40--Ecto hFas-TM-IC]
152	nt	Coding sequence of SEQ ID NO: 151
153	aa	12E12 binding peptide regions identified from Pepscan
154	aa	12E12 binding peptide regions identified from Pepscan
155	aa	12E12 binding peptide regions identified from Pepscan
156	aa	12E12 binding peptide regions identified from Pepscan
157	aa	12E12 binding peptide regions identified from Pepscan
158	aa	12E12 binding peptide regions identified from Pepscan
159	aa	11B6 binding peptide regions identified from Pepscan
160	aa	11B6 binding peptide regions identified from Pepscan
161	aa	11B6 binding peptide regions identified from Pepscan
162	aa	11B6 binding peptide regions identified from Pepscan
163	aa	11B6 binding peptide regions identified from Pepscan
164	aa	11B6 binding peptide regions identified from Pepscan
165	aa	11B6 binding peptide regions identified from Pepscan
166	aa	11B6 binding peptide regions identified from Pepscan
167	aa	11B6 binding peptide regions identified from Pepscan
168	aa	monomeric streptavidin 2 domain
169	nt	Nucleotide coding sequence of monomeric streptavidin 2 domain
170	aa	C3948:rAB-cetHS-puro[hIgG4H-Flex-v1-S.Aureusmono-
		Streptavidin-EPEA]
171	nt	Coding sequence of C3948

TABLE 6
SEQ
ID
NO:	Full Sequence
1	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
2	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECAS
3	EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWI
	GRINPYNGATSYNQNFKDRVTLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
4	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECAS
5	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECASQTPTNTISVTPTNNSTPTNNSNPKPNPASMQ
	KGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTV
	KRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSA
	KPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
6	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
7	ATGGTTCGTCTGCCTCTGCAGTGCGTCCTCTGGGGCTGCTTGCTGACCG
	CTGTCCATCCAGAACCACCCACTGCATGCAGAGAAAAACAGTACCTAA
	TAAACAGTCAGTGCTGTTCTTTGTGCCAGCCAGGACAGAAACTGGTGA
	GTGACTGCACAGAGTTCACTGAAACGGAATGCCTTCCTTGCGGTGAAA
	GCGAATTCCTAGACACCTGGAACAGAGAGACACACTGCCACCAGCAC
	AAATACTGCGACCCCAACCTAGGGCTTCGGGTCCAGCAGAAGGGCACC
	TCAGAAACAGACACCATCTGCACCTGTGAAGAAGGCTGGCACTGTACG
	AGTGAGGCCTGTGAGAGCTGTGTCCTGCACCGCTCATGCTCGCCCGGC
	TTTGGGGTCAAGCAGATTGCTACAGGGGTTTCTGATACCATCTGCGAG
	CCCTGCCCAGTCGGCTTCTTCTCCAATGTGTCATCTGCTTTCGAAAAAT
	GTCACCCTTGGACAAGCTGTGAGACCAAAGACCTGGTTGTGCAACAGG
	CAGGCACAAACAAGACTGATGTTGTCTGTGGTCCCCAGGATCGGCTGA
	GAGCCCTGGTGGTGATCCCCATCATCTTCGGGATCCTGTTTGCCATCCT
	CTTGGTGCTGGTCTTTATCAAAAAGGTGGCCAAGAAGCCAACCAATAA
	GGCCCCCCACCCCAAGCAGGAACCCCAGGAGATCAATTTTCCCGACGA
	TCTTCCTGGCTCCAACACTGCTGCTCCAGTGCAGGAGACTTTACATGGA
	TGCCAACCGGTCACCCAGGAGGATGGCAAAGAGAGTCGCATCTCAGTG
	CAGGAGAGACAG
8	EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWI
	GRINPYNGATSYNQNFKDRVTLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLEPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
9	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLEPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASQTPTNTIS
	VTPTNNSTPTNNSNPKPNPASEKIRLRPGGKKKYKLKHIVASSSVSPTTSVH
	PTPTSVPPTPTKSSPASNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDASPTS
	TPADSSTITPTATPTATPTIKGASHTQGYFPDWQNYTPGPGVRYPLTFGWL
	YKLASTVTPTATATPSAIVTTITPTATTKPASVGFPVTPQVPLRPMTYKAA
	VDLSHFLKEKGGLASTNGSITVAATAPTVTPTVNATPSAAASAIFQSSMTK
	ILEPFRKQNPDIVIYQYMDDLYAS
10	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECAS
11	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLEPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASQTPTNTIS
	VTPTNNSTPTNNSNPKPNPASEKIRLRPGGKKKYKLKHIVASSSVSPTTSVH
	PTPTSVPPTPTKSSPASNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDASPTS
	TPADSSTITPTATPTATPTIKGASHTQGYFPDWQNYTPGPGVRYPLTFGWL
	YKLASTVTPTATATPSAIVTTITPTATTKPASVGFPVTPQVPLRPMTYKAA
	VDLSHFLKEKGGLASTNGSITVAATAPTVTPTVNATPSAAASAIFQSSMTK
	ILEPFRKQNPDIVIYQYMDDLYAS
12	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECASQTPTNTISVTPTNNSTPTNNSNPKPNPASMQ
	KGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTV
	KRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSA
	KPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
13	MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSD
	CTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETD
	TICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFS
	NVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLRALVVIPIIF
	GILFAILLVLVFIKKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQET
	LHGCQPVTQEDGKESRISVQERQ
14	MQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQL
	TVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHS
	SAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
15	QTPTNTISVTPTNNSTPTNNSNPKPNP
16	EKIRLRPGGKKKYKLKHIV
17	NPPIPVGEIYKRWIILGLNKIVRMYSPTSILD
18	HTQGYFPDWQNYTPGPGVRYPLTFGWLYKL
19	AIFQSSMTKILEPFRKQNPDIVIYQYMDDLY
20	VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL
21	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
22	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECAS
23	EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWI
	GRINPYNGATSYNQNFKDRVTLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
24	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
25	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGCTGA
26	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGTCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
27	GYSFTGYYMH
28	RINPYNGATSYNQNFKDR
29	EDYVY
30	RSSQSLVHSNGNTYLH
31	KVSNRFS
32	SQSTHVPWT
33	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
34	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGCTGA
35	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGTCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
36	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGCTGA
37	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGTCAGACCCCCA
	CCAACACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACA
	ACAGCAACCCCAAGCCCAACCCCGCTAGCATGCAGAAGGGAGACCAG
	AACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCTTCTTCCAAGACC
	ACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAAC
	AACCTGGTGACACTGGAGAACGGCAAGCAGCTCACAGTCAAGCGGCA
	GGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGCTCCAACAGGGA
	GGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCA
	GGCAGATTCGAGAGGATTCTCCTGCGCGCCGCCAATACACACAGCTCA
	GCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGGGGGGTCTTTGAG
	TTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAG
	GTGAGCCATGGCACTGGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
38	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
39	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGTCAGACCCCCA
	CCAACACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACA
	ACAGCAACCCCAAGCCCAACCCCGCTAGCATGCAGAAGGGAGACCAG
	AACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCTTCTTCCAAGACC
	ACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAAC
	AACCTGGTGACACTGGAGAACGGCAAGCAGCTCACAGTCAAGCGGCA
	GGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGCTCCAACAGGGA
	GGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCA
	GGCAGATTCGAGAGGATTCTCCTGCGCGCCGCCAATACACACAGCTCA
	GCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGGGGGGTCTTTGAG
	TTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAG
	GTGAGCCATGGCACTGGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
40	EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLEWVA
	YINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCARR
	GLPFHAMDYWGQGTSVTVSSAK
41	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGTCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
42	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGCTGA
43	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGTCAGACCCCCACCAA
	CACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACAACAG
	CAACCCCAAGCCCAACCCCGCTAGTGAGAAGATCCGGCTGCGGCCCGG
	CGGCAAGAAGAAGTACAAGCTGAAGCACATCGTGGCTAGTAGCAGCG
	TGAGCCCCACCACCAGCGTGCACCCCACCCCCACCAGCGTGCCCCCCA
	CCCCCACCAAGAGCAGCCCCGCTAGTAACCCCCCCATCCCCGTGGGCG
	AGATCTACAAGCGGTGGATCATCCTGGGCCTGAACAAGATCGTGCGGA
	TGTACAGCCCCACCAGCATCCTGGACGCTAGTCCCACCAGCACCCCCG
	CCGACAGCAGCACCATCACCCCCACCGCCACCCCCACCGCCACCCCCA
	CCATCAAGGGCGCTAGTCACACCCAGGGCTACTTCCCCGACTGGCAGA
	ACTACACCCCCGGCCCCGGCGTGCGGTACCCCCTGACCTTCGGCTGGC
	TGTACAAGCTGGCTAGTACCGTGACCCCCACCGCCACCGCCACCCCCA
	GCGCCATCGTGACCACCATCACCCCCACCGCCACCACCAAGCCCGCTA
	GTGTGGGCTTCCCCGTGACCCCCCAGGTGCCCCTGCGGCCCATGACCT
	ACAAGGCCGCCGTGGACCTGAGCCACTTCCTGAAGGAGAAGGGCGGC
	CTGGCTAGTACCAACGGCAGCATCACCGTGGCCGCCACCGCCCCCACC
	GTGACCCCCACCGTGAACGCCACCCCCAGCGCCGCCGCTAGTGCCATC
	TTCCAGAGCAGCATGACCAAGATCCTGGAGCCCTTCCGGAAGCAGAAC
	CCCGACATCGTGATCTACCAGTACATGGACGACCTGTACGCTAGCTGA
44	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGTCAGACCCCCA
	CCAACACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACA
	ACAGCAACCCCAAGCCCAACCCCGCTAGCATGCAGAAGGGAGACCAG
	AACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCTTCTTCCAAGACC
	ACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAAC
	AACCTGGTGACACTGGAGAACGGCAAGCAGCTCACAGTCAAGCGGCA
	GGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGCTCCAACAGGGA
	GGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCA
	GGCAGATTCGAGAGGATTCTCCTGCGCGCCGCCAATACACACAGCTCA
	GCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGGGGGGTCTTTGAG
	TTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAG
	GTGAGCCATGGCACTGGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
45	AQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKA
	FSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEW
	DRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYK
	RWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVK
	NWMTETLLVQNANPDCKTILKALGPGATLEEMMTACQGVG
46	MGGKWSKRSVVGWPTVRERMRRAEPAADGVGAVSRDLEKHGAITSSNT
	AANNADCAWLEAQEEEEVGFPVRPQVPLRPMTYKGALDLSHF'LKEKGGL
	EGLIYSQKRQDILDLWVYHTQGYFPDWQNYTPGPGIRYPLTFGWCFKLVP
	VEPEKVEEANEGENNSLLHPMSLHGMDDPEREVLVWKFDSRLAFHHMAR
	ELHPEYYKDC
47	MGARASILSGGELDRWEKIRLRPGGNKQYKLKHIVWASRELERFAVNPGL
	LETSEGCRQILGQLQPSLQTGSEELRSLYNTVATLYCVHQRIEIKDTKEALD
	KIEEEQNKS
48	ASQTPTNTISVTPTNNSTPTNNSNPKPNPASLEMGARASILSGGELDRWEKI
	RLRPGGNKQYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQ
	TGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSVDTVTPTAT
	ATPSAIVTTITPTATTKPVDMGGKWSKRSVVGWPTVRERMRRAEPAADG
	VGAVSRDLEKHGAITSSNTAANNADCAWLEAQEEEEVGFPVRPQVPLRP
	MTYKGALDLSHF'LKEKGGLEGLIYSQKRQDILDLWVYHTQGYFPDWQNY
	TPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMDDPE
	REVLVWKFDSRLAFHHMARELHPEYYKDCEFTNGSITVAATAPTVTPTVN
	ATPSAAQFAQQAAADTGHSNQVSQNYPIVQNIQGQMVHQAISPRTLNAW
	VKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKET
	INEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNP
	PIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAE
	QASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTACQGVGH
	HHHHH
49	GCACAGCAAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCA
	AAATTACCCTATAGTGCAGAACATCCAGGGGCAAATGGTACATCAGGC
	CATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAA
	GGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGG
	AGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGAC
	ATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCT
	GCAGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCA
	GGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTACTAG
	TACCCTTCAGGAACAAATAGGATGGATGACACATAATCCACCTATCCC
	AGTAGGAGAAATCTATAAAAGGTGGATAATCCTGGGATTAAATAAAAT
	AGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGGACC
	AAAGGAACCCTTTAGAGACTATGTAGACCGATTCTATAAAACTCTAAG
	AGCCGAGCAAGCTTCACAAGAGGTAAAAAATTGGATGACAGAAACCT
	TGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTTTAAAAGCAT
	TGGGACCAGGAGCGACACTAGAAGAAATGATGACAGCATGTCAGGGA
	GTGGGG
50	ATGGGAGGCAAATGGAGTAAAAGAAGTGTTGTGGGTTGGCCAACTGT
	GAGAGAAAGAATGAGAAGGGCTGAACCAGCCGCTGATGGTGTAGGTG
	CTGTGTCACGAGATCTGGAAAAACACGGAGCAATAACATCCTCTAATA
	CCGCCGCAAATAACGCAGACTGTGCCTGGCTCGAAGCTCAAGAAGAA
	GAAGAAGTCGGATTCCCCGTGCGACCCCAAGTTCCCCTCAGACCAATG
	ACTTATAAAGGCGCTCTGGATCTTAGCCACTTTCTTAAAGAAAAAGGA
	GGACTGGAAGGACTTATTTATTCACAAAAAAGACAAGACATCCTCGAT
	TTGTGGGTATATCATACTCAAGGTTATTTCCCAGACTGGCAAAATTATA
	CTCCTGGACCCGGCATTCGATATCCCCTTACCTTTGGATGGTGCTTTAA
	ACTTGTCCCCGTCGAACCTGAAAAAGTAGAAGAAGCAAATGAAGGCG
	AAAATAATTCACTGCTCCACCCTATGTCACTGCACGGAATGGATGACC
	CCGAACGCGAAGTTCTGGTATGGAAATTTGATTCAAGACTTGCTTTTCA
	CCACATGGCTAGAGAACTTCACCCCGAATATTATAAAGACTGT
51	ATGGGTGCGAGAGCGTCAATATTAAGCGGTGGCGAATTAGATAGATGG
	GAAAAAATTCGGTTAAGGCCAGGGGGAAACAAACAATATAAATTAAA
	ACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCC
	TGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCT
	ACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTATATAA
	TACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGA
	CACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGT
52	GCTAGTCAGACCCCCACCAACACCATCAGCGTGACCCCCACCAACAAC
	AGCACCCCCACCAACAACAGCAACCCCAAGCCCAACCCCGCTAGCCTC
	GAGATGGGTGCGAGAGCGTCAATATTAAGCGGTGGCGAATTAGATAG
	ATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAACAAACAATATAAAT
	TAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
	ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGAC
	AGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATCATTAT
	ATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAA
	AAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAA
	AGTGTCGATACCGTGACCCCCACCGCCACCGCCACCCCCAGCGCCATC
	GTGACCACCATCACCCCCACCGCCACCACCAAGCCCGTCGACATGGGA
	GGCAAATGGAGTAAAAGAAGTGTTGTGGGTTGGCCAACTGTGAGAGA
	AAGAATGAGAAGGGCTGAACCAGCCGCTGATGGTGTAGGTGCTGTGTC
	ACGAGATCTGGAAAAACACGGAGCAATAACATCCTCTAATACCGCCGC
	AAATAACGCAGACTGTGCCTGGCTCGAAGCTCAAGAAGAAGAAGAAG
	TCGGATTCCCCGTGCGACCCCAAGTTCCCCTCAGACCAATGACTTATAA
	AGGCGCTCTGGATCTTAGCCACTTTCTTAAAGAAAAAGGAGGACTGGA
	AGGACTTATTTATTCACAAAAAAGACAAGACATCCTCGATTTGTGGGT
	ATATCATACTCAAGGTTATTTCCCAGACTGGCAAAATTATACTCCTGGA
	CCCGGCATTCGATATCCCCTTACCTTTGGATGGTGCTTTAAACTTGTCC
	CCGTCGAACCTGAAAAAGTAGAAGAAGCAAATGAAGGCGAAAATAAT
	TCACTGCTCCACCCTATGTCACTGCACGGAATGGATGACCCCGAACGC
	GAAGTTCTGGTATGGAAATTTGATTCAAGACTTGCTTTTCACCACATGG
	CTAGAGAACTTCACCCCGAATATTATAAAGACTGTGAATTCACCAACG
	GCAGCATCACCGTGGCCGCCACCGCCCCCACCGTGACCCCCACCGTGA
	ACGCCACCCCCAGCGCCGCCCAATTCGCACAGCAAGCAGCAGCTGACA
	CAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACA
	TCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATG
	CATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTGATA
	CCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAAC
	ACCATGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTA
	AAAGAGACCATCAATGAGGAAGCTGCAGAATGGGATAGAGTGCATCC
	AGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGG
	GAAGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGAT
	GGATGACACATAATCCACCTATCCCAGTAGGAGAAATCTATAAAAGGT
	GGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTACCA
	GCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATG
	TAGACCGATTCTATAAAACTCTAAGAGCCGAGCAAGCTTCACAAGAGG
	TAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGAACCCAG
	ATTGTAAGACTATTTTAAAAGCATTGGGACCAGGAGCGACACTAGAAG
	AAATGATGACAGCATGTCAGGGAGTGGGGCATCACCATCACCATCACT
	GA
53	TVTPTATATPSAIVTTITPTATTKP
54	TNGSITVAATAPTVTPTVNATPSAA
55	MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVG
	DFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSVYGTTLEQQYN
	KPLCDLLIRCINCQKPLCPEASMHGDTPTLHEYMLDLQPETTDLYGYGQL
	NDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCK
56	ASSSVSPTTSVHPTPTSVPPTPTKSSPAS
57	ASQTPTNTISVTPTNNSTPTNNSNPKPNPASMHQKRTAMFQDPQERPRKLP
	QLCTELQTTIHDIILECVYCKQQLLRREVGDFAFRDLCIVYRDGNPYAVCD
	KCLKFYSKISEYRHYCYSVYGTTLEQQYNKPLCDLLIRCINCQKPLCPEAS
	MHGDTPTLHEYMLDLQPETTDLYGYGQLNDSSEEEDEIDGPAGQAEPDR
	AHYNIVTFCCKASSSVSPTTSVHPTPTSVPPTPTKSSPAS
58	EVQLQQSGPELVKPGASVKMSCKASGYTFTDYVLHWVKQKPGQGLEWI
	GYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCAR
	GYPAYSGYAMDYWGQGTSVTVSSAK
59	DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYT
	SRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCHHGNTLPWTFGGGT
	K
60	DVQLQESGPDLVKPSQSLSLTCTVTGYSITSDYSWHWIRQFPGNKLEWMG
	YIYYSGSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDSATYFCARFYYG
	YSFFDYWGQGTTLTVSSAK
61	QIVLTQSPAFMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDT
	SKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGT
	K
62	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW
	MGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYC
	ARDQPLGYCTNGVCSYFDYWGQGTLVTVSSAS
63	DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYT
	ASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGT
	K
64	EVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWV
	AYINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA
	RRGLPFHAMDYWGQGTLVTVSSAK
65	DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYT
	SILHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTK
66	GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCT
	TCAGTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTGACTAT
	GTTTTGCACTGGGTGAAACAGAAGCCTGGGCAGGGCCTTGAGTGGATT
	GGATATATTAATCCTTACAATGATGGTACTAAGTACAATGAGAAGTTC
	AAAGGCAAGGCCACACTGACTTCAGACAAATCCTCCAGCACAGCCTAC
	ATGGAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTCTATTACTGT
	GCAAGGGGCTATCCGGCCTACTCTGGGTATGCTATGGACTACTGGGGT
	CAAGGAACCTCAGTCACCGTCTCCTCAGCCAAA
67	GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAG
	ACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACATTAGCAATTATT
	TAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCT
	ACTACACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCA
	GTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAG
	AAGATATTGCCACTTACTTTTGCCATCATGGTAATACGCTTCCGTGGAC
	GTTCGGTGGAGGCACCAAG
68	GATGTGCAGCTTCAGGAGTCAGGACCTGACCTGGTGAAACCTTCTCAG
	TCACTTTCACTCACCTGCACTGTCACTGGCTACTCCATCACCAGTGATT
	ATAGCTGGCACTGGATCCGGCAGTTCCCAGGAAACAAACTGGAATGGA
	TGGGCTACATATATTACAGTGGTAGCACTAACTACAACCCATCTCTCA
	AAAGTCGAATCTCTATCACTCGAGACACATCCAAGAACCAGTTCTTCC
	TGCAGTTGAATTCTGTGACTACTGAGGACTCAGCCACATATTTCTGTGC
	AAGATTTTACTACGGTTATAGCTTCTTTGACTACTGGGGCCAAGGCACC
	ACTCTCACAGTCTCCTCAGCCAAA
69	CAAATTGTTCTCACCCAGTCTCCAGCATTCATGTCTGCATCTCCAGGGG
	AGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTCAGTTACATGC
	ACTGGTACCAGCAGAAGTCAGGCACCTCCCCCAAAAGATGGATTTATG
	ACACATCCAAACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTG
	GGTCTGGGACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAG
	ATGCTGCCACTTATTACTGCCAGCAGTGGAGTAGTAACCCACTCACGTT
	CGGTGCTGGGACCAAG
70	CAAGTGCAGCTGGTTCAGTCTGGGGCTGAGGTGAAAAAGCCTGGGGCC
	AGTGTCAAGGTCAGCTGCAAGGCCTCTGGCTACACATTTACTGGATAT
	TACATGCATTGGGTTCGACAGGCCCCCGGACAGGGGCTCGAATGGATG
	GGATGGATAAACCCAGACAGCGGCGGAACGAACTATGCCCAAAAATT
	TCAGGGCAGGGTGACCATGACCCGGGACACCTCCATCAGCACAGCCTA
	CATGGAGCTGAATAGACTTCGGAGTGACGATACAGCCGTCTACTATTG
	CGCAAGGGATCAGCCGCTGGGCTACTGTACAAATGGCGTGTGTTCATA
	CTTCGACTATTGGGGTCAGGGTACGCTCGTGACCGTGTCATCTGCGTCC
71	GACATTCAGATGACACAATCTCCCTCCTCCGTAAGCGCCTCTGTGGGC
	GATCGCGTTACAATCACTTGCCGGGCTAGTCAGGGCATCTATAGCTGG
	CTCGCTTGGTACCAGCAAAAGCCTGGCAAAGCGCCTAATCTGCTGATT
	TATACCGCCTCTACGCTGCAGAGCGGGGTCCCAAGCAGATTTTCAGGG
	TCCGGGTCAGGAACCGATTTCACTCTGACTATCAGCTCCCTGCAGCCCG
	AGGACTTCGCAACCTACTACTGCCAGCAAGCCAACATATTCCCCCTGA
	CCTTTGGTGGAGGTACAAAG
72	GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCCGGAGG
	GTCCCTGAAACTCTCCTGTGCAACCTCTGGATTCACTTTCAGTGACTAT
	TACATGTATTGGGTTCGCCAGGCCCCAGGCAAGGGCCTGGAGTGGGTC
	GCATACATTAATTCTGGTGGTGGTAGCACCTATTATCCAGACACTGTAA
	AGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACC
	TGCAAATGAACAGCCTGAGGGCCGAGGACACAGCCGTGTATTACTGTG
	CAAGACGGGGGTTACCGTTCCATGCTATGGACTATTGGGGTCAAGGAA
	CCCTGGTCACCGTCTCCTCAGCCAAA
73	GATATCCAGATGACACAGAGCCCTTCCTCCCTGTCTGCCTCTGTGGGAG
	ACAGAGTCACCATCACCTGCAGTGCAAGTCAGGGCATTAGCAATTATT
	TAAACTGGTATCAGCAGAAACCAGGCAAGGCCGTTAAACTCCTGATCT
	ATTACACATCAATTTTACACTCAGGAGTCCCATCAAGGTTCAGTGGCA
	GTGGGTCTGGGACAGATTATACCCTCACCATCAGCTCCCTGCAGCCTG
	AAGATTTCGCCACTTACTATTGTCAGCAGTTTAATAAGCTTCCTCCGAC
	GTTCGGTGGAGGCACCAAA
74	GYTFTDYVLH
75	YINPYNDGTKYNEKFKG
76	GYPAYSGYAMDY
77	RASQDISNYLN
78	YTSRLHS
79	HHGNTLPWT
80	GYSITSDYSWH
81	YIYYSGSTNYNPSLKS
82	FYYGYSFFDY
83	SASSSVSYMH
84	DTSKLAS
85	QQWSSNPLT
86	GYTFTGYYMH
87	WINPDSGGTNYAQKFQG
88	DQPLGYCTNGVCSYFDY
89	RASQGIYSWLA
90	TASTLQS
91	QQANIFPLT
92	GFTFSDYYMY
93	YINSGGGSTYYPDTVKG
94	GLPFHAMDY
95	SASQGISNYLN
96	YTSILHS
97	QQFNKLPPT
98	EVQLQQSGPELVKPGASVKMSCKASGYTFTDYVLHWVKQKPGQGLEWI
	GYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCA
	RGYPAYSGYAMDYWGQGTSVTVSSAK
99	DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY
	TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCHHGNTLPWTFGG
	GTK
100	EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLEWV
	AYINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCA
	RRGLPFHAMDYWGQGTSVTVSSAK
101	DIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLLIYYT
	SILHSGVPSRFSGSGSGTDYSLTIGNLEPEDIATYYCQQFNKLPPTFGGGT
	K
102	EVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWV
	AYINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA
	RRGLPFHAMDYWGQGTLVTVSSAK
103	EVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWV
	AYINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA
	RRGLPFHAMDYWGQGTLVTVSSAK
104	DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYY
	TSILHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQFNKLPPTFGGG
	TK
105	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW
	MGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYY
	CARDQPLGYCTNGVCSYFDYWGQGTLVTVSSAS
106	DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYT
	ASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGG
	TK
107	DVQLQESGPDLVKPSQSLSLTCTVTGYSITSDYSWHWIRQFPGNKLEWM
	GYIYYSGSSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDSATFYCARFY
	YGYSFFDYWGQGTTLTVSSAK
108	QIVLTQSPAFMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYD
	TSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGA
	GTK
109	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVP
	WTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
	QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
110	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCA
	REDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
	PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCN
	VDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISR
	TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVS
	VLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPS
	QEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
	FLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASNSPQ
	NEVLYGDVNDDGKVNSTDLTLLKRYVLKAVSTLPSSKAEKNADVNRDGR
	VDSSDVTILSRYLIRVIEKLPI
111	NSPQNEVLYGDVNDDGKVNSTDLTLLKRYVLKAVSTLPSSKAEKNADVN
	RDGRVDSSDVTILSRYLIRVIEKLPI
112	EKIRLRPGGKKKYKLKHIVASSSVSPTTSVHPTPTSVPPTPTKSSPASNPPIP
	VGEIYKRWIILGLNKIVRMYSPTSILDASPTSTPADSSTITPTATPTATPTIKG
	ASHTQGYFPDWQNYTPGPGVRYPLTFGWLYKLASTVTPTATATPSAIVTTI
	TPTATTKPASVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLASTNGSITV
	AATAPTVTPTVNATPSAAASAIF'QSSMTKILEPFRKQNPDIVIYQYMDDLY
	AS
113	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGTCAGACCCCCA
	CCAACACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACA
	ACAGCAACCCCAAGCCCAACCCCGCTAGCATGCAGAAGGGAGACCAG
	AACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCTTCTTCCAAGACC
	ACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAAC
	AACCTGGTGACACTGGAGAACGGCAAGCAGCTCACAGTCAAGCGGCA
	GGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGCTCCAACAGGGA
	GGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCA
	GGCAGATTCGAGAGGATTCTCCTGCGCGCCGCCAATACACACAGCTCA
	GCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGGGGGGTCTTTGAG
	TTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAG
	GTGAGCCATGGCACTGGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
114	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCAATTCTCCTCAAAAT
	GAAGTACTGTACGGAGATGTGAATGATGACGGAAAAGTAAACTCCACT
	GACTTGACTTTGTTAAAAAGATATGTTCTTAAAGCCGTCTCAACTCTGC
	CTTCTTCCAAAGCTGAAAAGAACGCAGATGTAAATCGTGACGGAAGAG
	TTGACTCCAGTGATGTCACAATACTTTCAAGATATTTGATAAGGGTAAT
	CGAGAAATTACCAATATAA
115	GAGAAGATCCGGCTGCGGCCCGGCGGCAAGAAGAAGTACAAGCTGAA
	GCACATCGTGGCTAGTAGCAGCGTGAGCCCCACCACCAGCGTGCACCC
	CACCCCCACCAGCGTGCCCCCCACCCCCACCAAGAGCAGCCCCGCTAG
	TAACCCCCCCATCCCCGTGGGCGAGATCTACAAGCGGTGGATCATCCT
	GGGCCTGAACAAGATCGTGCGGATGTACAGCCCCACCAGCATCCTGGA
	CGCTAGTCCCACCAGCACCCCCGCCGACAGCAGCACCATCACCCCCAC
	CGCCACCCCCACCGCCACCCCCACCATCAAGGGCGCTAGTCACACCCA
	GGGCTACTTCCCCGACTGGCAGAACTACACCCCCGGCCCCGGCGTGCG
	GTACCCCCTGACCTTCGGCTGGCTGTACAAGCTGGCTAGTACCGTGAC
	CCCCACCGCCACCGCCACCCCCAGCGCCATCGTGACCACCATCACCCC
	CACCGCCACCACCAAGCCCGCTAGTGTGGGCTTCCCCGTGACCCCCCA
	GGTGCCCCTGCGGCCCATGACCTACAAGGCCGCCGTGGACCTGAGCCA
	CTTCCTGAAGGAGAAGGGCGGCCTGGCTAGTACCAACGGCAGCATCAC
	CGTGGCCGCCACCGCCCCCACCGTGACCCCCACCGTGAACGCCACCCC
	CAGCGCCGCCGCTAGTGCCATCTTCCAGAGCAGCATGACCAAGATCCT
	GGAGCCCTTCCGGAAGCAGAACCCCGACATCGTGATCTACCAGTACAT
	GGACGACCTGTACGCTAGCTGA
116	GCTAGTCAGACCCCCACCAACACCATCAGCGTGACCCCCACCAACAAC
	AGCACCCCCACCAACAACAGCAACCCCAAGCCCAACCCCGCTAGTATG
	CACCAAAAAAGGACCGCAATGTTTCAGGACCCCCAAGAGAGGCCCCG
	CAAACTGCCACAACTTTGCACGGAGCTGCAGACAACAATACATGACAT
	CATTCTCGAATGTGTTTACTGTAAGCAGCAGTTGTTGCGAAGAGAAGT
	GGGAGACTTCGCTTTCAGAGACCTGTGTATCGTATATCGCGATGGCAA
	TCCTTATGCCGTCTGCGATAAATGCCTCAAGTTTTACTCCAAGATCAGC
	GAGTACCGGCACTACTGTTACTCTGTGTATGGGACTACCCTCGAACAG
	CAGTATAACAAGCCGCTGTGCGATCTCCTTATCCGGTGCATTAACTGCC
	AGAAGCCACTGTGTCCTGAGGCTAGTATGCACGGGGATACCCCCACAC
	TCCACGAATACATGCTTGATTTGCAACCTGAAACGACCGACCTGTACG
	GCTATGGTCAGCTGAATGACTCCAGCGAGGAAGAGGATGAGATTGAC
	GGACCGGCAGGCCAGGCCGAGCCAGACCGGGCTCATTATAACATCGTG
	ACTTTCTGCTGTAAGGCTAGTAGCAGCGTGAGCCCCACCACCAGCGTG
	CACCCCACCCCCACCAGCGTGCCCCCCACCCCCACCAAGAGCAGCCCC
	GCTAGCTGA
117	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWI
	GRINPYNGATSYNQNFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASQTPTNTIS
	VTPTNNSTPTNNSNPKPNPASEKIRLRPGGKKKYKLKHIVASSSVSPTTSVH
	PTPTSVPPTPTKSSPASNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDASPTS
	TPADSSTITPTATPTATPTIKGASHTQGYFPDWQNYTPGPGVRYPLTFGWL
	YKLASTVTPTATATPSAIVTTITPTATTKPASVGFPVTPQVPLRPMTYKAA
	VDLSHF'LKEKGGLASTNGSITVAATAPTVTPTVNATPSAAASAIFQSSMTK
	ILEPFRKQNPDIVIYQYMDDLYAS
118	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGTCAGACCCCCACCAA
	CACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACAACAG
	CAACCCCAAGCCCAACCCCGCTAGTGAGAAGATCCGGCTGCGGCCCGG
	CGGCAAGAAGAAGTACAAGCTGAAGCACATCGTGGCTAGTAGCAGCG
	TGAGCCCCACCACCAGCGTGCACCCCACCCCCACCAGCGTGCCCCCCA
	CCCCCACCAAGAGCAGCCCCGCTAGTAACCCCCCCATCCCCGTGGGCG
	AGATCTACAAGCGGTGGATCATCCTGGGCCTGAACAAGATCGTGCGGA
	TGTACAGCCCCACCAGCATCCTGGACGCTAGTCCCACCAGCACCCCCG
	CCGACAGCAGCACCATCACCCCCACCGCCACCCCCACCGCCACCCCCA
	CCATCAAGGGCGCTAGTCACACCCAGGGCTACTTCCCCGACTGGCAGA
	ACTACACCCCCGGCCCCGGCGTGCGGTACCCCCTGACCTTCGGCTGGC
	TGTACAAGCTGGCTAGTACCGTGACCCCCACCGCCACCGCCACCCCCA
	GCGCCATCGTGACCACCATCACCCCCACCGCCACCACCAAGCCCGCTA
	GTGTGGGCTTCCCCGTGACCCCCCAGGTGCCCCTGCGGCCCATGACCT
	ACAAGGCCGCCGTGGACCTGAGCCACTTCCTGAAGGAGAAGGGCGGC
	CTGGCTAGTACCAACGGCAGCATCACCGTGGCCGCCACCGCCCCCACC
	GTGACCCCCACCGTGAACGCCACCCCCAGCGCCGCCGCTAGTGCCATC
	TTCCAGAGCAGCATGACCAAGATCCTGGAGCCCTTCCGGAAGCAGAAC
	CCCGACATCGTGATCTACCAGTACATGGACGACCTGTACGCTAGCTGA
119	DIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLLIYYT
	SILHSGVPSRFSGSGSGTDYSLTIGNLEPEDIATYYCQQFNKLPPTFGGGTK
120	GATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTAGGAG
	ACAGAGTCACCATCAGTTGCAGTGCAAGTCAGGGCATTAGCAATTATT
	TAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCT
	ATTACACATCAATTTTACACTCAGGAGTCCCATCAAGGTTCAGTGGCA
	GTGGGTCTGGGACAGATTATTCTCTCACCATCGGCAACCTGGAACCTG
	AAGATATTGCCACTTACTATTGTCAGCAGTTTAATAAGCTTCCTCCGAC
	GTTCGGTGGAGGCACCAAA
121	EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWI
	GRINPYNGATSYNQNFKDRVTLTVDKSTSTAYMELSSLRSEDTAVYYCAR
	EDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP
	EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV
	DHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLEPPKPKDTLMISRTP
	EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVL
	TVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEE
	MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
	SRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS
122	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECAS
123	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPR
	LLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPW
	TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
	WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV
	THQGLSSPVTKSFNRGECASQTPTNTISVTPTNNSTPTNNSNPKPNPASMQ
	KGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTV
	KRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSA
	KPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
124	MDLDAVRIKVDTVNAKPGDTVNIPVRESGIPSKGIANADFVYSYDPNVLEI
	IEIKPGELIVDPNPTKSFDTAVYPDRKMIVFLFAEDSGTGAYAITKDGVFAT
	IVAKVKEGAPNGLSVIKFVEVGGFANNDLVEQKTQFFDGGVNVGDTTEPA
	TPTTPVTTPTTTDDLDAASLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGK
	NTDLEVLMEWLKTRPILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNG
	NGDPNNMDKAVKLYRKLKREITFHGAKEIALSYSAGALASCMGLIYNRM
	GAVTTEVAFGLVCATCEQIADSQHRSHRQMVTTTNPLIRHENRMVLASTT
	AKAMEQMAGSSEQAAEAMDIASQARQMVQAMRTIGTHPSSSAGLKDDL
	LENLQAYQKRMGVQMQRFKLEHHHHHH
125	ATGGATCTGGATGCAGTAAGGATTAAAGTGGACACAGTAAATGCAAA
	ACCGGGAGACACAGTAAATATACCTGTAAGATTCAGTGGTATACCATC
	CAAGGGAATAGCAAACGCTGACTTTGTATACAGCTATGACCCGAATGT
	ACTTGAGATAATAGAGATAAAACCGGGAGAATTGATAGTTGACCCGA
	ATCCTACCAAGAGCTTTGATACTGCAGTATATCCTGACAGAAAGATGA
	TAGTATTCCTGTTTGCGGAAGACAGCGGAACAGGAGCGTATGCAATAA
	CTAAAGACGGAGTATTTGCTACGATAGTAGCGAAAGTAAAAGAAGGA
	GCACCTAACGGGCTCAGTGTAATCAAATTTGTAGAAGTAGGCGGATTT
	GCGAACAATGACCTTGTAGAACAGAAGACACAGTTCTTTGACGGTGGA
	GTAAATGTTGGAGATACAACAGAACCTGCAACACCTACAACACCTGTA
	ACAACACCGACAACAACAGATGATCTGGATGCAGCTAGCCTTCTAACC
	GAGGTCGAAACGTACGTTCTCTCTATCATCCCGTCAGGCCCCCTCAAA
	GCCGAGATCGCACAGAGACTTGAAGATGTCTTTGCAGGGAAGAACACC
	GATCTTGAGGTTCTCATGGAATGGCTAAAGACAAGACCAATCCTGTCA
	CCTCTGACTAAGGGGATTTTAGGATTTGTGTTCACGCTCACCGTGCCCA
	GTGAGCGGGGACTGCAGCGTAGACGCTTTGTCCAAAATGCTCTTAATG
	GGAACGGAGATCCAAATAACATGGACAAAGCAGTTAAACTGTATAGG
	AAGCTTAAGAGGGAGATAACATTCCATGGGGCCAAAGAAATAGCACT
	CAGTTATTCTGCTGGTGCACTTGCCAGTTGTATGGGCCTCATATACAAC
	AGGATGGGGGCTGTGACCACTGAAGTGGCATTTGGCCTGGTATGCGCA
	ACCTGTGAACAGATTGCTGACTCCCAGCATCGGTCTCATAGGCAAATG
	GTGACAACAACCAATCCACTAATCAGACATGAGAACAGAATGGTTCTA
	GCCAGCACTACAGCTAAGGCTATGGAGCAAATGGCTGGATCGAGTGA
	GCAAGCAGCAGAGGCCATGGATATTGCTAGTCAGGCCAGGCAAATGG
	TGCAGGCGATGAGAACCATTGGGACTCATCCTAGCTCCAGTGCTGGTC
	TAAAAGATGATCTTCTTGAAAATTTGCAGGCTTACCAGAAACGGATGG
	GGGTGCAGATGCAGCGATTCAAGCTCGAGCACCACCACCACCACCACT
	GA
126	GAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGG
	GTCCCTGAAACTCTCCTGTGCAACCTCTGGATTCACTTTCAGTGACTAT
	TACATGTATTGGGTTCGCCAGACTCCAGAGAAGAGGCTGGAGTGGGTC
	GCATACATTAATTCTGGTGGTGGTAGCACCTATTATCCAGACACTGTAA
	AGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACC
	TGCAAATGAGCCGGCTGAAGTCTGAGGACACAGCCATGTATTACTGTG
	CAAGACGGGGGTTACCGTTCCATGCTATGGACTATTGGGGTCAAGGAA
	CCTCAGTCACCGTCTCCTCAGCCAAA
127	GAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCCGGAGG
	GTCCCTGAAACTCTCCTGTGCAACCTCTGGATTCACTTTCAGTGACTAT
	TACATGTATTGGGTTCGCCAGGCCCCAGGCAAGGGCCTGGAGTGGGTC
	GCATACATTAATTCTGGTGGTGGTAGCACCTATTATCCAGACACTGTAA
	AGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACC
	TGCAAATGAACAGCCTGAGGGCCGAGGACACAGCCGTGTATTACTGTG
	CAAGACGGGGGTTACCGTTCCATGCTATGGACTATTGGGGTCAAGGAA
	CCCTGGTCACCGTCTCCTCAGCCAAA
128	GAGGTCCAGCTGGTGCAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCT
	TCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTCACTGGCTACT
	ACATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATTG
	GAAGGATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAACTTCA
	AGGACAGAGTCACCTTGACTGTAGACAAGTCCACGAGCACAGCCTACA
	TGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTG
	CAAGAGAGGACTACGTGTACTGGGGCCAAGGCACCACGGTCACCGTCT
	CCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCT
	CCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG
	ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGA
	CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTA
	CTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAA
	GACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG
	ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAG
	CACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAAC
	CCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGG
	TGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG
	TGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG
	CAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAA
	AGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCA
	GCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGAT
	GACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCC
	CAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACA
	ACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCT
	CTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATG
	TCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACA
	GAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA
129	GATGTTGTGATGACCCAATCTCCACTCTCCCTGCCTGTCACCCTTGGAC
	AGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTTGTACACAGTA
	ATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTC
	CAAGGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGA
	CAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAG
	CAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTAC
	ACATGTTCCTTGGACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACG
	AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG
	TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATC
	CCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG
	GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC
	CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGA
	AACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGC
	CCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGCTGA
130	PTSTPADSSTITPTATPTATPTIKG
131	EVQLQQSGPELVKPGASVKISCKASGYSFTGYYMHWVKQSHVKSLEWIGRINPYNGATSYNQNFKDKASLTV
	DKSSSTAYMELHSLTSEDSAVYYCAREDYVYWGQGTTLTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVK
	DYEPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
	GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
	QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT
	CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
	KSLSLSLGKAS
132	ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCAGCTGCAA
	CAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGTTACTCATTC
	ACTGGCTACTACATGCACTGGGTGAAGCAAAGCCATGTAAAGAGCCTTGAGTGGATTGGACGTATTAATCCT
	TACAATGGTGCTACTAGCTACAACCAGAATTTCAAGGACAAGGCCAGCTTGACTGTAGATAAGTCCTCCAGC
	ACAGCCTACATGGAGCTCCACAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGAGAGGACTAC
	GTCTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG
	GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
	CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
	TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
	AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCA
	CCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
	ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
	AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
	TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC
	TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
	GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
	TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
	CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAG
	GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
	TCTCTGGGTAAAGCTAGCTGA
133	DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGS
	GTDFALKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
	YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
	GECASMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCS
	NREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGT
	GFTSFGLLKL
134	ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATGTTGTGATGACC
	CAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCCGGTCTAGTCAGAGCCTT
	GTACACAGTAATGGAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATC
	TACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCGCA
	CTCAAGATCAGTAGAGTGGAGGCCGAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTGG
	ACGTTCGGTGGAGGCACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
	TCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCC
	AAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC
	AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAT
	GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGC
	ATGCAGAAGGGAGACCAGAACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCTTCTTCCAAGACCACCTCC
	GTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAACAACCTGGTGACACTGGAGAACGGCAAGCAG
	CTCACAGTCAAGCGGCAGGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGCTCCAACAGGGAGGCCTCC
	AGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCAGGCAGATTCGAGAGGATTCTCCTGCGCGCC
	GCCAATACACACAGCTCAGCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGGGGGGTCTTTGAGTTGCAG
	CCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAGGTGAGCCATGGCACTGGCTTTACTAGCTTT
	GGGTTGCTGAAACTGTGA
135	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPYNGATSYNQNFKDRATLTV
	DKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVK
	DYEPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
	GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
	QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT
	CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
	KSLSLSLGKASQTPTNTISVTPTNNSTPTNNSNPKPNPASMQKGDQNPQIAAHVISEASSKTTSVLQWAEKG
	YYTMSNNLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAK
	PCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
136	ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCAGCTGGTG
	CAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTC
	ACTGGCTACTACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTGGAAGGATTAATCCT
	TACAATGGTGCTACTAGCTACAACCAGAACTTCAAGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGC
	ACAGCCTACATGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTGCAAGAGAGGACTAC
	GTGTACTGGGGCCAAGGCACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG
	GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
	CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
	TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
	AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCA
	CCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
	ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
	AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
	TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC
	TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
	GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
	TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
	CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAG
	GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
	TCTCTGGGTAAAGCTAGTCAGACCCCCACCAACACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACC
	AACAACAGCAACCCCAAGCCCAACCCCGCTAGCATGCAGAAGGGAGACCAGAACCCTCAGATCGCAGCTCAC
	GTCATCTCCGAGGCTTCTTCCAAGACCACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGC
	AACAACCTGGTGACACTGGAGAACGGCAAGCAGCTCACAGTCAAGCGGCAGGGCCTTTACTACATCTATGCC
	CAGGTGACCTTCTGCTCCAACAGGGAGGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGC
	CCAGGCAGATTCGAGAGGATTCTCCTGCGCGCCGCCAATACACACAGCTCAGCCAAACCCTGCGGGCAACAG
	TCAATTCACCTGGGGGGGGTCTTTGAGTTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGT
	CAGGTGAGCCATGGCACTGGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
137	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKVSNRFSGVPDRFSGSGS
	GTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
	YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
	GECAS
138	ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATGTTGTGATGACC
	CAATCTCCACTCTCCCTGCCTGTCACCCTTGGACAGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTT
	GTACACAGTAATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTCCAAGGCTCCTGATC
	TACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACA
	CTCAAGATCAGCAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCTTGG
	ACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
	TCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCC
	AAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC
	AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAT
	GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGC
	TGA
139	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKVSNRFSGVPDRFSGSGS
	GTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
	YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
	GECASQTPTNTISVTPTNNSTPTNNSNPKPNPASMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSN
	NLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQS
	IHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL
140	ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATGTTGTGATGACC
	CAATCTCCACTCTCCCTGCCTGTCACCCTTGGACAGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTT
	GTACACAGTAATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTCCAAGGCTCCTGATC
	TACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACA
	CTCAAGATCAGCAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCTTGG
	ACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
	TCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCC
	AAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC
	AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAT
	GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGT
	CAGACCCCCACCAACACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACAACAGCAACCCCAAG
	CCCAACCCCGCTAGCATGCAGAAGGGAGACCAGAACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCTTCT
	TCCAAGACCACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAACAACCTGGTGACACTG
	GAGAACGGCAAGCAGCTCACAGTCAAGCGGCAGGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGCTCC
	AACAGGGAGGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCAGGCAGATTCGAGAGG
	ATTCTCCTGCGCGCCGCCAATACACACAGCTCAGCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGGGGG
	GTCTTTGAGTTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAGGTGAGCCATGGCACT
	GGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
141	EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWIGRINPYNGATSYNQNFKDRVTLTV
	DKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVK
	DYEPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
	GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
	QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT
	CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
	KSLSLSLGKAS
142	ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCAGCTGGTG
	CAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCTTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTC
	ACTGGCTACTACATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATTGGAAGGATTAATCCT
	TACAATGGTGCTACTAGCTACAACCAGAACTTCAAGGACAGAGTCACCTTGACTGTAGACAAGTCCACGAGC
	ACAGCCTACATGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTGCAAGAGAGGACTAC
	GTGTACTGGGGCCAAGGCACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG
	GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
	CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
	TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
	AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCA
	CCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
	ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
	AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
	TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC
	TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
	GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
	TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
	CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAG
	GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
	TCTCTGGGTAAAGCTAGCTGA
143	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWKQAHGQGLEWIGRINPYNGATSYNQNFKDRATLTV
	DKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVK
	DYEPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
	GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
	QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT
	CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
	KSLSLSLGKASMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYIYA
	QVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPS
	QVSHGTGFTSFGLLKL
144	ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCAGCTGGTG
	CAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTC
	ACTGGCTACTACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTGGAAGGATTAATCCT
	TACAATGGTGCTACTAGCTACAACCAGAACTTCAAGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGC
	ACAGCCTACATGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTGCAAGAGAGGACTAC
	GTGTACTGGGGCCAAGGCACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG
	GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
	CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
	TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
	AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCA
	CCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
	ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
	AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
	TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC
	TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
	GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
	TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
	CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAG
	GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
	TCTCTGGGTAAAGCTAGCATGCAGAAGGGAGACCAGAACCCTCAGATCGCAGCTCACGTCATCTCCGAGGCT
	TCTTCCAAGACCACCTCCGTGCTCCAGTGGGCTGAAAAGGGATACTACACCATGAGCAACAACCTGGTGACA
	CTGGAGAACGGCAAGCAGCTCACAGTCAAGCGGCAGGGCCTTTACTACATCTATGCCCAGGTGACCTTCTGC
	TCCAACAGGGAGGCCTCCAGCCAGGCCCCTTTCATTGCCTCTCTGTGTCTCAAGAGCCCAGGCAGATTCGAG
	AGGATTCTCCTGCGCGCCGCCAATACACACAGCTCAGCCAAACCCTGCGGGCAACAGTCAATTCACCTGGGG
	GGGGTCTTTGAGTTGCAGCCAGGGGCCAGTGTCTTCGTGAACGTGACAGATCCCAGTCAGGTGAGCCATGGC
	ACTGGCTTTACTAGCTTTGGGTTGCTGAAACTGTGA
145	EVQLVQSGAEVKKPGASVKISCKASGYSFTGYYMHWVKQAHGQGLEWIGRINPYNGATSYNQNFKDRATLTV
	DKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVK
	DYEPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
	GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
	QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT
	CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
	KSLSLSLGKAS
146	ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCAGCTGGTG
	CAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCTTCTGGATACTCCTTC
	ACTGGCTACTACATGCACTGGGTGAAGCAGGCCCATGGACAAGGGCTTGAGTGGATTGGAAGGATTAATCCT
	TACAATGGTGCTACTAGCTACAACCAGAACTTCAAGGACAGAGCCACCTTGACTGTAGACAAGTCCACGAGC
	ACAGCCTACATGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTGCAAGAGAGGACTAC
	GTGTACTGGGGCCAAGGCACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG
	GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
	CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
	TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
	AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCA
	CCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
	ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
	AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
	TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC
	TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
	GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
	TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
	CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAG
	GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
	TCTCTGGGTAAAGCTAGCTGA
147	EVQLVQSGAEVKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGLEWIGRINPYNGATSYNQNFKDRVTLTV
	DKSTSTAYMELSSLRSEDTAVYYCAREDYVYWGQGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVK
	DYEPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
	GPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREE
	QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLT
	CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQ
	KSLSLSLGKAS
148	ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCAGCTGGTG
	CAATCTGGAGCTGAGGTGAAGAAGCCTGGGGCTTCAGTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTC
	ACTGGCTACTACATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATTGGAAGGATTAATCCT
	TACAATGGTGCTACTAGCTACAACCAGAACTTCAAGGACAGAGTCACCTTGACTGTAGACAAGTCCACGAGC
	ACAGCCTACATGGAGCTCAGCAGCCTGAGGTCTGAGGACACGGCAGTCTATTACTGTGCAAGAGAGGACTAC
	GTGTACTGGGGCCAAGGCACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG
	GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA
	CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCC
	TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGC
	AACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCA
	CCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTC
	ATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTC
	AACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG
	TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC
	TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG
	GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC
	TTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT
	CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAG
	GGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTG
	TCTCTGGGTAAAGCTAGCTGA
149	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYQQRPGQSPRLLIYKVSNRFSGVPDRFSGSGS
	GTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
	YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
	GECAS
150	ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATGTTGTGATGACC
	CAATCTCCACTCTCCCTGCCTGTCACCCTTGGACAGCCGGCCTCCATCTCTTGCAGGTCTAGTCAGAGCCTT
	GTACACAGTAATGGAAACACCTATTTACATTGGTACCAGCAGAGACCAGGCCAGTCTCCAAGGCTCCTGATC
	TACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACA
	CTCAAGATCAGCAGAGTGGAGGCTGAAGATGTTGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCTTGG
	ACGTTCGGCGGAGGGACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCA
	TCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCC
	AAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC
	AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAT
	GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGCTAGC
	TGA
151	EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQ
	QKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPW
	TSCETKDLVVQQAGTNKTDVVCGPQDRLRVDSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHES
	PTLNPETVAINLSDVDLSKYIATIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQL
	HGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV
152	ATGGTTCGTCTGCCTCTGCAGTGCGTCCTCTGGGGCTGCTTGCTGACCGCTGTCCATCCAGAACCACCCACT
	GCATGCAGAGAAAAACAGTACCTAATAAACAGTCAGTGCTGTTCTTTGTGCCAGCCAGGACAGAAACTGGTG
	AGTGACTGCACAGAGTTCACTGAAACGGAATGCCTTCCTTGCGGTGAAAGCGAATTCCTAGACACCTGGAAC
	AGAGAGACACACTGCCACCAGCACAAATACTGCGACCCCAACCTAGGGCTTCGGGTCCAGCAGAAGGGCACC
	TCAGAAACAGACACCATCTGCACCTGTGAAGAAGGCTGGCACTGTACGAGTGAGGCCTGTGAGAGCTGTGTC
	CTGCACCGCTCATGCTCGCCCGGCTTTGGGGTCAAGCAGATTGCTACAGGGGTTTCTGATACCATCTGCGAG
	CCCTGCCCAGTCGGCTTCTTCTCCAATGTGTCATCTGCTTTCGAAAAATGTCACCCTTGGACAAGCTGTGAG
	ACCAAAGACCTGGTTGTGCAACAGGCAGGCACAAACAAGACTGATGTTGTCTGTGGTCCCCAGGATCGGCTG
	AGAGTCGACTCTAACTTGGGGTGGCTTTGTCTTCTTCTTTTGCCAATTCCACTAATTGTTTGGGTGAAGAGA
	AAGGAAGTACAGAAAACATGCAGAAAGCACAGAAAGGAAAACCAAGGTTCTCATGAATCTCCAACCTTAAAT
	CCTGAAACAGTGGCAATAAATTTATCTGATGTTGACTTGAGTAAATATATCGCCACTATTGCTGGAGTCATG
	ACACTAAGTCAAGTTAAAGGCTTTGTTCGAAAGAATGGTGTCAATGAAGCCAAAATAGATGAGATCAAGAAT
	GACAATGTCCAAGACACAGCAGAACAGAAAGTTCAACTGCTTCGTAATTGGCATCAACTTCATGGAAAGAAA
	GAAGCGTATGACACATTGATTAAAGATCTCAAAAAAGCCAATCTTTGTACTCTTGCAGAGAAAATTCAGACT
	ATCATCCTCAAGGACATTACTAGTGACTCAGAAAATTCAAACTTCAGAAATGAAATCCAAAGCTTGGTCTAG
153
154	QCCSLCQPGQ
155
156
157
158
159	INSQCCSLCQPGQ
160
161
162
163
164
165
166
167
168	EFASAEAGITGTWYNQHGSTFTVTAGADGNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTEN
	CHSRTEWRGQYQGGAEARINTQWNLTYEGGSGPATEQGQDTFTKVKPSAASGSEPEA
169	GAGTTTGCTTCTGCTGAAGCTGGAATCACAGGCACATGGTATAATCAGCACGGCTCTACCTTTACAGTGACA
	GCCGGAGCTGATGGAAACCTGACCGGCCAGTATGAGAACAGAGCCCAGGGAACAGGATGTCAGAATAGTCCT
	TATACACTGACAGGCAGATATAACGGAACAAAGCTGGAGTGGAGAGTGGAGTGGAATAACTCTACAGAGAAC
	TGTCACTCTAGAACAGAGTGGAGAGGCCAGTACCAGGGCGGCGCTGAGGCTAGAATTAACACACAGTGGAAC
	CTGACATACGAGGGAGGCTCTGGACCTGCTACAGAACAGGGCCAGGATACATTCACAAAGGTGAAGCCTTCT
	GCTGCCTCTGGATCT
170	RLQLQESGPGLLKPSVTLSLTCTVSGDSVASSSYYWGWVRQPPGKGLEWIGTINFSGNMYYSPSLRSRVTMS
	ADMSENSFYLKLDSVTAADTAVYYCAAGHLVMGFGAHWGQGKLVSVSPASTKGPSVFPLAPCSRSTSESTAA
	LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDK
	RVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAK
	TKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTK
	NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL
	HNHYTQKSLSLSLGKASQTPTNTISVTPTNNSTPTNNSNPKPNPASEFASAEAGITGTWYNQHGSTFTVTAG
	ADGNLTGQYENRAQGTGCQNSPYTLTGRYNGTKLEWRVEWNNSTENCHSRTEWRGQYQGGAEARINTQWNLT
	YEGGSGPATEQGQDTFTKVKPSAASGSEPEA
171	ATGGACCTCCTGTGCAAGAACATGAAGCACCTGTGGTTCTTCCTCCTGCTGGTGGCGGCTCCCAGATGGGTC
	CTGTCCCGGCTGCAGCTGCAGGAGTCGGGCCCAGGCCTGCTGAAGCCTTCGGTGACCCTGTCCCTCACCTGC
	ACTGTCTCGGGTGACTCCGTCGCCAGTAGTTCTTATTACTGGGGCTGGGTCCGTCAGCCCCCAGGGAAGGGA
	CTCGAGTGGATAGGGACTATCAATTTTAGTGGCAATATGTATTATAGTCCGTCCCTCAGGAGTCGAGTGACC
	ATGTCGGCAGACATGTCCGAGAACTCCTTCTATCTGAAATTGGACTCTGTGACCGCAGCAGACACGGCCGTC
	TATTATTGTGCGGCAGGACACCTCGTTATGGGATTTGGGGCCCACTGGGGACAGGGAAAACTGGTCTCCGTC
	TCTCCAGCTTCCACCAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACA
	GCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTG
	ACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACC
	GTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTG
	GACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCA
	TCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTG
	GTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAAT
	GCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
	CAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAA
	ACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATG
	ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAG
	AGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC
	TACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAG
	GCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGTCAGACCCCCACCAAC
	ACCATCAGCGTGACCCCCACCAACAACAGCACCCCCACCAACAACAGCAACCCCAAGCCCAACCCCGCTAGC
	GAGTTTGCTTCTGCTGAAGCTGGAATCACAGGCACATGGTATAATCAGCACGGCTCTACCTTTACAGTGACA
	GCCGGAGCTGATGGAAACCTGACCGGCCAGTATGAGAACAGAGCCCAGGGAACAGGATGTCAGAATAGTCCT
	TATACACTGACAGGCAGATATAACGGAACAAAGCTGGAGTGGAGAGTGGAGTGGAATAACTCTACAGAGAAC
	TGTCACTCTAGAACAGAGTGGAGAGGCCAGTACCAGGGCGGCGCTGAGGCTAGAATTAACACACAGTGGAAC
	CTGACATACGAGGGAGGCTCTGGACCTGCTACAGAACAGGGCCAGGATACATTCACAAAGGTGAAGCCTTCT
	GCTGCCTCTGGATCTGAGCCTGAGGCTTGA
(for certain antibody sequences, CDRs are highlighted in bold font)